Out today!
An AI model infers spatial proteomic patterns at the single-cell level from routine H&E slides to predict molecular biomarkers, prognosis and immunotherapy response
www.nature.com/articles/s43018-026-01270-8
Nature Cancer
Nature Cancer is a monthly peer-reviewed academic journal published by Nature Portfolio. It was established in 2020. The editor-in-chief is Alexia-Ileana Zaromytidou. More on Wikipedia
-
Nature Cancer
@NatureCancer
-
Nature Cancer
@NatureCancer
Reach out to our Editor Julieta Alfonso at "Defining and defeating metastasis: from plasticity to immune evasion to therapy resistance" Symposium in Heidelberg from 10th-13th Nov www.embl.org/about/info/course-and-conference-office/even… via @embl
-
Nature Cancer
@NatureCancer
Online today!
OSM and TGFβ1 establish distinct stromal niches that sustain hybrid and late EMT states in mouse skin tumors
@CedricBlanpain
www.nature.com/articles/s43018-026-01259-3 -
Nature Cancer
@NatureCancer
News & Views
AI for detection of adverse events in the real world
by @GuillaumeJaume & Jakob Nikolas Kather @jnkath
👉www.nature.com/articles/s43018-026-01258-4
Nature Cancer
@NatureCancer
Read about an AI agent assisting clinicians in assessing immune-related adverse events now in Nature Cancer!
@dbittermanmd
www.nature.com/articles/s43018-026-01264-6 -
Nature Cancer
@NatureCancer
🌟Online now
@ednacukierman, Igor Astsaturov & co uncover that CAFs fuel pancreatic tumor growth and immune suppression by transferring membrane lipids to cancer cells through trogocytosis.
www.nature.com/articles/s43018-026-01265-5 -
Nature Cancer
@NatureCancer
Read about an AI agent assisting clinicians in assessing immune-related adverse events now in Nature Cancer!
@dbittermanmd
www.nature.com/articles/s43018-026-01264-6 -
Nature Cancer
@NatureCancer
Now Online!
A genome-wide screen in E. coli identifies genetic determinants of intratumoral bacterial fitness and targets for therapeutic application.
@arpaialab
www.nature.com/articles/s43018-026-01263-7 -
Nature Cancer
@NatureCancer
💫Now online!
de Sauvage and colleagues discuss the latest advances in therapy-driven cancer plasticity processes
🔗www.nature.com/articles/s43018-026-01232-0
Check out the rest of the Series on Tumor Heterogeneity and Plasticity here: nature.com/collections/gfbbjcecif
www.nature.com/articles/s43018-026-01232-0 -
Nature Cancer
@NatureCancer
🎃The October issue is live!
✅Computational cytopathology
✅PEGASUS trial
✅Stroke fuels glioma progression
✅Adipocyte methionine in cancer cachexia
✅and more
www.nature.com/natcancer/volumes/7/issues/10 -
Nature Cancer
@NatureCancer
Attending #esmo26? Our Senior Editor, @Vin_Giacco, will be there and looks forward to connecting with the oncology community. Get in touch to discuss your latest research and publishing opportunities at Nature Cancer.
Vincenzo Giacco, PhD
@Vin_Giacco
Looking forward to attending the #esmo26 Annual Meeting in Madrid! I'll be there representing @NatureCancer and meeting the oncology community.
Happy to discuss your latest research, publishing opportunities, or ideas for the journal, please reach out.
See you in Madrid 🇪🇸 -
Nature Cancer
@NatureCancer
🧬New in Nature Cancer:
The phase 2 PEGASUS trial explores a ctDNA-guided strategy to de-escalate or escalate adjuvant therapy in patients with high-risk stage II and stage III colon cancer, moving us closer to more personalised treatment decisions.
www.nature.com/articles/s43018-026-01237-9 -
Nature Cancer
@NatureCancer
📢Read our Series on Next-generation cancer therapeutics featuring commissioned Reviews and a selection of articles published in Nature Cancer!
www.nature.com/collections/hehdeeciac -
Nature Cancer
@NatureCancer
📢Our September Issue is out!
Read about generative AI for digital pathology, cancer immunometabolism, GITR antibody optimization, l-glutamine combination therapy, and more
🔗www.nature.com/natcancer/volumes/7/issues/9 -
Nature Cancer
@NatureCancer
🚨New in Nature Cancer
Dr Gong and colleagues report findings from the phase 1 study evaluating L-glutamine + gemcitabine/nab-paclitaxel in untreated advanced PDAC. ORR 44%, including 12.5% CR, with median OS of 22 months. #pancreaticcancer @jgong15
www.nature.com/articles/s43018-026-01225-z -
Nature Cancer
@NatureCancer
Now Online!
The neuropeptide galanin impairs antitumor immunity in glioblastoma by interacting with its receptor GALR3 on monocytic myeloid-derived suppressor cells, promoting their infiltration and ferroptosis resistance.
www.nature.com/articles/s43018-026-01221-3 -
Nature Cancer
@NatureCancer
Our August issue is live!🏖️
Featuring copper dependency in AML, iron-mediated ferroptosis, GPNMB-directed CAR-T cell therapy, IDH1-mutant vaccine in phase 1 trial, and more
🔗www.nature.com/natcancer/volumes/7/issues/8 -
Nature Cancer
@NatureCancer
The full agenda for Reframing Precision Medicine is now live.
We created this event with the goal of moving medicine beyond theory to show how multi-omics, AI, and big data can make truly personalised care the norm.
Join us in London: invt.io/1txbmzq1h21 -
Nature Cancer
@NatureCancer
💫Online today
The Review on intratumor heterogeneity by @Jonathancmwan, @NickyMcGranahan and @CharlesSwanton
🔗www.nature.com/articles/s43018-026-01198-z
Check out the rest of the Series on Tumor Heterogeneity and Plasticity here: nature.com/collections/gfbbjcecif -
Nature Cancer reposted
Nature Conferences
@NatureConf
Join @NancyFGoodman, @Gilles_Vassal and 15 other global experts at our event with @StJudeResearch, looking to address urgent challenges and opportunities in childhood cancer care. Secure a seat and submit an abstract by Aug 6. go.nature.com/4sT18WF
-
Nature Cancer
@NatureCancer
☀️Check out our July issue !
✅Tertiary lymphoid structures
✅DNA vaccine for GBM
✅CAR T cell therapy in lung metastases
✅adjuvant chemotherapy in nasopharyngeal carcinoma
✅neutrophil-driven contact-dependent immune suppression
✅GABA in GBM
www.nature.com/natcancer/volumes/7/issues/7 -
Nature Cancer
@NatureCancer
🌟Online today
A micropeptide encoded by the lncRNA USP30-AS1 promotes tumor growth by attenuating cGAS–STING–type I IFN signaling in macrophages
www.nature.com/articles/s43018-026-01195-2 -
Nature Cancer reposted
Tullia Bruno, PhD
@BcellBruno
Great week for the Bruno lab for publications. Check out our new commentary on #tls in @NatureCancer
@PittTweet @UPMCHillmanCC
www.nature.com/articles/s43018-026-01188-1 -
Nature Cancer
@NatureCancer
In first-in-human phase 1 NOA16 trial, Platten and colleagues report the long-term clinical and immunological follow-up outcomes of a vaccine targeting mutant IDH1 in persons with astrocytoma. @Platten_lab
www.nature.com/articles/s43018-026-01199-y -
Nature Cancer
@NatureCancer
🌻Check out our June issue !
✅Metastatic dissemination in CRC
✅Immunotherapy in GBM
✅BH3 mimetics sensitization in AML
✅ctDNA and PSA to monitor prostate cancer
✅Methylation-based CNS tumor classification
and more
www.nature.com/natcancer/volumes/7/issues/6 -
Nature Cancer
@NatureCancer
Zemp at al. found GPNMB as a targetable antigen for MiT/TFE-family fusion-driven soft-part sarcoma and translocation RCC and tested GPNMB-directed CAR T cell therapy in preclinical models and in first-in-human trial.
Read the N&Vs: www.nature.com/articles/s43018-026-01201-7
www.nature.com/articles/s43018-026-01194-3 -
Nature Cancer
@NatureCancer
🚨Check out our last release
Bayik and colleagues show that inhibition of GABBR signaling extends survival in female glioblastoma models, highlighting the potential for sex-specific cancer treatments and the unique immune landscape shaped by GABA
www.nature.com/articles/s43018-026-01192-5 -
Nature Cancer
@NatureCancer
⭐️Online now
Iron level and ferroptosis impair antitumor efficacy of CAR-T cells.
by Dongrui Wang, Yongxian Hu, Pengxu Qian, He Huang & colleagues
www.nature.com/articles/s43018-026-01187-2 -
Nature Cancer
@NatureCancer
📢Online now!
@MoritzGerstung, Felix Sahm & co developed an AI algorithm that leverages H&E slides to classify central nervous system tumors into methylation-based subtypes reducing turnaround time to 12 min in prospective evaluation.
www.nature.com/articles/s43018-026-01186-3 -
Nature Cancer
@NatureCancer
⭐️Now online
In a large cohort of patients with ICB-treated glioblastoma, Catherine J. Wu & colleagues show that baseline mesenchymal transcriptional state predicts therapy response, and transition to non-mesenchymal state results in acquired resistance.
www.nature.com/articles/s43018-026-01179-2 -
Nature Cancer reposted
Hidehito HORINOUCHI
@HHorinouchi
🔥Bacterial engineering for cancer therapy
🆙 @NatureCancer
☑Engineered bacteria as living drug delivery systems for cytotoxics & immunotherapeutics
🎯Payload selection, controlled release & safety optimization are key for clinical translation
🎙Dr. Noah Chen @arpaialab
@OncoAlert @Larvol
www.nature.com/articles/s43018-026-01171-w -
Nature Cancer reposted
Nature Conferences
@NatureConf
Calling all scientists working on bedside omics, biomarkers, therapeutics, & precision health-related topics. Share your latest findings w/ global experts + @NatureMedicine @NatureCancer & @CommsMedicine editors at our inaugural Flagship.
Submit by 6/30> go.nature.com/4uTnDww -
Nature Cancer reposted
Jakob Weiss @_JakobWeiss
Delighted to share our @NatureCancer paper, out today, on determinants of ICB response in GBM (link in 🧵)
With bulk and single-nucleus genomic profiling of 181 ICB-treated tumors, we found that tumor RNA subtype (and not TMB!) predicts survival and shapes acquired resistance. -
Nature Cancer reposted
Jack Ghannam @JackYGhannam
Excited to share some of my PhD work out today in @NatureCancer! Integrating bulk and single-nucleus genomic approaches, we identify distinct determinants of survival and acquired resistance to ICB versus standard chemoradiation in glioblastoma. www.nature.com/articles/s43018-026-01179-2
-
Nature Cancer
@NatureCancer
🍓☀️Check out our May Issue, now live!
Including:
☑️Oncolytic virus and cytokine-based gene therapies
☑️Myeloid plasticity, part of our Series on Tumor Heterogeneity and Plasticity
☑️DeepFAN, a model for human-AI collaboration
and more!
www.nature.com/natcancer/volumes/7/issues/5 -
Nature Cancer
@NatureCancer
🚨New in Nature Cancer
Kimberly J. Perez and colleague show that adding the VDR agonist paricalcitol to gemcitabine + nab‑paclitaxel in metastatic pancreatic cancer is feasible and and provides early indications of TME remodeling @DanaFarber @Cancer
www.nature.com/articles/s43018-026-01165-8 -
Nature Cancer
@NatureCancer
Out today!
CD300ld, upregulated in pathologically activated neutrophils, mediates contact-dependent suppression of cytotoxic CD8+ T cells by binding to phosphatidylserine, inhibiting antitumor immune responses and revealing a targetable checkpoint pathway
www.nature.com/articles/s43018-026-01169-4 -
Nature Cancer
@NatureCancer
🌟Online now!
The Review on myeloid cell plasticity in cancer therapy by Dmitry Gabrilovich & colleagues @GabrilovichLab
🔗www.nature.com/articles/s43018-026-01159-6
Check out the rest of the Series on Tumor Heterogeneity and Plasticity here:
www.nature.com/collections/gfbbjcecif -
Nature Cancer
@NatureCancer
⭐Out today!
Read the phase I clinical trial on neoantigen DNA vaccine for patients with glioblastoma
www.nature.com/articles/s43018-026-01163-w -
Nature Cancer
@NatureCancer
⭐️Check out the Perspective on cellular neighborhoods in cancer by @LichunMa, @KaiTanLab1 & co
🔗www.nature.com/articles/s43018-025-01107-w
Part of our Series on Tumor Heterogeneity and Plasticity:
www.nature.com/collections/gfbbjcecif -
Nature Cancer
@NatureCancer
A phase 1 clinical trial now published @naturecancer
'Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors'
✒️By Hilde De Winter & colleagues
🔗www.nature.com/articles/s43018-026-01150-1 -
Nature Cancer
@NatureCancer
⭐️Don't miss this Review published @NatureCancer
as part of our Series on Tumor Heterogeneity and Plasticity
'Heterogeneity and plasticity of cancer-associated fibroblasts'
✒️By Ruth Scherz-Shouval, Mara Sherman and co-authors
🔗www.nature.com/articles/s43018-026-01146-x -
Nature Cancer
@NatureCancer
🔥Online now, a Review on EMT as driver of tumor cell plasticity
By @NietoAngela and @ruljc
Part of our Series on Tumor Heterogeneity and Plasticity: www.nature.com/collections/gfbbjcecif
www.nature.com/articles/s43018-026-01154-x -
Nature Cancer
@NatureCancer
Our Senior Editor Julieta Alfonso is excited to join the Europe's Cancer Immunotherapy CIMT Annual Meeting on May 11-13 2026 in Mainz. Please reach out to her if you are around! www.meeting.cimt.eu
-
Nature Cancer
@NatureCancer
🌷Our April Issue is out!
Featuring:
☑️Our Series on Tumor Heterogeneity and Plasticity
☑️CAR T cell therapy in solid tumors
☑️An erythrocyte–anti-PD1 conjugate
☑️Pediatric tumors classification using cfDNA methylation
and more!
www.nature.com/natcancer/volumes/7/issues/4 -
Nature Cancer
@NatureCancer
📢Today we launch our Series on Tumor Heterogeneity and Plasticity featuring commissioned Reviews and a selection of articles published in Nature Cancer!
Read about EMT, CAF plasticity, immune cell plasticity, cellular neighborhoods and more here:
🔗www.nature.com/collections/gfbbjcecif -
Nature Cancer reposted
Nature Conferences
@NatureConf
Reframing Precision Medicine tackles a defining challenge: how do we implement precision medicine at scale?
Attend to:
- Gain real-world insight.
- Explore AI & multi-omics.
- Connect across the ecosystem.
Early bird ends 30 April → save up to £400: go.nature.com/4tx2ZBP -
Nature Cancer
@NatureCancer
📰Now on Nature Cancer: Li and colleagues show a dual STING/PI3Kγ nano‑therapy counters immune suppression in pancreatic cancer, activating myeloid cells, limiting regulatory B cells, and improving immunotherapy efficacy #cancer
👉www.nature.com/articles/s43018-026-01158-7 -
Nature Cancer
@NatureCancer
Our Senior Editor Julieta Alfonso will be attending #tumormetabolism : Diet, #microbiome and Beyond, this June in Killarney with @KeystoneSymp! Looking forward to big ideas, bold science, and great conversations. keysym.us/KSTumorMetab26 #kstumormetab26
-
Nature Cancer
@NatureCancer
From November 11-12, we're bringing together global experts, researchers, clinicians, policymakers, and patient advocates to discuss challenges and research improving survival outcomes for childhood cancer patients @Vin_Giacco
Free to register: go.nature.com/4sS5kpJ
Nature Conferences
@NatureConf
Join us in November for a multi-disciplinary event exploring the latest research improving survival outcomes for childhood cancer patients. Hear from researchers, clinicians, policymakers, and more.
Free reg: go.nature.com/4sT18WF
@StJudeResearch @NatureCancer @NatureMedicine -
Nature Cancer
@NatureCancer
🌟New Perspective out today presents the recent advances in predicting TCR–epitope recognition and the therapeutic applications in cancer immunotherapy.
by @GfellerD and colleagues
🔗www.nature.com/articles/s43018-026-01144-z -
Nature Cancer
@NatureCancer
🌟Now in Nature Cancer, multi-omics analysis of nasopharyngeal carcinoma identifies molecular subtypes with distinct immune profiles and responses to induction chemotherapy.
🖊️by Jia-Xing Yue, Na Liu, Aihua Sun, Jun Ma & Fuchu He and colleagues
www.nature.com/articles/s43018-026-01149-8 -
Nature Cancer
@NatureCancer
🌟New study in Nature Cancer evaluates the clinical significance of early PSMA upregulation in patients with metastatic castrate-resistant prostate cancer treated with enzalutamide with or without 177Lu-PSMA-617.
by @drlouiseemmett & colleagues
www.nature.com/articles/s43018-026-01140-3 -
Nature Cancer
@NatureCancer
Article now online @NatureCancer
'Leptomeningeal metastatic cancer cells induce a permissive choroid plexus vasculature through extracellular-vesicle-derived 5-HIAA signaling'
✒️By Yudan Chi and colleagues
🔗 www.nature.com/articles/s43018-026-01145-y -
Nature Cancer
@NatureCancer
New REVIEW published @NatureCancer !
'Single-cell and spatial profiling in cancer biology and clinical oncology'
✏️By Benjamin Izar, Elham Azizi and co-authors
🔗www.nature.com/articles/s43018-026-01142-1 -
Nature Cancer
@NatureCancer
🗒️Technical Report now published @NatureCancer
'PRET is a few-shot system for pan-cancer recognition without example training'
By Xiaomeng Li, Kang Zhang, Qingling Zhang & colleagues
🔗 www.nature.com/articles/s43018-026-01141-2 -
Nature Cancer
@NatureCancer
🚨Our March issue is now live! Have a look at Nature Cancer issue featuring
✅HER2+ breast cancer
✅TNBC & immunotherapy
✅Proteomic imaging
✅m6A epitranscriptomics
✅AI in breast screening
✅GENEVA platform models
...and more...
www.nature.com/natcancer/volumes/7/issues/3 -
Nature Cancer
@NatureCancer
🌟Out today at Nature Cancer
Stromal cells and chemokine gradients organize the loss of tissue architecture in lymph nodes in B cell lymphoma
by Judith B. Zaugg, Daniel Hübschmann, Simon Haas & Sascha Dietrich & co
www.nature.com/articles/s43018-026-01136-z -
Nature Cancer
@NatureCancer
Now in Nature Cancer!
@rashmikmurthy and colleagues provide evidence suggesting clinical benefit with the combination of tucatinib, capecitabine and trastuzumab as systemic regimen for women with HER2+ leptomeningeal metastasis
www.nature.com/articles/s43018-026-01120-7 -
Nature Cancer
@NatureCancer
📢Come join our editorial team @NatureCancer
We're hiring an Associate or Senior Editor!
Apply to join our team in Shanghai, Beijing, Nanjing or Madrid.
⏲️Application deadline: March 29th
Details:
👉springernature.wd3.myworkdayjobs.com/SpringerNatureCareer… -
Nature Cancer
@NatureCancer
📢Hot off the press @NatureCancer
Don’t miss these 3 new Articles along with the accompanying News&Views on the use of AI in breast cancer screening!
Nature Cancer
@NatureCancer
‘Prospective evaluation of artificial intelligence integration into breast cancer screening in multiple workflow settings: the GEMINI study’
By Clarisse de Vries and colleagues
Link: www.nature.com/articles/s43018-026-01126-1
Nature Cancer
@NatureCancer
‘Diagnostic accuracy, fairness and clinical implementation of AI for breast cancer screening: results of multicenter retrospective and prospective technical feasibility studies’
By Christopher Kelly and colleagues
Link: www.nature.com/articles/s43018-026-01127-0
Nature Cancer
@NatureCancer
‘Impact of using artificial intelligence as a second reader in breast screening including arbitration’
By Lucy Warren and colleagues
Link: www.nature.com/articles/s43018-026-01128-z
Nature Cancer
@NatureCancer
News and Views: ‘AI for breast cancer screening’
By Allan Hackshaw & Rosalind Given-Wilson
Link: www.nature.com/articles/s43018-025-01109-8 -
Nature Cancer
@NatureCancer
🚨 Our February Issue is out!
Featuring:
☑️ Neoadjuvant PD‑1 in desmoplastic melanoma
☑️ FBXL2 inhibition sensitizes HER2‑neg breast cancer
☑️ Genomic model for prostate cancer screening
☑️ Organoid model for H3.3K27M glioma
…and more!
www.nature.com/natcancer/volumes/7/issues/2 -
Nature Cancer
@NatureCancer
🌟New Resource article
Read about the pancancer landscape of cancer-specific cell-free DNA methylation and fragmentomic features from plasma samples from 1,294 patients
✒️Yong Zeng, @MatLupien, @PughLab, Housheng Hansen He & colleagues
www.nature.com/articles/s43018-026-01116-3 -
Nature Cancer
@NatureCancer
PERSPECTIVE hot off the press @NatureCancer ! 'Setting higher standards for reports of microbial species in human cancers'
🔗nature.com/articles/s43018-026-01121-6
✒️By Steven Salzberg, Jacques Neefjes & Niranjan Nagarajan and co-authors
#tumormicrobiome -
Nature Cancer
@NatureCancer
🌟Out today in Nature Cancer, two automated tools to analyze prognostic spatial features of TNBC @MikeAngeloLab @JoleneRanek @NoahGreenwald
🔗www.nature.com/articles/s43018-026-01122-5
🔗www.nature.com/articles/s43018-026-01114-5
And read the associated News & Views from @hartjackson
www.nature.com/articles/s43018-026-01123-4
Nature Cancer
@NatureCancer
QUICHE is a computational method that analyzes proteomic imaging and detects differentially enriched cellular niches, including low-prevalence niches. The tool informs antitumor responses in triple-negative breast cancer.
www.nature.com/articles/s43018-026-01122-5
Nature Cancer
@NatureCancer
SpaceCat analyzes multiplex imaging data and establishes spatial patterns within triple-negative breast cancer microenvironment that are predictive of immune checkpoint blockade response across treatment time course.
www.nature.com/articles/s43018-026-01114-5 -
Nature Cancer
@NatureCancer
⭐Technical Report out today at Nature Cancer
The deep neural network M-PACT uses low-input cell-free DNA methylation profiles to classify pediatric brain tumors
🖊️By Paul A. Northcott & colleagues @StJudeResearch
www.nature.com/articles/s43018-026-01115-4 -
Nature Cancer reposted
UCLA Broad Stem Cell
@UCLAstemcell
Join us on Tuesday, Feb. 17 as Luca Danelli @NatureComms @NatureCancer presents, "Understanding the editorial process at Nature journals" at 12:30pm in Boyer 130. The seminar is open to all UCLA faculty, students and staff! 🐻
-
Nature Cancer
@NatureCancer
Meeting Report | Insights from ESMO Immuno-Oncology Congress 2025
www.nature.com/articles/s43018-026-01133-2 -
Nature Cancer
@NatureCancer
📢Don't miss this recently published @NatureCancer Article!
'METTL3-based epitranscriptomic editing screening identifies functional m6A sites in cancers'
✒️By Housheng Hansen He, Xin Xu and colleagues
🔗www.nature.com/articles/s43018-026-01117-2 -
Nature Cancer
@NatureCancer
❄️Our January Issue is out!
Featuring:
☑️immune atlas in multiple myeloma
☑️tumor microbiome in head & neck cancer
☑️MEK–RAF molecular glue against RAS/BRAF-mutant cancers
☑️atypical EMT
☑️CheckMate 77T phase 3 trial in patients with NSCLC
and more!
www.nature.com/natcancer/volumes/7/issues/1 -
Nature Cancer
@NatureCancer
🌟New Perspective at Nature Cancer
Tan and colleagues discuss recent advances in spatial omics and computational models that inform the classification and clinical relevance of cellular neighborhoods in cancer.
🔗www.nature.com/articles/s43018-025-01107-w
@cdktmw -
Nature Cancer
@NatureCancer
🌟New Perspective to read at Nature Cancer
Learn about the current clinical and preclinical evidence of the effects of GLP-1 medicines on cancer outcomes and their mechanism in cancer cells and the TME.
✏️Julian M. Yabut & @DanielJDrucker
www.nature.com/articles/s43018-025-01110-1 -
Nature Cancer
@NatureCancer
🚨 Check out our last clinical research:
In CheckMate 77T, @MARIANOPROVENCI et al. report improved outcomes for N2 NSCLC with perioperative nivolumab + chemotherapy
#nsclc #immunotherapy #clinicaltrials #oncology
🔗 www.nature.com/articles/s43018-025-01104-z -
Nature Cancer
@NatureCancer
🔎 Check out our latest clinical research:
Paolo Strati et al. report ZUMA‑14 trial results showing durable responses with axi‑cel + rituximab in refractory LBCL
#car_t #lbcl #clinicaltrial #immunotherapy
🔗 www.nature.com/articles/s43018-025-01102-1 -
Nature Cancer
@NatureCancer
🚨Don't miss this window-of-opportunity phase 2 RCT now published @NatureCancer:
'Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive #breastcancer'
✒️By Richard Baird and colleagues
🔗
www.nature.com/articles/s43018-025-01087-x -
Nature Cancer
@NatureCancer
🚨New Article now published @NatureCancer
'TGFβ induces an atypical #emt to evade #immune mechanosurveillance in #lungadenocarcinoma dormant #metastasis'
✏️By Joan Massagué and colleagues
🔗 www.nature.com/articles/s43018-025-01094-y -
Nature Cancer
@NatureCancer
📢Check out this Article published @NatureCancer
'The MEK–RAF molecular glue IK-595 has potent antitumor activity across RAS/MAPK pathway-altered cancers'
✒️By Jeffrey Ecsedy and colleagues
🔗www.nature.com/articles/s43018-025-01081-3 -
Nature Cancer
@NatureCancer
Check out this timely Review about the tumor immune microenvironment in glioblastoma by A. Golebiewska and colleagues @NatureCancer👇
doi.org/10.1038/s43018-025-01097-9 -
Nature Cancer
@NatureCancer
🎆New year, new papers at Nature Cancer!
The amount of tumor bacteria is now shown to influence immunotherapy outcomes in head and neck cancer in two papers out today:
🔗www.nature.com/articles/s43018-025-01067-1
🔗www.nature.com/articles/s43018-025-01068-0
With the associated N&Vs:
www.nature.com/articles/s43018-025-01074-2 -
Nature Cancer
@NatureCancer
🚨 Breakthrough for T cell cancers!
Suman Paul and colleagues developed an ADC targeting TRBC2 that kills malignant T cells while sparing most normal ones, offering a promising off-the-shelf therapy #cancerresearch #adc
🔗 www.nature.com/articles/s43018-025-01069-z -
Nature Cancer
@NatureCancer
🚨New Clinical Outlook published as part of the 2025-in-review @NatureCancer content!
✏️By Sandra Misale
'The evolving landscape of RAS-targeted therapies'
🔗www.nature.com/articles/s43018-025-01077-z -
Nature Cancer
@NatureCancer
⭐Check out this Comment published in the 2025 year-in-review @NatureCancer Focus Issue
✏️By Michelle Monje & Frank Winkler
'Key developments in the cancer neuroscience field'
🔗www.nature.com/articles/s43018-025-01082-2 -
Nature Cancer
@NatureCancer
🚨Check out this Technical Report published @NatureCancer
✒️By Tieliang Gong, Chen Li, Mireia Crispin-Ortuzar and colleagues
'SMMILe enables accurate spatial quantification in digital pathology using multiple-instance learning'
🔗www.nature.com/articles/s43018-025-01060-8?platform=oscar… -
Nature Cancer
@NatureCancer
🚨Nature Cancer’s 2025 In Review Focus is here! Discover the year’s most impactful developments in cancer research and oncology, with insights from leading experts and curated highlights from top studies.
www.nature.com/collections/icejjchcfj -
Nature Cancer
@NatureCancer
🚨Our latest ESMO meeting report 🔍 highlights the most impactful clinical trial updates driving progress in oncology 🧬. At Nature Cancer, we’re committed to fostering dialogue and collaboration with the clinical oncology community @myESMO
📰Read more: doi.org/10.1038/s43018-025-01095-x -
Nature Cancer
@NatureCancer
🌟 Check out new content @NatureCancer by Francisco Quintana and collaborators 👇
doi.org/10.1038/s43018-025-01070-6 -
Nature Cancer reposted
Anirban Maitra
@Aiims1742
Companion paper in @NatureCancer from @StraussmanR @WeizmannScience with comparable findings:
Characterization of the tumor microbiome of brain metastases and glioblastoma reveals tumor-type-specific and location-specific microbial signatures
www.nature.com/articles/s43018-025-01073-3
Anirban Maitra
@Aiims1742
Provocative new data in @NatureMedicine from @JenWargoMD @nadim_ajami & colleagues @MDAndersonNews
Microbial signals in primary and metastatic brain tumors
www.nature.com/articles/s41591-025-03957-4
Orthogonal validation using multiple platforms provides support for this observation -
Nature Cancer
@NatureCancer
🚨New article published at Nature Cancer
Using multiple visualization and profiling methods, Gigi et al. characterize the microbiome diversity of 322 brain tumors including brain metastases and glioblastomas.
www.nature.com/articles/s43018-025-01073-3 -
Nature Cancer
@NatureCancer
New article published @NatureCancer !
'Spatiotemporal control of SMARCA5 by a MAPK–RUNX1 axis distinguishes mutant KRAS-driven pancreatic malignancy from tissue regeneration'
✏️By Charles David, Mo Chen and colleagues
🔗www.nature.com/articles/s43018-025-01065-3 -
Nature Cancer
@NatureCancer
Article now published @NatureCancer !
'Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial'
✒️By Ye Li, Peng Wang and colleagues
🔗www.nature.com/articles/s43018-025-01058-2 -
Nature Cancer
@NatureCancer
🍂In case you haven't yet done so, check out our October issue now!
🔗www.nature.com/natcancer/volumes/6/issues/10 -
Nature Cancer reposted
Arndt Vogel
@ArndtVogel
Cryoablation plus sintilimab & lenvatinib in advanced intrahepatic cholangiocarcinoma: a phase 2 trial
@NatureCancer
doi.org/10.1038/s43018-025-01058-2
👉Interesting approach
👉ORR 75%, mPFS 16.8 mo, mOS 25.4 months
🧐Seems to be very promising
@myESMO @EASLedu @ILCAnews @curecca -
Nature Cancer
@NatureCancer
Tao et al. show that SCRN1 acts as a scaffold to facilitate GPX4 phosphorylation by STK38, thereby preventing chaperone-mediated autophagy of GPX4 and subsequent ferroptosis in patient-derived organoids and mouse models for hepatocellular carcinoma.
🔗www.nature.com/articles/s43018-025-01061-7 -
Nature Cancer
@NatureCancer
📢 Our Senior Editor @Vin_Giacco will be attending ESMO Conference in Berlin #esmo25. If you’d like to discuss your research or explore opportunities with Nature Cancer, feel free to reach out and connect during the event @myESMO
-
Nature Cancer
@NatureCancer
Our Associate Editor Julieta Alfonso is attending the EACR Conference on Cancer Neuroscience in Bilbao, Spain, 14-16 October 2025, reach out to her!
www.eacr.org/conference/cancerneuroscience2025 #cancerresearch #oncology -
Nature Cancer
@NatureCancer
🌟Latest online content: A. Tsankov and colleagues present a new study included in the HTAN consortium
doi.org/10.1038/s43018-025-01053-7 -
Nature Cancer
@NatureCancer
🌟Check out this new study @NatureCancer by Thoas Fioretos and colleagues 👇
doi.org/10.1038/s43018-025-01054-6 -
Nature Cancer
@NatureCancer
Save the date! We are hosting the @cassyniapp webinar "Inflammatory cell death and anti-tumor immunity". Join us and our speakers Dmitri Krysko, Judy Lieberman, Lorenzo Galluzzi @deadoc80 and Pascal Meier
📅 Tuesday 14th Oct 2025
⏰ 16.00 PM (GMT+1)
cassyni.com/events/QAERnqXA3ZqH3FzTrAmm5P?cb=0.4n0l -
Nature Cancer
@NatureCancer
🚨Check out this article published now @NatureCancer !
✏️By Scott Lowe and colleagues
'SMAD4 induces opposite effects on metastatic growth from pancreatic tumors depending on the organ of residence'
🔗www.nature.com/articles/s43018-025-01047-5 -
Nature Cancer
@NatureCancer
🍂Our September issue is OUT NOW!
Featuring, among others:
- A Perspective on #drugconjugates
- #immunotherapy studies
- research on GBM invasion
- method for #singlecell analyses of #ctcs
🔗www.nature.com/natcancer/volumes/6/issues/9 -
Nature Cancer
@NatureCancer
Check out this recent Review published @NatureCancer
✒️By Dario Neri and colleagues
'Past, present and future of #drugconjugates for #cancertherapy'
🔗www.nature.com/articles/s43018-025-01042-w -
Nature Cancer
@NatureCancer
🚨Our Senior Editor Elena Skourti @skourti_elena will be at the #esmo Molecular Analysis for Precision Oncology Congress over the next two days. Find her and talk to her about your research!
-
Nature Cancer
@NatureCancer
Our Associate Editor Julieta Alfonso
is attending the 12th International Heidelberg Symposium on Stem Cells and Cancer – SCC2025 stem-cells-cancer.de/event/scc2025/
Please find her and connect! -
Nature Cancer
@NatureCancer
Shao et al. developed an MRI–pathology-based foundation model to assess the pathology of prostate cancer for diagnosis and grading of tumors. The model is noninvasive and outperforms current pathological assessments.
www.nature.com/articles/s43018-025-01041-x -
Nature Cancer
@NatureCancer
Resource article published now @NatureCancer
'Spatiotemporal analyses of the pan-cancer single-cell landscape reveal widespread profibrotic ecotypes associated with tumor immunity'
✒️By Qiu Wu, Chenfei Wang and colleagues
🔗
www.nature.com/articles/s43018-025-01039-5 -
Nature Cancer
@NatureCancer
Article now ONLINE @NatureCancer !
'A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer'
✏️By Jianqin Lu and colleagues
🔗 www.nature.com/articles/s43018-025-01029-7 -
Nature Cancer
@NatureCancer
🤩Our associate Editor Julieta Alfonso will attend the ISREC-SCCL Symposium -at Lausanne 1st-4rd September- and will be happy to connect with you, please reach out during the meeting!
isrec-sccl-symposium.epfl.ch -
Nature Cancer
@NatureCancer
📢New Article now published @NatureCancer
'Colorectal cancer cells hijack a brain–gut polysynaptic circuit from the lateral septum to enteric neurons to sustain tumor growth'
✏️By Tian-Ming Gao, Jian-Ming Li and colleagues
🔗www.nature.com/articles/s43018-025-01033-x -
Nature Cancer
@NatureCancer
⭐️New Article published @NatureCancer
'Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling'
✒️By Wies Vallentgoed and colleagues
🔗www.nature.com/articles/s43018-025-01023-z -
Nature Cancer
@NatureCancer
🚨New REVIEW article online @NatureCancer
'Prospects for ferroptosis therapies in cancer'
✒️By Jessalyn Ubellacker & Scott Dixon
🔗www.nature.com/articles/s43018-025-01037-7 -
Nature Cancer
@NatureCancer
Our August issue is OUT NOW! ☀️
Check it out here:
🔗www.nature.com/natcancer/volumes/6/issues/8
⭐️Featuring:
- review on #nanotechnology for immuno-oncology
- review on #ferroptosis for #cancertherapy
- AI in clinical oncology
- cancer #cachexia
- #immunotherapy clinical trial -
Nature Cancer
@NatureCancer
🚨 New article alert! 🚨 Check out our last release by @IrenemGhobrial and colleagues on "SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors" @DanaFarber
👉www.nature.com/articles/s43018-025-01006-0 -
Nature Cancer
@NatureCancer
👇Check out new Review article @NatureCancer on cancer nanotechnology by Betty Kim and colleagues
doi.org/10.1038/s43018-025-01025-x -
Nature Cancer
@NatureCancer
🚨Don't miss the July issue of Nature Cancer!
Check it out here:
🔗www.nature.com/natcancer/volumes/6/issues/7
Featuring:
⭐️Review on clonal hematopoiesis in cancer
⭐️Review on CAR engineering for cancer therapy
⭐️immunotherapy
⭐️AI for tumour classification
⭐️single-cell analyses in B-ALL -
Nature Cancer
@NatureCancer
🚨ARTICLE now published @NatureCancer !
✏️By Valsamo Anagnostou and colleagues
'Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer'
🔗www.nature.com/articles/s43018-025-01018-w -
Nature Cancer
@NatureCancer
📢New Article published @NatureCancer !
✒️By Christopher Klebanoff and colleagues
'CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit'
🔗www.nature.com/articles/s43018-025-01009-x -
Nature Cancer
@NatureCancer
🌟New article online @NatureCancer
by L. Galluzzi's team 👇
doi.org/10.1038/s43018-025-01007-z -
Nature Cancer
@NatureCancer
Check out a new Review article on clonal hematopoiesis by Jen Trowbridge and collaborators @NatureCancer
doi.org/10.1038/s43018-025-01014-0 -
Nature Cancer
@NatureCancer
🌟Another timely Review @NatureCancer, by G. Dotti and collaborators 👇
doi.org/10.1038/s43018-025-01015-z -
Nature Cancer
@NatureCancer
Our Senior Editor Elena Skourti @skourti_elena is attending the @AACR Special Conference in Artificial Intelligence & Machine Learning this week. If you are there, find her and connect!
-
Nature Cancer
@NatureCancer
🚨 Clinical Trial published @NatureCancer !
David Cibula and colleagues report on the final outcome of the SENTIX international trial, assessing sentinel LN biopsy without systematic pelvic lymphadenectomy in early-stage cervical cancer.
🔗www.nature.com/articles/s43018-025-01016-y -
Nature Cancer
@NatureCancer
🚨New Article Alert from @NatureCancer !
'Self-amplifying NRF2–EZH2 epigenetic loop converts KRAS-initiated progenitors to invasive pancreatic cancer'
✏️ By Michael Karin and colleagues
🔗 www.nature.com/articles/s43018-025-01003-3 -
Nature Cancer
@NatureCancer
📢Another Article ONLINE @NatureCancer
'Profiling antigen-binding affinity of B cell repertoires in tumors by deep learning predicts immune-checkpoint inhibitor treatment outcomes'
✒️By Junzhou Huang, David Gerber, Tao Wang and colleagues
🔗www.nature.com/articles/s43018-025-01001-5 -
Nature Cancer
@NatureCancer
🚨New Article ONLINE @natureCancer !
'Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features'
✒️ By John Dick, Charles Mullighan and colleagues
🔗www.nature.com/articles/s43018-025-00987-2 -
Nature Cancer
@NatureCancer
📢Another REVIEW now ONLINE @Naturecancer 'Advancing therapeutics in small-cell lung cancer'
✒️By Anish Thomas, Chirayu Mohindroo & Giuseppe Giaccone
🔗www.nature.com/articles/s43018-025-00996-1 -
Nature Cancer
@NatureCancer
🚨Read this REVIEW published @NatureCancer !
'The tumor microenvironment’s role in the response to immune checkpoint blockade'
✏️By Vassiliki Boussiotis and co-authors
🔗www.nature.com/articles/s43018-025-00986-3 -
Nature Cancer
@NatureCancer
🚨 New article alert! 🚨 Check out our last release Christophe Le Tourneau and colleague on "Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial"
👉 www.nature.com/articles/s43018-025-01004-2 -
Nature Cancer
@NatureCancer
New Article out @NatureCancer
'p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy'
✒️By Linda McAllister-Lucas, Peter Lucas, Dong Hu and colleagues
🔗www.nature.com/articles/s43018-025-00969-4 -
Nature Cancer
@NatureCancer
⭐️New Article ONLINE @NatureCancer !
Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles
✏️By Xiaorui Wang and colleagues
🔗www.nature.com/articles/s43018-025-00997-0 -
Nature Cancer
@NatureCancer
📢We’ve partnered with MD Anderson to explore recent breakthroughs in understanding the tumor ecosystem and how its various components influence cancer development, progression, diagnosis, and treatment. Learn more and save your seat!
🔗go.nature.com/44cJT9Z -
Nature Cancer
@NatureCancer
Nature Cancer
@NatureCancer
🚨Our JUNE Issue is OUT NOW! ☀️
Check it out here:
🔗www.nature.com/natcancer/volumes/6/issues/6 -
Nature Cancer
@NatureCancer
🚨Our JUNE Issue is OUT NOW! ☀️
Check it out here:
🔗www.nature.com/natcancer/volumes/6/issues/6 -
Nature Cancer
@NatureCancer
📢New Article published @NatureCancer !
'Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation'
✒️By Cédric Blanpain and colleagues
🔗www.nature.com/articles/s43018-025-00994-3 -
Nature Cancer
@NatureCancer
🚨 New article alert! 🚨 Check out our last release by Eric M. Thompson and colleagues, testing a peptide vaccine in CAYA with recurrent high-grade glioma and medulloblastoma in their phase I trial 🧠
👉 www.nature.com/articles/s43018-025-00998-z -
Nature Cancer
@NatureCancer
Our Senior Editor Elena Skourti @skourti_elena is attending the @pezcoller Symposium this week. If you are there, find her and connect!
-
Nature Cancer
@NatureCancer
🚨Join us for this webinar TODAY!
Nature Cancer
@NatureCancer
🛎️LAST CHANCE to register for tomorrow's webinar on Liquid Biopsies in Clinical Oncology hosted by
@NatureCancer & @NatureBiotech
🔗cassyni.com/events/5evgfsJt5tQyTywGypPR8h?ei1egj
⏰Wednesday 11th June 2025 10am ET/3pm BST
⭐️Speakers:
Caroline Dive
Lillian Siu
Chairs: Eleni Skourti & Barbara Cheifet -
Nature Cancer
@NatureCancer
🛎️LAST CHANCE to register for tomorrow's webinar on Liquid Biopsies in Clinical Oncology hosted by
@NatureCancer & @NatureBiotech
🔗cassyni.com/events/5evgfsJt5tQyTywGypPR8h?ei1egj
⏰Wednesday 11th June 2025 10am ET/3pm BST
⭐️Speakers:
Caroline Dive
Lillian Siu
Chairs: Eleni Skourti & Barbara Cheifet -
Nature Cancer
@NatureCancer
📢Don't miss this recent REVIEW published at Nature Cancer:
'The diverse roles of the circadian clock in cancer'
✏️By Nicholas Pannunzio, Selma Masri and colleagues
🔗www.nature.com/articles/s43018-025-00981-8 -
Nature Cancer
@NatureCancer
🚨REVIEW ARTICLE JUST OUT @NatureCancer !
'The current and emerging #immunotherapy paradigm in small-cell #lungcancer'
✏️By Lauren Byers, Jianjun Zhang and colleagues
🔗www.nature.com/articles/s43018-025-00992-5 -
Nature Cancer
@NatureCancer
📢Article now online @NatureCancer
'Skeletal muscle endothelial dysfunction through the activin A–PGC1α axis drives progression of cancer cachexia'
✏️By Young-Mee Kim, Jalees Rehman and colleagues
🔗www.nature.com/articles/s43018-025-00975-6 -
Nature Cancer
@NatureCancer
🔔New ARTICLE now online!
'Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic microRNAs and receptor–ligand interactions'
✏️By Mariella Fillbin and colleagues
🔗www.nature.com/articles/s43018-025-00964-9 -
Nature Cancer
@NatureCancer
🔔Take a look at this article now published @NatureCancer !
'Tumor antigens preferentially derive from unmutated genomic sequences in #melanoma and non-small cell #lungcancer'
✏️By Pierre Thibault, Claude Perreault and colleagues
🔗www.nature.com/articles/s43018-025-00979-2 -
Nature Cancer
@NatureCancer
🛎️Register NOW for the webinar on Liquid Biopsies in Clinical Oncology hosted by @NatureCancer and @NatureBiotech!
🔗cassyni.com/events/5evgfsJt5tQyTywGypPR8h?ru4byo
⭐️Speakers:
Caroline Dive
Lillian Siu
⏰Wednesday 11th June 2025, 10am ET/3pm UK time Chairs: Eleni Skourti & Barbara Chiefet -
Nature Cancer
@NatureCancer
🔔We’ve partnered with MD Anderson to explore recent breakthroughs in understanding the tumor ecosystem and how its various components influence cancer development, progression, diagnosis, and treatment. Learn more and save your seat:
go.nature.com/44cJT9Z -
Nature Cancer reposted
Vincenzo Giacco, PhD
@Vin_Giacco
Task force of oncology editors reunited to support the cancer community at #asco25! Even if the work makes us compatitors at times, we're all friends in the fight. 💪❤️ @WisdomVania
@NatureCancer
@NatureMedicine
@TheLancet
@TheLancetOncol -
Nature Cancer
@NatureCancer
Nature Cancer is at #asco25! Our Senior Editor @Vin_Giacco will be there—get in touch if you are interested in learning more about the journal or just want to chat about the latest in cancer research 🧬
Vincenzo Giacco, PhD
@Vin_Giacco
Excited to be attending #asco25! If you're curious about Nature Cancer or want to explore publishing opportunities, come say hello. I'm always happy to connect and chat about research—looking forward to insightful conversations with the oncology community! @NatureCancer @ASCO
-
Nature Cancer
@NatureCancer
Join us for discussions and panels on the latest research advancing our understanding of the tumor ecosystem and its influence over cancer development and treatment @NatureConf @NaturePortfolio
👉natureconferences.streamgo.live/tumor-ecosystem/register?… -
Nature Cancer
@NatureCancer
🛎️Register NOW for the webinar on Liquid Biopsies in Clinical Oncology hosted by @NatureCancer and @NatureBiotech!
🔗cassyni.com/events/5evgfsJt5tQyTywGypPR8h?lva718
⭐️Speakers:
Caroline Dive
Lillian Siu
⏰Wednesday 11th June 2025, 10am ET/3pm UK time
Chairs: Eleni Skourti & Barbara Chiefet -
Nature Cancer
@NatureCancer
New online content 👇Check out the work from Vanini and colleagues on aging-related effects on CAR-T cell therapy
doi.org/10.1038/s43018-025-00982-7 -
Nature Cancer
@NatureCancer
Check the latest article by M. Werner-Klein and colleagues on melanoma metastatic colonization:
doi.org/10.1038/s43018-025-00963-w -
Nature Cancer
@NatureCancer
🔔Register now!
'The Tumour Ecosystem' Nature Conference
Nature Conferences
@NatureConf
Register your interest to attend a free conference exploring breakthroughs in understanding the #tumor ecosystem and its influence in #cancer development, progression, diagnosis, and treatment.
👉go.nature.com/44vavDt
@MDAndersonNews @nature @NatureCancer @NatureRevCancer -
Nature Cancer
@NatureCancer
Check out this Research Article now online @NatureCancer
Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer
By Noelia Tarazona and colleagues
www.nature.com/articles/s43018-025-00960-z -
Nature Cancer
@NatureCancer
Resource article now online @NatureCancer
'An organoid library unveils subtype-specific IGF-1 dependency via a YAP–AP1 axis in human small cell lung cancer'
✏️By Toshiro Sato and colleagues
📎www.nature.com/articles/s43018-025-00945-y -
Nature Cancer
@NatureCancer
RESEARCH ARTICLE NOW ONLINE @NatureCancer !
'PILRα on tumor cells interacts with the T cell surface protein CD99 to suppress antitumor immunity'
✏️By Lin Xia, Wen-xin Luo, Ning-shao Xia, Wen Liu and colleagues
Check it out here:
📎 www.nature.com/articles/s43018-025-00958-7 -
Nature Cancer
@NatureCancer
Our editor Elena Skourti will be attending
the #ismrc 2025 on liquid biopsies in Nice later this week!
Reach out to her to discuss your ongoing research! -
Nature Cancer
@NatureCancer
Inside April Issue: have a look at Nature Cancer issue featuring GEP-NETs, CART, prostate cancer, renal cell carcinoma, bacteria in cancer therapy, gallbladder lesions, lung cancer, ESMO TAT reports, and much more
👉www.nature.com/natcancer/ -
Nature Cancer
@NatureCancer
🚨Research Article now published @NatureCancer
✏️By Fengfeng Cai, Ningzi Guan & Haifeng Ye and collleagues 'Engineered bacteria for near-infrared light-inducible expression of #cancertherapeutics'
🔗www.nature.com/articles/s43018-025-00932-3 -
Nature Cancer
@NatureCancer
ONLINE now! @naturecancer
✏️By Helen He Zhu and colleagues: 'A Gremlin 1-expressing splenic niche cell population restrains chronic myeloid leukemia by antagonizing the BMP pathway'
🔗www.nature.com/articles/s43018-025-00933-2 -
Nature Cancer
@NatureCancer
🚨Check out this #phase2 clinical trial of odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma published at @naturecancer by Won Seog Kim and colleagues:
www.nature.com/articles/s43018-025-00921-6 -
Nature Cancer
@NatureCancer
🚨 New article alert! 🚨 Check out our last release by Guillaume Cartron @CHU_Montpellier and colleagues on "Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study".
Read more here: www.nature.com/articles/s43018-025-00941-2 -
Nature Cancer
@NatureCancer
Fengfeng Cai, Ningzi Guan & Haifeng Ye and team report the design and characterization of an optogenetic platform for the dynamic control of protein expression and secretion by engineered bacteria, with implications for cancer therapy.
⬇️
www.nature.com/articles/s43018-025-00932-3 -
Nature Cancer
@NatureCancer
Helen He Zhu and colleagues show that a subpopulation of spleen-derived fibroblasts secrete Gremlin 1, which suppresses chronic myeloid leukemia progression by inducing leukemia stem cell apoptosis through the BMP signaling pathway.
⬇️
www.nature.com/articles/s43018-025-00933-2 -
Nature Cancer
@NatureCancer
Kim and colleagues perform a phase 2 clinical trial (ELM-2) of odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma and report on the primary analyses of the efficacy and safety profile.
⬇️
www.nature.com/articles/s43018-025-00921-6 -
Nature Cancer
@NatureCancer
Sylvain Simon & Stanley Riddell and team report the design and characterization of monospecific and bispecific synthetic chimeric TCR, conferring increased antigen sensitivity and antitumor activity in B cell malignancies and multiple myeloma.
⬇️
www.nature.com/articles/s43018-025-00927-0 -
Nature Cancer
@NatureCancer
Hanqiu Zheng and colleagues report that targeting both the death domain and the paracaspase domain of MALT1 with antisense oligonucleotides sensitizes resistant tumors to immune-checkpoint inhibition.
@Tsinghua_Uni
⬇️
www.nature.com/articles/s43018-025-00930-5 -
Nature Cancer
@NatureCancer
By integrating single-cell RNA and physically interacting cell sequencing analysis, here Cohen and colleagues report that neutrophils are enriched in physical crosstalk with breast tumor cells, promoting cancer aggressiveness.
by @meravcohen8 & team
⬇️
www.nature.com/articles/s43018-025-00924-3 -
Nature Cancer
@NatureCancer
Phase 2 single-arm #clinicaltrial of neoadjuvant cabozantinib in patients with locally advanced nonmetastatic ccRCC, assesses efficacy and finds antitumor CD8+ T cell response activation upon treatment.
by @bilenma @virajmaster @HaydnKissick
⬇️
www.nature.com/articles/s43018-025-00922-5 -
Nature Cancer
@NatureCancer
Schrank et al. report the design and characterization of an antibody–toxin conjugate targeting CD47, promoting anti-tumor immunity in preclinical cancer models.
⬇️
www.nature.com/articles/s43018-025-00919-0 -
Nature Cancer
@NatureCancer
Aurelien Marabelle et al. present updated data from the KEYNOTE-158 trial after ~4.5 years of follow-up, reporting an overall response rate of 34% and a median OS of 19.8 months in participants with MSI-H/MMR advanced noncolorectal solid tumors.
www.nature.com/articles/s43018-024-00894-y -
Nature Cancer
@NatureCancer
Ajay Goel, Fan Bai & Guoxiang Cai and team show through single-cell and functional data that TME remodeling promotes peritoneal metastasis of CRC through microbiome dysbiosis, neutrophil recruitment and mesenchymal transition of mesothelial cells.
⬇️
www.nature.com/articles/s43018-025-00910-9
Nature Cancer
@NatureCancer
Read the associated News&Views here: www.nature.com/articles/s43018-024-00878-y
-
Nature Cancer
@NatureCancer
Yuzhang Jiang, Haiping Hao, Yibei Xiao & Peng Yang and colleagues present a small-molecule inhibitor for ADAR1 and show that its use is therapeutically beneficial in the context of prostate cancer.
👇
www.nature.com/articles/s43018-025-00907-4 -
Nature Cancer
@NatureCancer
David G. Kirsch, Yanqing Gong & Yi Fan and colleagues show that FLASH radiation promotes proinflammatory polarization of tumor-associated macrophages, which in turn increases T cell influx in medulloblastoma and synergizes with CAR-T cell therapy.
www.nature.com/articles/s43018-025-00905-6 -
Nature Cancer
@NatureCancer
🚨 New article alert! 🚨 Check out our last release by the team of Bando H. et colleagues on "safety and efficacy of the anti-PD-L1 antibody atezolizumab following definitive CRT in patients with unresectable, locally advanced ESCC".
👇
doi.org/10.1038/s43018-025-00918-1 -
Nature Cancer
@NatureCancer
New Review from Tracy McGaha and colleagues in our last issue, check out 👇
doi.org/10.1038/s43018-025-00909-2 -
Nature Cancer
@NatureCancer
📢Check out this Research Article by Jens Kleesiek, Martin Schuler, Frederick Klauschen and colleagues @NatureCancer
'Decoding #pancancer treatment outcomes using #multimodal real-world data and explainable #artificialintelligence'
🔗www.nature.com/articles/s43018-024-00891-1 -
Nature Cancer
@NatureCancer
ONLINE NOW! @NatureCancer
'Spatially resolved transcriptomics and graph-based #deeplearning improve accuracy of routine #cnstumor #diagnostics'
✏️By Dieter Henrik Heiland & Felix Sahm and colleagues
🔗 www.nature.com/articles/s43018-024-00904-z
#spatialtranscriptomics -
Nature Cancer
@NatureCancer
🎂Our 5-YEAR ANNIVERSARY Issue is now ONLINE!
@NatureCancer
Find it here:
📎www.nature.com/natcancer/volumes/6/issues/1
We celebrate this milestone, sharing with you a collection of:
⭐️Reviews and opinion pieces
⭐️Research articles
on key developments in #cancerresearch and #oncology -
Nature Cancer
@NatureCancer
Online now!
TRIM28-dependent developmental heterogeneity determines cancer susceptibility through distinct epigenetic states
🖊️by Ilaria Panzeri & John Andrew Pospisilik and colleagues
@Bi0lilla @PospisilikJ
👇
www.nature.com/articles/s43018-024-00900-3 -
Nature Cancer
@NatureCancer
Online now!
@sibilia_maria and team propose a strategy to boost immunotherapy by combining topically applied TLR7/8 agonists with systemic interferon-I, sensitizing dendritic cells to produce IL-12 for tumor clearance
👇
www.nature.com/articles/s43018-024-00889-9 -
Nature Cancer
@NatureCancer
Online now!
@CantorLab reports that increased DNA end resection in BRCA-deficient, PARP inhibitor-resistant cancers leads to increased sensitivity to DNA nicks, limiting tumor formation in mice, and propose the therapeutic exploration of nickases
👇
www.nature.com/articles/s43018-024-00902-1 -
Nature Cancer
@NatureCancer
Online Now
@PpuigserverB and team show that genetic targeting of specific mitochondrial respiratory complex I subunits in melanoma and breast cancer cells boosts tumor immune surveillance via upregulation of antigen-processing and presentation components
www.nature.com/articles/s43018-024-00895-x -
Nature Cancer
@NatureCancer
🚨Don't miss The #htan live webinar later today!
🔗 www.workcast.com/register?cpak=2277554086809869
With HTAN leaders: Li Ding, Ken Lau, Shannon Hughes and Michael Snyder
Chaired by: Alexia-Ileana Zaromytidou (Chief Editor, Nature Cancer)
Produced by: Nature/Nature Portfolio -
Nature Cancer
@NatureCancer
Reach out to our editor Julieta Alfonso at @KeystoneSymp from next Saturday 18th January "Neural Influence on Cancer, Tumor Microenvironment and Cancer Immunology"
-
Nature Cancer
@NatureCancer
💫New Article
Ongoing replication stress pathways and T cell clonal responses differentiate liver and lung recurrence and are associated with different clinical outcomes in PDAC.
✏️by Jason Link & Rosalie Sears and team
www.nature.com/articles/s43018-024-00881-3 -
Nature Cancer
@NatureCancer
💫New Article
@dhruva_biswas , @nbirkbak & @CharlesSwanton and team present a clonal expression signature, ORACLE, which, in combination with clinicopathological and molecular risk factors, can predict survival of patients with lung adenocarcinoma.
www.nature.com/articles/s43018-024-00883-1 -
Nature Cancer
@NatureCancer
💫Now Online
@DrChoueiri, @BraunMDPhD & @ShuklaSachet and teams profiled exceptional responders to immunotherapy in renal cell carcinoma; such responses could be related to tertiary lymphoid structures, clonal neoantigen load and altered metabolism.
www.nature.com/articles/s43018-024-00896-w -
Nature Cancer reposted
Dana-Farber News
@DanaFarberNews
New research in @NatureCancer examines genomic and transcriptomic data for insight into what may lead to exceptional responses to immunotherapy in advanced #kidneycancer. Collaboration co-led by @DrChoueiri @DanaFarber_GU @MDAndersonNews @YaleMed
-
Nature Cancer
@NatureCancer
Now online - Article
"Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling"
✏️Roberto Würth & Andreas Trumpp and team @DKFZ
www.nature.com/articles/s43018-024-00882-2 -
Nature Cancer
@NatureCancer
💫New Article online at Nature Cancer
"Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer"
www.nature.com/articles/s43018-024-00876-0
✏️Francesca Ciccarelli @fcicca and team
@TheCrick -
Nature Cancer
@NatureCancer
📒Systematic review @NatureCancer NOW ONLINE!
'The global impact of the #covid19 pandemic on delays and disruptions in #cancercareservices'
✏️ By Richa Shah and co-authors
Read it here:
🔗www.nature.com/articles/s43018-024-00880-4 -
Nature Cancer
@NatureCancer
⭐️In case you haven't yet checked it out, don't miss the #newpis in #cancerresearch Viewpoint ONLINE @NatureCancer, featuring in the 2024 in Review Focus Issue!
'The 2024 generation'
🔗doi.org/10.1038/s43018-024-00866-2 -
Nature Cancer
@NatureCancer
📃Don't miss this Comment @NatureCancer 's Focus Issue - 2024 in Review:
'Toward clinical applications of #spatialomics in #cancerresearch'
✏️By Cameron Walker & Michael Angelo
🔗doi.org/10.1038/s43018-024-00868-0 -
Nature Cancer
@NatureCancer
As part of our Focus Issue '2024 in Review', we are excited to share with you the Clinical Outlook on:
'T cells lead the charge against solid tumors'
✏️by Rigel Kishton & Nicholas Restifo @nrestifo
🔗doi.org/10.1038/s43018-024-00860-8 -
Nature Cancer
@NatureCancer
⭐️Check out this News Feature:
'Beyond the hype of AI in cancer R&D'
✏️by Melanie Senior
@NatureCancer 's Focus Issue #2024inreview
doi.org/10.1038/s43018-024-00857-3🔗 -
Nature Cancer
@NatureCancer
🚨As we are bidding goodbye to 2024, our editorial team has highlighted a collection of impressive studies across the #cancerresearch areas through 12 Research Highlights!
Check them out within our 2024 in Review Focus Issue here:
🔗www.nature.com/collections/chiegfhchj -
Nature Cancer
@NatureCancer
🚨Don't miss this Comment @NatureCancer on
'Navigating CAR-T cell therapy long-term complications'
by Céline Grégoire & J. Joseph Melenhorst @j_melenhorst
🔗doi.org/10.1038/s43018-024-00867-1
part of our Focus Issue - 2024 in Review! -
Nature Cancer
@NatureCancer
📃Don't miss the Comment now ONLINE @NatureCancer
on 'How AI agents will change cancer research and oncology'
by Aviv Regev, Jakob Nikolas Kather @jnkath and co-authors
🔗doi.org/10.1038/s43018-024-00861-7
featuring into our year-in-review Focus Issue! -
Nature Cancer
@NatureCancer
🚨Check out the @NatureCancer Editorial featuring in our #2024inreview Focus Issue!
'The highs and lows of 2024'
overviewing the Focus Issue exciting content!
🔗doi.org/10.1038/s43018-024-00885-z -
Nature Cancer
@NatureCancer
📃News feature ONLINE now! @NatureCancer
featuring in our Focus Issue 2024 in Review:
'Cancer drug approvals and setbacks in 2024'
✏️By Elie Dolgin
🔗doi.org/10.1038/s43018-024-00873-3 -
Nature Cancer
@NatureCancer
⭐️Don't miss our 2024 year-in-review Focus Issue!
🔗www.nature.com/collections/chiegfhchj
Featuring:
*Editorial on 2024 #cancerresearch highlights
*#newpis Viewpoint
*#ai and #spatialomics in #oncology
*(CAR-)T cell therapies in cancer
*12 Research Highlights on remarkable 2024 publications -
Nature Cancer
@NatureCancer
Viewpoint now ONLINE! @NatureCancer
⭐️'The 2024 generation'
🔗www.nature.com/articles/s43018-024-00866-2
Don't miss this piece where 12 #ecrs who started their #cancerresearch labs in 2024 reflect on the experience so far, including the ups and downs of the journey, and their plans for the future. -
Nature Cancer
@NatureCancer
🚨 New article alert! 🚨 Check out our last release by the team of Bing Zhang on "Mapping the functional network of human cancer through machine learning and pan-cancer proteogenomics"
Read more here: www.nature.com/articles/s43018-024-00869-z -
Nature Cancer
@NatureCancer
Check out new content by the team of David Lyden
"Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression"
👇
doi.org/10.1038/s43018-024-00862-6 -
Nature Cancer reposted
Yael David
@Yael_David__
Excited to share our new paper w/ David Lyden, @HanSangKim5 & Jackie Bromberg @WeillCornell led by the amazing Inbal Wortzel & @IfeAkano revealing a new & unexpected function for chromatin on the surface of exosomes in #cancer #metastasis @NatureCancer
www.nature.com/articles/s43018-024-00862-6 -
Nature Cancer reposted
UChicago Medicine Comprehensive Cancer Center
@UCCancerCenter
📕 New publication: Lixing Yang, PhD, and his collaborators at @UCSF have published an exciting work in @NatureCancer demonstrating the novel approaches to treat aggressive cancers.
#geneticinstability #collision #dnarepair
@jonchou05 @UChicagoCCB
www.uchicagomedicine.org/forefront/research-and-discoveri… -
Nature Cancer reposted
Dana-Farber News
@DanaFarberNews
New research in @NatureCancer led by @BradEBernstein underscores the importance of early detection & treatment and points to possible new strategies for extending patients’ lives, including immunotherapy. go.nature.com/3OjPEJX
Broad Institute
@broadinstitute
New research from @jingyi_wu_bio, @BradEBernstein, @MarioSuva's lab, and others shows how slow-growing brain tumors called gliomas turn aggressive and deadly. The team pinpointed genetic shifts that push these tumors into the fast lane. broad.io/gliomas-news
-
Nature Cancer
@NatureCancer
💫Now Online at Nature Cancer
"A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia"
✏️Kai Tan & David T. Teachey and colleagues @KaiTanLab1 @ChildrensPhila
www.nature.com/articles/s43018-024-00863-5 -
Nature Cancer
@NatureCancer
🔉ARTICLE ONLINE @NatureCancer NOW!
'Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas'
✏️By Bradley Bernstein @BradEBernstein and colleagues
📎www.nature.com/articles/s43018-024-00865-3 -
Nature Cancer
@NatureCancer
📢Our November issue is OUT NOW! @NatureCancer
📎www.nature.com/natcancer/volumes/5/issues/11
⭐️Featuring, among others:
#htan pieces on tumor evolution and chromatin accessibility
CAR-T research
#emt
#llps in breast cancer
mutant #egfr in lung cancer -
Nature Cancer
@NatureCancer
📢Check out this Article NOW ONLINE! @NatureCancer
'#transcription and #dnareplication collisions lead to large tandem duplications and expose targetable #therapeutic vulnerabilities in #cancer'
✏️By Jonathan Chou, Lixing Yang and colleagues
📎www.nature.com/articles/s43018-024-00848-4 -
Nature Cancer
@NatureCancer
🌟ONLINE NOW at NatureCancer. Check the recent article by Hongmeng Yu's team 👇
doi.org/10.1038/s43018-024-00855-5 -
Nature Cancer
@NatureCancer
🚨 New article alert! 🚨
Take a look at our last article "The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export is live".
@NCIDrDougLowy @theNCI
Read more here: www.nature.com/articles/s43018-024-00847-5 -
Nature Cancer
@NatureCancer
Our Associate Editor Tiffanie Chouleur is attending the @AACR Special Conference on Liquid Biopsy next week in San Diego. Reach out if you want to discuss your science or publishing in @NatureCancer
-
Nature Cancer
@NatureCancer
Access the full collection of the Human Tumor Atlas Network (#htan) here: www.nature.com/collections/fihchcjehc
@NCIHTAN @Nature @CommsBio @naturemethods @NatureCancer @NatureMedicine
National Cancer Institute
@theNCI
PRESS RELEASE: New insights from 10 Human Tumor Atlas Network studies provide critical information on how cancer tumors develop, spread, and respond to treatments. The research is to be published tomorrow in @NatureCancer. Learn more: go.nih.gov/YN70LjH #cancermoonshot #htan
-
Nature Cancer
@NatureCancer
And read the associated Research Briefing by Michael Iglesia & Li Ding where they summarize and discuss their paper.
Defining the transcriptional lineages of breast cancer subtypes
www.nature.com/articles/s43018-024-00774-5
Nature Cancer
@NatureCancer
Another Human Tumor Atlas Network article @NatureCancer OUT NOW!
'Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages'
✏️By Li Ding and colleagues
www.nature.com/articles/s43018-024-00773-6
Nature Cancer
@NatureCancer
-
Nature Cancer
@NatureCancer
Now ONLINE - Article
"Recapitulating the adenoma–carcinoma sequence by selection of four spontaneous oncogenic mutations in mismatch-repair-deficient human colon organoids"
✏️ @HansClevers and team @TheCleversLab
www.nature.com/articles/s43018-024-00841-x -
Nature Cancer
@NatureCancer
🔔ONLINE NOW! ARTICLE @NatureCancer from the Human Tumor Atlas Network:
'Multiomic analysis of familial adenomatous polyposis reveals molecular pathways associated with early tumorigenesis'
#htan
By Michael Snyder and colleagues
Read in full here:
www.nature.com/articles/s43018-024-00831-z -
Nature Cancer
@NatureCancer
Another Human Tumor Atlas Network article @NatureCancer OUT NOW!
'Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages'
✏️By Li Ding and colleagues
www.nature.com/articles/s43018-024-00773-6 -
Nature Cancer
@NatureCancer
🔔ONLINE NOW! ARTICLE from the Human Tumor Atlas Network!
'Global loss of promoter–enhancer connectivity and rebalancing of gene expression during early #colorectalcancer carcinogenesis' #htan
✏️By Michael Snyder and co-authors
🔗www.nature.com/articles/s43018-024-00823-z -
Nature Cancer reposted
Eric Topol
@EricTopol
A huge day for spatial omics of cancer, tracing the precise origin and evolution of 20 types of cancer, many in 3D, in ~2,000 individuals, with 12 publications @Nature @NatureCancer @NatureMedicine @naturemethods @CommsBio
Collection www.nature.com/immersive/d42859-024-00059-y/index.html -
Nature Cancer
@NatureCancer
To celebrate 100+ years of the #warburgeffect, #cancer editors from @SpringerNature put together a collection of articles highlighting the breadth of #cancermetabolism research & its potential for the clinic. @BioMedCentral @NatResCancer @NaturePortfolio www.nature.com/collections/djjgbfahdf
-
Nature Cancer
@NatureCancer
ONLINE now! Our October Issue
👇
www.nature.com/natcancer/volumes/5/issues/10 -
Nature Cancer
@NatureCancer
🌟Online now - Article
@NietoAngela and colleagues study EMT programs in breast cancer and identify two interdependent trajectories coexisting within tumors, with EMT transcription factors such as PRRX1 at their nexus.
🔗www.nature.com/articles/s43018-024-00839-5 -
Nature Cancer reposted
Nature Medicine
@NatureMedicine
To celebrate 100+ years of the #warburgeffect, #cancer editors from @SpringerNature put together a collection of articles highlighting the breadth of #cancermetabolism research & its potential for the clinic. @BioMedCentral @NatResCancer @NaturePortfolio www.nature.com/collections/djjgbfahdf
-
Nature Cancer
@NatureCancer
Online now!
Burr et al. analyze multiple primary EGFR-mutant lung tumors from ten patients and define developmental mosaicism as a mechanism underlying multiple tumor presentation in this setting.
✏️@getz_lab & Daniel A. Haber & team
www.nature.com/articles/s43018-024-00840-y -
Nature Cancer reposted
Rodrigo Romero Rangel @RRomero_PhD
🚨🚨Now online @NatureCancer, my postdoc work in @SawyersLabMSKCC with @dana_peer 🚨🚨 we establish a powerful organoid transplantation model of prostate cancer neuroendocrine transformation. Open access for all! @HHMINEWS
www.nature.com/articles/s43018-024-00838-6
A 🧵... /1 -
Nature Cancer
@NatureCancer
Online Now!
@SawyersLabMSKCC & co describe an in vivo platform used to explore the dynamics and key factors of neuroendocrine lineage transformation. They find that Ascl1 depletion blocks plasticity and leads to cancer that is sensitive to castration.
www.nature.com/articles/s43018-024-00838-6 -
Nature Cancer
@NatureCancer
Online NOW! - New Article @NatureCancer
'CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms'
✏️By Gianpietro Dotti and colleagues
Read it here:
🔗www.nature.com/articles/s43018-024-00830-0 -
Nature Cancer reposted
Florentia Dimitriou, MD PhD PD @FDimitriouMD
Science is cool 😎
Our recent article in @NatureCancer has been selected for the journal cover! 🎉
It is an honor to see our research featured in such a prestigious journal, pushing forward the boundaries of immunotherapy. Special thanks to @neutrophiu and F. Sella @AkoyaBio 🙏🏻
Nature Cancer
@NatureCancer
ONLINE NOW - our September issue
👇
www.nature.com/natcancer/volumes/5/issues/9 -
Nature Cancer reposted
Collaborative Centre for Genomic Cancer Medicine
@GenCancerCentre
How can the de-intensification of cancer treatment improve quality of life and reduce healthcare costs, while maintaining cancer outcomes?
🔖Read more about Dr Jennifer Soon's latest commentary in @NatureCancer journal: go.unimelb.edu.au/6w78 @UniMelbMDHS -
Nature Cancer
@NatureCancer
Online Now - Article
"Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease"
by @LabDfelsher & Renumathy Dhanasekaran and team
👇
www.nature.com/articles/s43018-024-00828-8 -
Nature Cancer
@NatureCancer
Online Now - Resource
"Spatial single-cell protein landscape reveals vimentinhigh macrophages as immune-suppressive in the microenvironment of hepatocellular carcinoma"
by Hongyang Wang & Lei Chen and team
www.nature.com/articles/s43018-024-00824-y -
Nature Cancer
@NatureCancer
Online now - Article
Phase 1b/2 clinical trial of glutaminase inhibitor telaglenastat combined with azacytidine in patients with advanced myelodysplastic syndromes and single cell transcriptomics analysis
by @TizianiLab @Amitvermamds @mkonople
🔗www.nature.com/articles/s43018-024-00811-3 -
Nature Cancer
@NatureCancer
New content 🌟Perspective🌟
"Targeting therapy-persistent residual disease"
by Xiaoxiao Sun, Lani Wu, Steven Altschuler & Aaron Hata @ucsfpharmacy @MGHCancerCenter
🔗www.nature.com/articles/s43018-024-00819-9 -
Nature Cancer
@NatureCancer
News & Views by Sigrid Ruuls & Paul Parren
"Antibody avidity meets multiple myeloma"
🔗www.nature.com/articles/s43018-024-00805-1
Nature Cancer
@NatureCancer
Mario Perro & colleagues develop a CD3+ T cell engager co-targeting BCMA and CD38 to improve immunotherapy for multiple myeloma, demonstrate cytotoxicity in patient-derived samples and murine models and develop a quantitative systems pharmacology model
🔗www.nature.com/articles/s43018-024-00821-1 -
Nature Cancer
@NatureCancer
Mario Perro & colleagues develop a CD3+ T cell engager co-targeting BCMA and CD38 to improve immunotherapy for multiple myeloma, demonstrate cytotoxicity in patient-derived samples and murine models and develop a quantitative systems pharmacology model
🔗www.nature.com/articles/s43018-024-00821-1 -
Nature Cancer
@NatureCancer
A phase 2 single-arm clinical trial of neoadjuvant chemotherapy plus checkpoint blockade in participants with resectable muscle-invasive bladder cancer and genomic and transcriptomic profiling
by Jian Huang, Tianxin Lin and colleagues
🔗www.nature.com/articles/s43018-024-00822-0 -
Nature Cancer
@NatureCancer
ONLINE NOW - our September issue
👇
www.nature.com/natcancer/volumes/5/issues/9
Nature Cancer
@NatureCancer
Find out about:
- multiomics profiling of immunotherapy-associated toxicities
- deep-learning framework predicting therapy response
- BCMA CAR T cell therapy in myeloma
- predicting the risk of prostate cancer recurrence through the lens of evolution
and more! -
Nature Cancer
@NatureCancer
Our Associate Editor Julieta Alfonso is looking forward to attending the EMBO-EMBL symposium in Heidelberg.
Reach out if you want to discuss your science or publishing in @NatureCancer- or find Julieta at the 'Meet-the-Editor' panel on Oct 1st.
www.embl.org/about/info/course-and-conference-office/even… -
Nature Cancer
@NatureCancer
check out NOW ONLINE @NatureCancer 'Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers' by Jun Qin's team
doi.org/10.1038/s43018-024-00820-2 -
Nature Cancer
@NatureCancer
NEW CONTENT @NatureCancer 'A protein expression atlas on tissue samples and cell lines from cancer patients provides insights into tumor heterogeneity and dependencies' by Akbani, Mills, Liang and collaborators
doi.org/10.1038/s43018-024-00817-x -
Nature Cancer
@NatureCancer
NOW ONLINE @NatureCancer
'A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma'
✏️By Florentia Dimitriou, Reinhard Dummer and co-authors
doi.org/10.1038/s43018-024-00810-4 -
Nature Cancer
@NatureCancer
🔔New Article! ONLINE NOW @NatureCancer
'Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer'
by Jie Li, Wei Zhao and colleagues
🔗doi.org/10.1038/s43018-024-00816-y -
Nature Cancer
@NatureCancer
✏️ONLINE NOW!
'Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial'
by Kavita Dhodapkar, Madhav Dhodapkar and colleagues
Read it here:
doi.org/10.1038/s43018-024-00818-w -
Nature Cancer
@NatureCancer
🔔ONLINE NOW! the @NatureCancer August issue! 🤩 Features:
- #machinelearning models in #clinicaloncology
- EGFR and PI3K inhibition to overcome adaptive resistance
- effects of cancer cell nucleotide metabolism on immune #tme
👇
www.nature.com/natcancer/volumes/5/issues/8 -
Nature Cancer reposted
Nature Communications
@NatureComms
Save the date! @NatureCancer and @NatureComms are hosting the webinar "The #microbiome in #cancer #immunotherapy" with Laurence Zitvogel @nsegata @tsonipeled @maria_rescigno
📅 Wednesday 18th Sep 2024
⏰ 10 am ET / 3 pm UK time
cassyni.com/events/FfJmtNoEbexsirDkR9sKfB?cb=functi -
Nature Cancer
@NatureCancer
🔔New Article ONLINE
Ulrike Rauh & Todd Golub and colleagues developed a selective MCL1 inhibitor that is efficacious in hematological and solid tumors and that limits cardiotoxicity via a more rapid clearance of the drug in vivo.
👇
www.nature.com/articles/s43018-024-00814-0 -
Nature Cancer
@NatureCancer
Save the date! @NatureCancer and @NatureComms are hosting the webinar "The #microbiome in #cancer #immunotherapy" with Laurence Zitvogel @nsegata @tsonipeled @maria_rescigno
📅 Wednesday 18th Sep 2024
⏰ 10 am ET / 3 pm UK time
cassyni.com/events/FfJmtNoEbexsirDkR9sKfB?cb=functi -
Nature Cancer
@NatureCancer
News & Views by Anders Hofer
How tumors hijack macrophages for immune evasion
Pancreatic cancer cells are now shown to create a TME that protects them from immunotherapy by overexpression of cytidine deaminase.
Nature Cancer
@NatureCancer
🌟NEW CONTENT @NatureCancer
"Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance" by Max Mazzone & colleagues (@LabMazzone)
www.nature.com/articles/s43018-024-00771-8
Nature Cancer
@NatureCancer
-
Nature Cancer
@NatureCancer
🔔Now Online - Analysis
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms
by @ZeminZhangLab & Sijin Cheng and colleagues
www.nature.com/articles/s43018-024-00807-z -
Nature Cancer
@NatureCancer
🚨REVIEW now ONLINE!
From Lawrence Fong and co-authors @NatureCancer on γδ T cells as critical anti-tumour immune effectors.
Read it here:
🔗doi.org/10.1038/s43018-024-00798-x -
Nature Cancer
@NatureCancer
🔔NOW ONLINE!
Research article @NatureCancer from Marco Hofmann, Venu Thatikonda and colleagues on targeting SOS1 to enhance the antitumor effects of KRAS-G12C inhibitors by tackling intrinsic and acquired resistance.
Read it here:
🔗doi.org/10.1038/s43018-024-00800-6 -
Nature Cancer
@NatureCancer
🚨REVIEW now ONLINE @NatureCancer from Vito Rebecca @VitoRebecca1 and colleagues: 'Determinants of resistance and response to melanoma therapy'
Read it here:
🔗doi.org/10.1038/s43018-024-00794-1 -
Nature Cancer
@NatureCancer
🔔Now online!
Check out this research article from Michael Flister, Zoltan Dezso and colleagues on building a translational cancer dependency map for The Cancer Genome Atlas.
Read it here:
🔗doi.org/10.1038/s43018-024-00789-y -
Nature Cancer
@NatureCancer
Now Online @NatureCancer "Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer" by Andrea Sottoriva's lab
doi.org/10.1038/s43018-024-00787-0 -
Nature Cancer
@NatureCancer
Check out new content @NatureCancer "A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance"
doi.org/10.1038/s43018-024-00781-6
by Judith Sebolt-Leopold's lab -
Nature Cancer reposted
Eric Topol
@EricTopol
Clinical implementation of #ai assist for pathologists to assess breast cancer metastasis led to significant reduction of time and cost. And "making their work more enjoyable"
www.nature.com/articles/s43018-024-00788-z
@NatureCancer -
Nature Cancer reposted
Nathaniel Mabe,PharmD,PhD @Nathaniel_Mabe
With 3 approved epigenetic drug classes and many more under clinical investigation, epigenetic targets are gaining traction. Here, we take survey of developments and hurdles in targeting the cancer epigenome. Thank you @NatureCancer for the opportunity
www.nature.com/articles/s43018-024-00777-2 -
Nature Cancer
@NatureCancer
ONLINE – the @NatureCancer June issue! 🤩
Read on:
- tumor vascularization
- clinical trials in breast cancer and in sarcoma
- precision oncology
- DNA replication stress in PDAC
- targeting AML with prolyl hydroxylase inhibitor
- cancer epigenomes
www.nature.com/natcancer/volumes/5/issues/6 -
Nature Cancer
@NatureCancer
PERSPECTIVE now ONLINE @NatureCancer 'Milestones in tumor vascularization and its therapeutic targeting'
✏️by Michele De Palma & Douglas Hanahan
Read it here: doi.org/10.1038/s43018-024-00780-7 -
Nature Cancer
@NatureCancer
🌟Check out @NatureCancer
"LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features" by Eytan Ruppin & colleagues
doi.org/10.1038/s43018-024-00772-7 -
Nature Cancer
@NatureCancer
Join us for the Meet-the-Editor panel at #eacr2024 RTM Stage at 9:00 AM to learn about publishing and ask your 🔥questions about @NatureCancer.
-
Nature Cancer
@NatureCancer
🌟NEW CONTENT @NatureCancer
"Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance" by Max Mazzone & colleagues (@LabMazzone)
www.nature.com/articles/s43018-024-00771-8 -
Nature Cancer reposted
Nature Conferences
@NatureConf
The poster session is in full swing! Over 30 posters are being presented today.
@DanaFarber @DanaFarberNews @NatureCancer @NatureMedicine @NatImmunol @NatRevImmunol -
Nature Cancer reposted
Andrew M. Evens, DO, MBA, MSc
@DrAEvens
🚨🚨 Elegant modeling via ML among ~3000 cases across mult. tumor types using primarily CLINICAL FEATURES (age, albumin, prior Tx, neut/lymp count, etc) to predict outcomes w/ CPI immunotherapy!
👏Kudos to @NCIResearchCtr & all authors!
@NatureCancer
www.nature.com/articles/s43018-024-00772-7 -
Nature Cancer
@NatureCancer
🔔NEW RESEARCH CONTENT @NatureCancer on 'Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment'
Check it out here:
doi.org/10.1038/s43018-024-00775-4 -
Nature Cancer
@NatureCancer
⭐️Check out this recent @NatureCancer research article on 'Targeting a lineage-specific PI3Kɣ–Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule'
👉doi.org/10.1038/s43018-024-00782-5 -
Nature Cancer
@NatureCancer
ONLINE NOW – the
@NatureCancer May issue!🌷
#metabolism, #immunotherapy, #metastasis and more!
👇
www.nature.com/natcancer/volumes/5/issues/5
Cover from Astuti et al on link of efferocytosis to macrophage reprogramming & liver metastasis in this issue.
(Image: Yuliana Astuti, Design: Allen Beattie) -
Nature Cancer
@NatureCancer
Our Senior Editor @LisaHaas0107 is looking forward to attending the #eacr2024 in Rotterdam 🇳🇱 next week.
Reach out if you want to discuss your science or publishing in @NatureCancer - or find Lisa after the 'Meet-the-Editor' panel on Thursday morning.
EACR
@EACRnews
Registration for the #eacr2024 Congress closes TONIGHT 🏃♀️🏃♂️
And the scientific programme is jam-packed for 2024 with a mix of symposia, keynote lectures, panel discussions with institute directors and journal editors, career discovery sessions and more!
2024.eacr.org -
Nature Cancer reposted
Pearson Lab
@lab_pearson
Now available @NatureCancer : We describe #quantumcomputing fundamentals w/ focus on applications in #cancer research. Hope for big potential gains in modeling molecular interactions, processing high-dimensional data, and sensing biological states.
Link: rdcu.be/dIdIx -
Nature Cancer
@NatureCancer
Check out the latest articles @NatureCancer "Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling" doi.org/10.1038/s43018-024-00768-3
-
Nature Cancer
@NatureCancer
NEW CONTENT @NatureCancer "Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome" doi.org/10.1038/s43018-024-00764-7
-
Nature Cancer
@NatureCancer
Our @NatureCancer Senior Editor @LisaHaas0107 Lisa Hoffmann-Haas is attending the CIMT meeting in Mainz 🇩🇪. Reach out to her if you want to discuss your science and publishing in Nature Cancer or find her at the meet-the-editor table (Booth #33) at 3PM today.
#cimt2024 -
Nature Cancer
@NatureCancer
⭐️NEW REVIEW ARTICLE @NatureCancer
“Cycling back to folate metabolism in cancer”
Read it here:
👉doi.org/10.1038/s43018-024-00739-8
#cancermetabolism -
Nature Cancer
@NatureCancer
✨NEW CONTENT @NatureCancer “Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial” #clinicaltrial
www.nature.com/articles/s43018-024-00749-6 -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma” #immunotherapy
www.nature.com/articles/s43018-024-00763-8 -
Nature Cancer
@NatureCancer
⭐️DON’T MISS @NatureCancer “PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors” #therapy
www.nature.com/articles/s43018-024-00756-7 -
Nature Cancer
@NatureCancer
ONLINE NOW – the @NatureCancer April issue! 🌺🌻🌷
Check out the content on #ferroptosis, #survivorship, #immunotherapy, #metabolism and more.
And isn’t the cover puzzling 🧩? Find it here: nature.com/natcancer/volumes/5/issues/4 -
Nature Cancer
@NatureCancer
💫NEW CONTENT @NatureCancer “The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia” #therapy
www.nature.com/articles/s43018-024-00761-w -
Nature Cancer
@NatureCancer
✨ONLINE NOW @NatureCancer “An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy” #immunotherapy
www.nature.com/articles/s43018-024-00760-x -
Nature Cancer
@NatureCancer
WE ARE HIRING @NatureCancer
2 Locum Associate/Senior Editors - Berlin, Heidelberg, London – application deadline May 8th
A permanent Associate/Senior Editor - Shanghai, Beijing, New York or Philadelphia– application deadline April 28th
Please spread the word! Links 👇 -
Nature Cancer
@NatureCancer
✨ONLINE NOW @NatureCancer “Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming” #glioblastoma
Read it here 👇
www.nature.com/articles/s43018-024-00748-7 -
Nature Cancer
@NatureCancer
💫DON’T MISS @NatureCancer “Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers” #immunotherapy
Read it here 👇
www.nature.com/articles/s43018-024-00752-x -
Nature Cancer
@NatureCancer
⭐️NEW CONTENT @NatureCancer - “Associations of seven measures of biological age acceleration with frailty and all-cause mortality among adult survivors of childhood cancer in the St. Jude Lifetime Cohort”
Read it here👇
www.nature.com/articles/s43018-024-00745-w -
Nature Cancer
@NatureCancer
📢Come join our @NatureCancer editorial team!
We're hiring an Associate/Senior Editor in our Shanghai, Beijing, New York or Philadelphia offices🌎.
Application deadline April 28th🗓️
Please spread the word‼️
Find details here:
www.nature.com/naturecareers/job/12816285/associate-or-se… -
Nature Cancer
@NatureCancer
ONLINE NOW @NatureCancer “Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers” #therapy
Read it here 👇
www.nature.com/articles/s43018-024-00754-9 -
Nature Cancer
@NatureCancer
✨NEW REVIEW ARTICLE @NatureCancer “The pleiotropic functions of reactive oxygen species in cancer”
Find it here👇
www.nature.com/articles/s43018-024-00738-9 -
Nature Cancer
@NatureCancer
⭐️ONLINE NOW @NatureCancer - "Trans-Atlantic twists and turns" - a Turning Point Article describing career-defining moments by @Johanna_A_Joyce
www.nature.com/articles/s43018-024-00747-8 -
Nature Cancer reposted
Nature Portfolio
@NaturePortfolio
Explore the forefront of cancer immunotherapy at our upcoming conference in Boston with @DanaFarber. Leaders in the field will present cutting-edge research, focusing on translating fundamental knowledge to the clinic and back. Learn more: go.nature.com/CancerImm
-
Nature Cancer
@NatureCancer
✨ONLINE NOW @NatureCancer “Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies” #cartcells
www.nature.com/articles/s43018-024-00744-x?platform=oscar… -
Nature Cancer
@NatureCancer
✨ONLINE NOW @NatureCancer “Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies” #cartcells
www.nature.com/articles/s43018-024-00744-x?platform=oscar… -
Nature Cancer
@NatureCancer
💫DON’T MISS @NatureCancer “A deep learning model of tumor cell architecture elucidates response and resistance to CDK4/6 inhibitors”
www.nature.com/articles/s43018-024-00740-1?platform=oscar… -
Nature Cancer
@NatureCancer
⭐️NEW CONTENT @NatureCancer “Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells”
www.nature.com/articles/s43018-024-00742-z?platform=oscar… -
Nature Cancer
@NatureCancer
✨ONLINE NOW @NatureCancer “Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy” #immunotherapy
www.nature.com/articles/s43018-024-00743-y?platform=oscar… -
Nature Cancer
@NatureCancer
⭐️NEW CONTENT @NatureCancer “Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols” #immunotherapy
www.nature.com/articles/s43018-024-00734-z?platform=oscar… -
Nature Cancer
@NatureCancer
✨DON’T MISS @NatureCancer “Temporal changes in treatment and late mortality and morbidity in adult survivors of childhood glioma: a report from the Childhood Cancer Survivor Study”
www.nature.com/articles/s43018-024-00733-0?platform=oscar… -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity” #tumorimmunology
www.nature.com/articles/s43018-024-00736-x?platform=oscar… -
Nature Cancer
@NatureCancer
⭐️NEW CONTENT @NatureCancer “Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial” #clinicaltrial #breastcancer
www.nature.com/articles/s43018-024-00729-w?platform=oscar… -
Nature Cancer reposted
Nature Medicine
@NatureMedicine
📢< 1 month until abstracts are due for our upcoming @NatureConf on #cancer #immunotherapy! This event is co-organized w/ @DanaFarber @NatureCancer @NatImmunol @NatRevImmunol
🗓️Deadline = April 12th
🎟️To register, submit an abstract & learn more, visit go.nature.com/CancerImm -
Nature Cancer
@NatureCancer
💫DON’T MISS @NatureCancer “Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis” #metastasis
www.nature.com/articles/s43018-024-00731-2 -
Nature Cancer
@NatureCancer
✨ONLINE NOW @NatureCancer “The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors”
www.nature.com/articles/s43018-024-00727-y -
Nature Cancer
@NatureCancer
⭐️DON’T MISS @NatureCancer “Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities” #breastcancer
www.nature.com/articles/s43018-024-00725-0 -
Nature Cancer
@NatureCancer
✨NEW CONTENT @NatureCancer “A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma”
www.nature.com/articles/s43018-024-00726-z -
Nature Cancer reposted
Hellmut Augustin @HellmutAugustin
Finally out in @NatureCancer: Deconvoluting at single cell resolution how endothelial cells drive tumor cell fate decisions in the metastatic niche. Congratulations to Moritz Jakab (@moviqu), Ki Hong Lee, and all contributors to this exciting landmark work www.nature.com/articles/s43018-023-00716-7
-
Nature Cancer reposted
Evanthia Roussos Torres, MD, PhD
@RoussosTorres
1/3: Excited to announce publication of our results in @NatureCancer from the breast expansion cohort of NCI-9844 testing dual checkpoint blockade with entinostat in patients with HER2 negative advanced breast cancer which demonstrates great promise; rdcu.be/dyBLJ.
-
Nature Cancer
@NatureCancer
⭐️NEW CONTENT @NatureCancer “Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial” #breastcancer #clinicaltrial
www.nature.com/articles/s43018-024-00729-w -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Lung endothelium exploits susceptible tumor cell states to instruct metastatic latency” #metastasis
www.nature.com/articles/s43018-023-00716-7 -
Nature Cancer reposted
Nature Conferences
@NatureConf
We're thrilled to announce @DanaFarber @NatureCancer @NatureMedicine @NatImmunol @NatRevImmunol have partnered for an amazing event in #boston
This event will discuss recent biological, clinical, and translational advances in the field
Get your tix today🎟️go.nature.com/CancerImm -
Nature Cancer
@NatureCancer
💫DON’T MISS @NatureCancer “Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance”
www.nature.com/articles/s43018-023-00715-8
rdcu.be/dxoGD -
Nature Cancer
@NatureCancer
✨ONLINE NOW @NatureCancer “Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma”
www.nature.com/articles/s43018-023-00721-w
rdcu.be/dxoF4 -
Nature Cancer
@NatureCancer
⭐️NEW CONTENT @NatureCancer “Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation”
www.nature.com/articles/s43018-023-00704-x
rdcu.be/dxoFX -
Nature Cancer
@NatureCancer
💫DON’T MISS @NatureCancer “The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2”
www.nature.com/articles/s43018-023-00712-x
rdcu.be/dxoFU -
Nature Cancer
@NatureCancer
⭐️ONLINE NOW @NatureCancer “Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy”
www.nature.com/articles/s43018-023-00720-x
rdcu.be/dxoFS -
Nature Cancer
@NatureCancer
✨NEW CONTENT @NatureCancer “The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients”
www.nature.com/articles/s43018-023-00697-7
rdcu.be/dxoFR -
Nature Cancer
@NatureCancer
💫DON’T MISS @NatureCancer “INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas”
www.nature.com/articles/s43018-023-00710-z
rdcu.be/dxoEX -
Nature Cancer
@NatureCancer
⭐️ONLINE NOW @NatureCancer “Intra-tumoral T cells in pediatric brain tumors display clonal expansion and effector properties”
www.nature.com/articles/s43018-023-00706-9
rdcu.be/dxoEK -
Nature Cancer reposted
Nada Kalaany @nada_kalaany
Blocking cancer while preventing harm to normal tissues? an unceasing challenge in therapy. Should hope be reignited with new #glutamine analogs? My News & Views on 2 recent articles #aleckimmelman @Cosimo_Commisso @NatureCancer rdcu.be/dxjBR
www.nature.com/articles/s43018-023-00678-w -
Nature Cancer
@NatureCancer
✨NEW CONTENT @NatureCancer “Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial”
www.nature.com/articles/s43018-023-00709-6
rdcu.be/dxoEC -
Nature Cancer
@NatureCancer
NEW REVIEW ARTICLE @NatureCancer – “Aneuploidy and complex genomic rearrangements in cancer evolution” by @VanLooLab #tobymbaker #sarawaise #maximetarabichi.
Read it here👇
www.nature.com/articles/s43018-023-00711-y
rdcu.be/dxoLb -
Nature Cancer
@NatureCancer
⭐️DON’T MISS @NatureCancer “Cell cycle gene alterations associate with a redistribution of mutation risk across chromosomal domains in human cancers”
www.nature.com/articles/s43018-023-00707-8
rdcu.be/dxoEm -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Sirpα on tumor-associated myeloid cells restrains antitumor immunity in colorectal cancer independent of its interaction with CD47”
www.nature.com/articles/s43018-023-00691-z
rdcu.be/dxoEb -
Nature Cancer
@NatureCancer
NEW REVIEW ARTICLE @NatureCancer – “Lipids as mediators of cancer progression and metastasis” by @almut_schulze #felixevogel and #adrianobchavesfilho.
Read it here👇
www.nature.com/articles/s43018-023-00702-z
rdcu.be/dxoKL -
Nature Cancer
@NatureCancer
✨NEW CONTENT @NatureCancer “The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma”.
www.nature.com/articles/s43018-023-00694-w
rdcu.be/dxoDY -
Nature Cancer
@NatureCancer
✨Our first @NatureCancer issue of 2024 is LIVE – check out the new content on #cancermetabolism in pancreatic cancer and glioblastoma, #metastatsis in prostate cancer and the #microbiome.
Find it here👇
www.nature.com/natcancer/volumes/5/issues/1 -
Nature Cancer
@NatureCancer
💫NEW CONTENT @NatureCancer “LncRNA Malat1 suppresses pyroptosis and T cell-mediated killing of incipient metastatic cells” by @BizarMd #dhirajkumar the late #filippogiancotti @Giancotti_Lab & Co.
Read it here👇
www.nature.com/articles/s43018-023-00695-9
rdcu.be/dvEPx -
Nature Cancer
@NatureCancer
🔥 HOT OFF THE PRESS @NatureCancer “Autotaxin–lysolipid signaling suppresses a CCL11–eosinophil axis to promote pancreatic cancer progression” by @MaraShermanLab & Co.
Read it here👇
www.nature.com/articles/s43018-023-00703-y
rdcu.be/dvEOx -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease” by @JosefLeibold @LoweLabMSKCC & Co.
Read it here👇
www.nature.com/articles/s43018-023-00686-w
rdcu.be/dvENM -
Nature Cancer
@NatureCancer
✨NEW CONTENT @NatureCancer “Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping” by @ResearchWyatt @piet_ost & Co.
Read it here👇
www.nature.com/articles/s43018-023-00692-y
rdcu.be/dvELI -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Lymphatic endothelial-like cells promote glioblastoma stem cell growth through cytokine-driven cholesterol metabolism” by #shengtaozhou #jeremynrich & CO.
Read it here👇
www.nature.com/articles/s43018-023-00658-0
rdcu.be/dvEK1 -
Nature Cancer
@NatureCancer
🔥HOT OFF THE PRESS @NatureCancer “Bacteria and bacteriophage consortia are associated with protective intestinal metabolites in patients receiving stem cell transplantation” by #ericthieleorberg #hendrikpoeck & Co.
Don’t miss it 👇
www.nature.com/articles/s43018-023-00669-x
rdcu.be/dvEKh -
Nature Cancer
@NatureCancer
🎆NEW 2024 CONTENT @NatureCancer – “PD-1 defines a distinct, functional, tissue-adapted state in Vδ1+ T cells with implications for cancer immunotherapy” by @HaydayLab @dr_yinwu & Co.
Read it here 👇
www.nature.com/articles/s43018-023-00690-0
rdcu.be/dvEJG -
Nature Cancer
@NatureCancer
🎇NEW YEAR, NEW PAPERS – “Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy” by @FGinhoux @asharmaiisc & Co.
Check it out👇
www.nature.com/articles/s43018-023-00672-2
rdcu.be/dvEIM -
Nature Cancer
@NatureCancer
🎆NEW YEAR, NEW PAPERS – “Blocking methionine catabolism induces senescence and confers vulnerability to GSK3 inhibition in liver cancer” by #fuminli #celestesimon & Co.
Read it here 👇
www.nature.com/articles/s43018-023-00671-3
rdcu.be/dvEIa -
Nature Cancer
@NatureCancer
💫NEW CONTENT AT @NatureCancer – “Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers” by #marcpayton #paulehughes & Co.
Read it here 👇
www.nature.com/articles/s43018-023-00699-5
rdcu.be/dvEG3 -
Nature Cancer
@NatureCancer
Application deadline extended until January 14th ‼️
10 days left to apply and join our @NatureCancer editorial team in NY, Berlin or Heidelberg.
Please RT and spread the word! 📢
#editorialcareers #jobopportunity
Details here👇
careers.springernature.com/job/New-York-Associate-or-Seni…
Nature Cancer
@NatureCancer
📢Come join our @NatureCancer editorial team!
We're hiring an Associate/Senior Editor in our NY, Berlin & Heidelberg offices🌎. Application deadline January 9th.
Find details here:
careers.springernature.com/job/New-York-Associate-or-Seni… -
Nature Cancer
@NatureCancer
📢Come join our @NatureCancer editorial team!
We're hiring an Associate/Senior Editor in our NY, Berlin & Heidelberg offices🌎. Application deadline January 9th.
Find details here:
careers.springernature.com/job/New-York-Associate-or-Seni… -
Nature Cancer
@NatureCancer
✨In our #2023inreview special we provide a collection of 12 research highlights summarizing impactful papers published in 2023 and present a collection of some of our most striking @NatureCancer publications.
Check them out for some end-of-year reading.
www.nature.com/collections/bcggjhfcea -
Nature Cancer
@NatureCancer
⭐️Want an overview on “Cancer drug approvals and setbacks in 2023?” – Check out our @NatureCancer piece in #2023inreview!
www.nature.com/articles/s43018-023-00683-z -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer – the #2023generation – 12 group leaders share their journey to becoming an independent PI. Very inspiring stories, please do not miss them!
www.nature.com/articles/s43018-023-00681-1 -
Nature Cancer
@NatureCancer
⭐️IT IS THE MOST WONDERFUL TIME OF THE YEAR 💫– the @NatureCancer special issue #2023inreview is live.
Check out the beautiful cover and pieces on cancer drug approvals, cyberwarfare in healthcare, #ai in Oncology, #neoantigens and more.
Here 👇
www.nature.com/collections/bcggjhfcea -
Nature Cancer reposted
Nature Methods
@naturemethods
Nature Methods' Method of the Year 2023 is methods for modeling development! For all #moty2023 content plus Methods to Watch, please see the Collection here: www.nature.com/collections/ejcfiieddc
We thank @BernaSozen_ and @ZernickaGoetz for the beautiful cover image of mouse blastocysts! -
Nature Cancer reposted
Nature Human Behaviour
@NatureHumBehav
We’re thrilled to present our new Focus on artificial intelligence - Navigating the AI Frontier. (1/20)
idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nat… -
Nature Cancer
@NatureCancer
📢HAPPENING ON THURSDAY NOVEMBER 30TH - 'Advances in Cancer Vaccines' brought to you by @moderna_tx and @NatureCancer. Don't miss the chance to register for free using the link below 👇
conferences.nature.com/event/a271d0c0-35a7-4dc0-aed3-7121…
Nature Cancer
@NatureCancer
📢ONE WEEK LEFT TO REGISTER FOR – ‘Advances in Cancer Vaccines’ brought to you by @moderna_tx and @NatureCancer. #immunotherapy
@NatureConf
Sign up FOR FREE using the link below and check out the fantastic speaker panel 👇
conferences.nature.com/event/a271d0c0-35a7-4dc0-aed3-7121… -
Nature Cancer
@NatureCancer
📢ONE WEEK LEFT TO REGISTER FOR – ‘Advances in Cancer Vaccines’ brought to you by @moderna_tx and @NatureCancer. #immunotherapy
@NatureConf
Sign up FOR FREE using the link below and check out the fantastic speaker panel 👇
conferences.nature.com/event/a271d0c0-35a7-4dc0-aed3-7121… -
Nature Cancer
@NatureCancer
💫NEW CONTENT @NatureCancer - “Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens” by @FrancescoMaura4 @DrOlaLandgren & Co.
Read it here 👇
www.nature.com/articles/s43018-023-00657-1
rdcu.be/drEGZ -
Nature Cancer
@NatureCancer
⭐️ONLINE NOW @NatureCancer - “Additivity predicts the efficacy of most approved combination therapies for advanced cancer” by @ac_palmer & Co.
Read it here 👇
www.nature.com/articles/s43018-023-00667-z
rdcu.be/drEES -
Nature Cancer
@NatureCancer
📢Only one week left to register for our Nature Conference presented by @moderna_tx & @NatureCancer - don't miss the many interesting talks on all facets of cancer vaccine therapy - from preclinical to clinical! 🖥️🧫🥼
@NatureConf
🗓️NOVEMBER 30th - VIRTUAL EVENT
Nature Conferences
@NatureConf
Don't miss your chance to hear from these experts the latest developments in antigen discovery, preclinical and clinical advances in cancer vaccine therapies. brought to you by @moderna_tx & @NatureCancer
Reserve your spot: go.nature.com/3rOUk2L -
Nature Cancer
@NatureCancer
⭐️ONLINE NOW @NatureCancer „Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia” by @AbdelWahablab and #ravtechlab.
Read it here 👇
www.nature.com/articles/s43018-023-00656-2
rdcu.be/dqAdG -
Nature Cancer
@NatureCancer
🔥NEW ARTICLE @NatureCancer “Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target” by @apwiita and colleagues. #aml
Find it here👇
www.nature.com/articles/s43018-023-00652-6
rdcu.be/dqAdc -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia” by @StevenLane_QIMR and colleagues.
Read it here 👇
www.nature.com/articles/s43018-023-00653-5
rdcu.be/dqz1d -
Nature Cancer
@NatureCancer
Don’t miss our @NatureCancer OCTOBER ISSUE 🎃
This one features interesting articles on #glioblastoma therapy, #immunotherapy for AML, #immunometabolism, a Phase I #clinicaltrial in ovarian cancer and more.
Check it out here👇
www.nature.com/natcancer/volumes/4/issues/10 -
Nature Cancer reposted
nature
@Nature
Did you know @nature has a new weekly newsletter? Nature Briefing: Anthropocene covers the footprint of humanity on Earth — including climate change, biodiversity, sustainability and geoengineering. Get it free in your inbox tomorrow by signing up here:
www.nature.com/briefing/anthropocene -
Nature Cancer reposted
Nature Conferences
@NatureConf
On Nov 30 @moderna_tx and @NatureCancer will host a free virtual event bringing together experts across disciplines to discuss developments in antigen discovery and preclinical and clinical advances
Reserve your spot: go.nature.com/3rOUk2L -
Nature Cancer reposted
NatureStructMolBiol
@NatureSMB
Want to be featured on NSMB cover? Submit a spectacular photo, a beautiful piece of data, an insightful drawing to our 30th anniversary cover competition.
Details: rdcu.be/doiBQ -
Nature Cancer reposted
Nature Computational Science
@NatComputSci
Happy #adalovelaceday! To celebrate this day, we have a Special collection that includes conversations with female researchers at various career stages. #ald23
👉go.nature.com/3PHMhg0
🧵1/6 -
Nature Cancer
@NatureCancer
💫NEW CONENT @NatureCancer "Targeting pancreatic cancer metabolic dependencies through glutamine antagonism” by #alecmkimmelman & Co.
Read it here 👇
www.nature.com/articles/s43018-023-00647-3?platform=oscar…
rdcu.be/dob47 -
Nature Cancer
@NatureCancer
💫NEW CONTENT @NatureCancer “Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma” by @Cosimo_Commisso & Co.
Read it here 👇
www.nature.com/articles/s43018-023-00649-1
rdcu.be/dobZP -
Nature Cancer reposted
Michael Metzger
@themetzgerm
I am excited to present the second biggest science news today (congrats to Drs Kariko and Weissman)—the analysis of the genomic changes in the evolution of the bivalve transmissible neoplasia in soft-shell clams! @NatureCancer @PNRIGenetics www.nature.com/articles/s43018-023-00643-7
-
Nature Cancer reposted
Profesor Tubio - Mobile Genomes Lab @MobileGenomes
Delighted to announce that our paper on somatic evolution of marine transmissible cancers is finally out in @NatureCancer. For 7 years we investigated a marine leukemia that propagates through marine water to infect cockles in the Coasts of Europe 🤯
1/25 www.nature.com/articles/s43018-023-00641-9 -
Nature Cancer
@NatureCancer
🔥CHECK OUT “and “Centuries of genome instability and evolution in soft-shell clam, Mya arenaria, bivalve transmissible neoplasia” by @themetzgerm & Co.”
www.nature.com/articles/s43018-023-00643-7?platform=oscar…
rdcu.be/dob2R -
Nature Cancer
@NatureCancer
🐚DON’T MISS „Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule” @NatureCancer by @MobileGenomes
www.nature.com/articles/s43018-023-00641-9?platform=oscar…
rdcu.be/dob2G -
Nature Cancer
@NatureCancer
⭐️NEW CONTENT @NatureCancer „A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo” by @JOlweus #steneirikwjacobsen #petterswoll & Co.
www.nature.com/articles/s43018-023-00642-8?platform=oscar…
rdcu.be/dob07 -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “ Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial” by @DietrichLab & Co. #leukemia #lymphoma👇
www.nature.com/articles/s43018-023-00645-5?platform=oscar…
rdcu.be/dob0I -
Nature Cancer reposted
Nature Conferences
@NatureConf
LAST CALL⚠️
Get your tickets while you still can for #tumourlandscape23! Registration will be closing on Friday, October 6. Cancer experts across several disciplines await you in New York.
conferences.nature.com/TumourLandscape
@MSKCancerCenter @NatureCancer @NatureRevCancer @Nature -
Nature Cancer reposted
bizarMD
@BizarMd
Loss of a true giant in cancer research, mentor, friend, and family man.
www.nature.com/articles/s43018-023-00639-3 -
Nature Cancer
@NatureCancer
⭐️NEW ARTICLE @NatureCancer „Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia” by @Andreas73629100 @J_RodriguezVita @jac_a_taylor & Co.
www.nature.com/articles/s43018-023-00622-y
rdcu.be/dndGN -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer” @CoukosGeorge & Co.
www.nature.com/articles/s43018-023-00623-x
rdcu.be/dndFX -
Nature Cancer
@NatureCancer
✨NEW ARTICLE @NatureCancer “Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations” by #romelsomwar & CO.
www.nature.com/articles/s43018-023-00630-y
rdcu.be/dndFb -
Nature Cancer reposted
Andreas Fischer @Andreas73629100
Excited to share our recent work just published in @NatureCancer about the vasculature in adipose tissue wasting during cancer progression.
www.nature.com/articles/s43018-023-00622-y
by Jacqueline Taylor @jac_a_taylor
Funded @dfg_public @yourUMG
great collaboration @J_RodriguezVita @RohmMaria -
Nature Cancer
@NatureCancer
ONLINE NOW @NatureCancer “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” by #zacharyschug & Co.
www.nature.com/articles/s43018-023-00636-6
rdcu.be/dndEL -
Nature Cancer
@NatureCancer
✨ONLINE NOW @NatureCancer “PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma” by #jürgenRuland #timwartewig @jaehyukchoimd & Co.
www.nature.com/articles/s43018-023-00635-7
rdcu.be/dnaNF -
Nature Cancer
@NatureCancer
💫NEW CONTENT @NatureCancer - “A designer peptide against the EAG2–Kvβ2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma” by #xihuang & Co.
www.nature.com/articles/s43018-023-00626-8
rdcu.be/dnaMS -
Nature Cancer
@NatureCancer
✨ONLINE @NatureCancer - “Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC” by #thilohackert #francofortunato #johnpneoptolemos & #peterbailey & Co.
www.nature.com/articles/s43018-023-00628-6
rdcu.be/dnaMG -
Nature Cancer
@NatureCancer
💫“Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study” ONLINE @NatureCancer - by #chunfengqu #wanqingchen & Co. #hcc
www.nature.com/articles/s43018-023-00618-8
rdcu.be/dnaLF -
Nature Cancer
@NatureCancer
💫CHECK OUT THIS NEW REVIEW @NatureCancer “Harnessing progress in radiotherapy for global cancer control” by #davidajaffray #feliciaknaul #michaelbaumann & #marygospodarowicz.
www.nature.com/articles/s43018-023-00619-7
rdcu.be/dnaOE -
Nature Cancer
@NatureCancer
🍂🍁🍂DON’T MISS our @NatureCancer September issue – this one is full of exciting articles about #immunotherapy & #tcells, persister cells in #pancreaticancer and #drugdevelopment.
Check it out here 👇
www.nature.com/natcancer/volumes/4/issues/9 -
Nature Cancer reposted
Nature Portfolio
@NaturePortfolio
Join us on October 29 for the @NatureConf on the Tumour Landscape with Memorial Sloan Kettering in New York. Speakers include Levi Garraway (Roche), Miriam Merad (Icahn) and Elizabeth Jaffee (Johns Hopkins). #tumourlandscape23 go.nature.com/3HB2IYC
-
Nature Cancer
@NatureCancer
📢DON’T FORGET TO REGISTER – and join us for this very important discussion on September 28th on “Black in cancer research and oncology" presented by @DrBlueMD @TheOncDocs @kilanbishop and @runciecwc.
Find all infos below👇
@SN_Oncology
Check out the seminar "Roundtable on Black in cancer research and oncology" presented by @DrBlueMD, @TheOncDocs, @kilanbishop and @runciecwc, chaired by Nature Portfolio editors.
🗓️ Thursday 28th Sep 2023
⏲️ 14.00 PM (Europe/London)
cassyni.com/events/2ZYBm3LDWSqgwbq5FLEtAH?vxce1h -
Nature Cancer reposted
Nature Conferences
@NatureConf
Don't forget to get your tix to #tumourlandscape23 and learn from all these experts!
@JudithAgudo1 @LeilaAkkari1 @MDAndersonNews @thalexandrov @WeillCornell @FAndreMD @Armstrong_dfci @michal_bassani @MAF_Dawson @ldiaz1971 @CRUK_MI @FendtLab
Book here: conferences.nature.com/TumourLandscape -
Nature Cancer
@NatureCancer
📢On Sep 28th 🗓️Nature Portfolio editors will host - "Roundtable on Black in cancer research and oncology" presented by @DrBlueMD, @TheOncDocs, @kilanbishop and @runciecwc.
We look forward to discussing challenges and brainstorming about solutions ‼️
Register for free here 👇
@SN_Oncology
Check out the seminar "Roundtable on Black in cancer research and oncology" presented by @DrBlueMD, @TheOncDocs, @kilanbishop and @runciecwc, chaired by Nature Portfolio editors.
🗓️ Thursday 28th Sep 2023
⏲️ 14.00 PM (Europe/London)
cassyni.com/events/2ZYBm3LDWSqgwbq5FLEtAH?vxce1h -
Nature Cancer
@NatureCancer
✨ONLINE NOW @NatureCancer - “Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade” by @PamSharmaMDPhD @SGoswamiMDPhD & Co.
Find it here👇
www.nature.com/articles/s43018-023-00620-0
rdcu.be/dlt7U -
Nature Cancer
@NatureCancer
💫NEW @NatureCancer - “A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer” by @thomasrcox @TCox_Lab @GarvanInstitute & CO.
Read it here👇
www.nature.com/articles/s43018-023-00614-y
rdcu.be/dlt7r -
Nature Cancer
@NatureCancer
✨ONLINE NOW @NatureCancer “Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma” by #takmak & Co @pmcancercentre.
Read it here👇
www.nature.com/articles/s43018-023-00624-w
rdcu.be/dlt6l -
Nature Cancer reposted
Thomas R. Cox @thomasrcox
We are happy to announce that our program of work on the development & deployment of a novel anti-fibrotic in pancreatic cancer has just been published (OpenAccess) in @NatureCancer | → www.nature.com/articles/s43018-023-00614-y ← | @TCox_Lab @GarvanInstitute #extracellularmatrix #ecm #cancer
-
Nature Cancer
@NatureCancer
DON’T MISS the @NatureCancer AUGUST ISSUE – with exciting new content on lineage switch in #cartcell therapy, WNTinib for #hcc, tumor immunology, #gammadeltatcells, translation in #prostatecancer and more.
Find it here👇
www.nature.com/natcancer/volumes/4/issues/8 -
Nature Cancer
@NatureCancer
⭐️DON’T MISS @NatureCancer “IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells” by #kaijiehe & Co.
Read it here👇
www.nature.com/articles/s43018-023-00612-0
rdcu.be/djQVq -
Nature Cancer
@NatureCancer
✨ONLINE NOW @NatureCancer “Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms” by #simonmendezferrer & Co.
Read it here👇
www.nature.com/articles/s43018-023-00607-x
rdcu.be/djQUG -
Nature Cancer
@NatureCancer
💫NEW REVIEW ARTICLE @NatureCancer “Cancer cell plasticity during tumor progression, metastasis and response to therapy” by @CedricBlanpain
@Andreapg_1998 & Co.
Read it here👇
www.nature.com/articles/s43018-023-00595-y
rdcu.be/djQTp -
Nature Cancer
@NatureCancer
NEW REVIEW ARTICLE @NatureCancer “Understanding the mechanisms and translational implications of the microbiome for cancer therapy innovation” by @DrCindySears & CO.
Read it here👇
www.nature.com/articles/s43018-023-00602-2
rdcu.be/djQRy -
Nature Cancer
@NatureCancer
📢Don't forget to submit your abstract for our upcoming conference #tumourlandscape23 at @MSKCancerCenter by August 28th!
(checks notes)
💫stellar speaker line-up
💡amazing science
🍂fall in New York
✍️Brush up on your writing skills and submit your abstract soon!
Nature Conferences
@NatureConf
Deadline: Aug 28
Submit at: www.cvent.com/c/abstracts/d6bb97fe-d00c-4608-be5f-3182298…
Topics:
#mappingtumours #tumors #microenvironment
#systemicenvironment #therapeutictargeting #therapyresistance and more
@MSKCancerCenter @NatureCancer @NatureRevCancer
#tumourlandscape23 -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Protein-level mutant p53 reporters identify druggable rare precancerous clones in noncancerous tissues” by #yuanwang & Co.
Read it here👇
www.nature.com/articles/s43018-023-00608-w?platform=oscar…
rdcu.be/diuDF -
Nature Cancer
@NatureCancer
🔥HOT OFF THE PRESS @NatureCancer “WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma” by @DarArvin & Co.
Read it here👇
www.nature.com/articles/s43018-023-00609-9?platform=oscar…
rdcu.be/diyDz -
Nature Cancer
@NatureCancer
⭐️NEW ARTICLE @NatureCancer “CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axis” by @EmilyCLerner @PeterFecci & Co.
Don’t miss it👇
www.nature.com/articles/s43018-023-00600-4?platform=oscar…
rdcu.be/diyEb -
Nature Cancer
@NatureCancer
💫DON’T MISS – “Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma” @NatureCancer by @RoeschAlexander & Co.
Read it here👇
www.nature.com/articles/s43018-023-00610-2
rdcu.be/diyE0 -
Nature Cancer reposted
Arvin Dar @DarArvin
How can you selectively block an oncogenic transcription factor? We found that reactivating the epigenetic repressor ezh2 does the job against mutant b-catenin. Mechanism uncovered with a new KI that we developed and named WNTinib. Check out the paper @NatureCancer
-
Nature Cancer
@NatureCancer
⭐️“Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response” by #qinglingzhang #qibinleng #junchen & #guangshuaijia & Co.
Read it here @NatureCancer
www.nature.com/articles/s43018-023-00598-9?platform=oscar…
rdcu.be/dhpTF -
Nature Cancer
@NatureCancer
💫DON’T MISS “The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells” by #andreaalimonti & Co. #prostatecancer
www.nature.com/articles/s43018-023-00594-z?platform=oscar…
rdcu.be/dhpSM -
Nature Cancer
@NatureCancer
🔥HOT OFF THE PRESS @NatureCancer “Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy” by @TimCoorens @broadinstitute @sangerinstitute @getz_lab #sambehjati & Co
Read it here 👇
www.nature.com/articles/s43018-023-00604-0?platform=oscar…
rdcu.be/dhpRI -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “γδ T cell dichotomy with opposing cytotoxic and wound healing functions in human solid tumors” by @CathalHarmon @lynchielydia & Co.
Get some new insights into γδ T cells here👇
www.nature.com/articles/s43018-023-00589-w
rdcu.be/dhpQW -
Nature Cancer reposted
Lydia Lynch
@lynchielydia
Congratulations @CathalHarmon leading this study, a great collaboration between @HaimMoore and Alex Zaborowski, and clinicial colleagues @des_winter and @donalb5. Our bet is on gd for a cell therapy for solid tumors, and we aimed to understand them better
doi.org/10.1038/s43018-023-00589-w -
Nature Cancer reposted
Tim Coorens
@TimCoorens
Very excited to see our study on a case of ALL to AML switch after CAR-T treatment out in @NatureCancer! Using deep genome sequencing, we show the cancer switched cell types to escape therapy.
@broadinstitute @sangerinstitute @getz_lab
Thread below 🧵
www.nature.com/articles/s43018-023-00604-0 -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer – “ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer” by @chiarlelab & Co.
Read it here👇
www.nature.com/articles/s43018-023-00591-2?platform=oscar…
rdcu.be/dgPwX -
Nature Cancer
@NatureCancer
💫Check out this beautiful REVIEW ARTICLE @NatureCancer – “The landscape of T cell antigens for cancer immunotherapy” by @samuels_yardena @macropino @AviyahPeri @YochaiW @tronmainz #nadjasalomon #sebastiankreiter
Read it here👇
www.nature.com/articles/s43018-023-00588-x
rdcu.be/dgPrV -
Nature Cancer reposted
yardena samuels @samuels_yardena
Happy to share our latest review @NatureCancer on The landscape of T cell antigens for cancer immunotherapy | Nature Cancer . A Great collaboration with @macropino @sebastian Kreiter, @YochaiW @nadia salomon and @AviyahPeri !!!! www.nature.com/articles/s43018-023-00588-x
-
Nature Cancer
@NatureCancer
💫NEW CONTENT @NatureCancer “High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers” by #sandrosantagata #peterksorger & Co. #biomarker
www.nature.com/articles/s43018-023-00576-1
rdcu.be/dfFGa -
Nature Cancer
@NatureCancer
‼️A new position has opened @Nature Cancer - come join our editorial team ‼️
We're hiring Associate/Senior Editors in our NY, Washington DC, Philadelphia, London, Madrid, Heidelberg, Berlin & Pune offices. Application deadline July 16th.
Details⬇️
www.nature.com/naturecareers/job/12801124/associate-or-se… -
Nature Cancer
@NatureCancer
ONLINE NOW @NatureCancer “Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer” @LabGenovese & CO. #kidneycancer
Read it here 👇
www.nature.com/articles/s43018-023-00584-1
rdcu.be/dfFFb -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation” by #prasadadusumilli & Co.
#cartcells #immunotherapy
Read it here👇
www.nature.com/articles/s43018-023-00573-4
rdcu.be/dfFH0 -
Nature Cancer
@NatureCancer
☀️THE @NatureCancer JUNE ISSUE IS OUT 🏖️– time for some summer reading on resistance to #krasinhibitors, adverse events of #immunotherapy, #clinicaltrials in #nsclc, #metabolism and #metastasis and much more!
CHECK IT OUT HERE👇
www.nature.com/natcancer/volumes/4/issues/6
And what a cover 😍 -
Nature Cancer reposted
Nature Conferences
@NatureConf
Who else can't wait for #tumourlandscape23 to hear about the latest cancer research from @vib_ccb @SJMorrison_ @jnkath @DrIgMelero @GustaveRoussy @EKFStiftung @PKU1898 !
🎟️Get your tix at: conferences.nature.com/TumourLandscape
@MSKCancerCenter @NatureCancer @NatureRevCancer @Nature -
Nature Cancer
@NatureCancer
💫ONLINE NOW - @NatureCancer „Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer” by #jungkyoonchoi #sookryunpark & Co.
Read it here👇
www.nature.com/articles/s43018-023-00572-5
rdcu.be/dePqA -
Nature Cancer
@NatureCancer
💫“Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC” by #caicunzhou & Co. #clinicaltrials #lungcancer
Read it here👇
www.nature.com/articles/s43018-023-00578-z
rdcu.be/deRub -
Nature Cancer
@NatureCancer
💫“Non-lethal outcomes of engaging regulated cell death pathways in cancer” – a perspective by #douglasrgreen & Co. #celldeath
Read it here👇
www.nature.com/articles/s43018-023-00571-6
rdcu.be/ddRel -
Nature Cancer
@NatureCancer
☀️NEW ARTICLE @NatureCancer “Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS” – by #hiromichiebi & Co.
Read it here 👇
www.nature.com/articles/s43018-023-00575-2
rdcu.be/ddRdZ -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance” by #marieevangelista #xinye #jamesjcrawford #anweshadey & Co.
Read it here👇
www.nature.com/articles/s43018-023-00577-0
rdcu.be/ddRcP -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “CD4+ T cells in cancer” by #danielespeiser #obinnachijioke #karinschaeuble & #christianmünz.
Find it here👇
www.nature.com/articles/s43018-023-00521-2
rdcu.be/c77WL -
Nature Cancer
@NatureCancer
ONLINE NOW @NatureCancer “Understanding inequities in precision oncology diagnostics” – a Perspective by #franklinwhuang, @TimRebbeck & CO.
Don’t miss it👇
www.nature.com/articles/s43018-023-00568-1
rdcu.be/ddrMY -
Nature Cancer
@NatureCancer
“Breathing room – focusing on the ‘other’ lung cancer” – a #turningpoint by @charlesrudin. Don’t miss this interesting read. 👇
www.nature.com/articles/s43018-023-00569-0 -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias” by #franciscavazquez, #aviadtsherniak & #constantinesmitsiades.
Here👇
www.nature.com/articles/s43018-023-00550-x
rdcu.be/ddrKb -
Nature Cancer
@NatureCancer
Read this N&Vs by @LabScorrano on work by @JustinLathia & Co recently published in @NatureCancer.
www.nature.com/articles/s43018-023-00556-5
Check it out:
www.nature.com/articles/s43018-023-00564-5 -
Nature Cancer
@NatureCancer
Don’t miss this N&Vs discussing two recent @NatureCancer papers by:
@YMerbl & Co
www.nature.com/articles/s43018-023-00557-4
@michal_bassani & Co
www.nature.com/articles/s43018-023-00548-5
Read it here 👇www.nature.com/articles/s43018-023-00552-9 -
Nature Cancer
@NatureCancer
☀️Just before the month is over – have a look at our @NatureCancer MAY ISSUE including exciting new science on #glioblastoma, #immunotherapy, #nsclc & more. Check out our new article format #turningpoints and an editorial on the art of scientific writing.
www.nature.com/natcancer/volumes/4/issues/5 -
Nature Cancer
@NatureCancer
💫NEW CONTENT @NatureCancer – “Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity” by @BoussoLab & Co.
Find it here👇
www.nature.com/articles/s43018-023-00570-7
rdcu.be/ddqbN -
Nature Cancer
@NatureCancer
🔥ONLINE NOW @NatureCancer – “Limiting mitochondrial plasticity by targeting DRP1 induces metabolic reprogramming and reduces breast cancer brain metastases” by @MalladiLab & Co. #metastasis
Read it here 👇
www.nature.com/articles/s43018-023-00563-6
rdcu.be/ddrFA -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “ALK-positive lung cancer: a moving target” by, @DrJaimeLaurel @JessicaJLinMD & #alicetshaw.
Find it here👇
www.nature.com/articles/s43018-023-00515-0
rdcu.be/c77V4 -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “Artificial intelligence in histopathology: enhancing cancer research and clinical oncology” by #artemshmatko # @MoritzGerstung @jnkath.
Find it here👇
www.nature.com/articles/s43018-022-00436-4
rdcu.be/c77VP -
Nature Cancer
@NatureCancer
Don’t miss our new format – TURNING POINTS @NatureCancer, where scientists discuss career-changing life choices and encounters. Check out our first two – inspiring stories by #elaineemardis or @MAF_Dawson
Find them here 👇
www.nature.com/articles/s43018-023-00565-4
www.nature.com/articles/s43018-023-00558-3 -
Nature Cancer
@NatureCancer
What should be our standards on reporting sex and gender in research? Our @NatureCancer editorial discusses how we raise the standards on reporting these aspects.
Find it here👇
www.nature.com/articles/s43018-022-00392-z
rdcu.be/c8cra -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “Cancer-associated fibroblasts in the single-cell era” by #dorlavie #aviadbenshmuel @ErezNeta @shouval.
Find it here👇
www.nature.com/articles/s43018-022-00411-z
rdcu.be/c77U6 -
Nature Cancer reposted
Case Comp Cancer Ctr
@caseccc
Co-leader of Case CCC's Molecular Oncology Program, @JustinLathia, and colleagues recently published work in @NatureCancer that shows that mitochondria transfer is a prevalent phenomenon in glioblastoma www.nature.com/articles/s43018-023-00556-5
#cancerresearch -
Nature Cancer reposted
Yifat Merbl lab
@YMerbl
Curious how cancer cells manipulate their protein degradation machinery to suppress anti-tumor immunity? Today, we report in @NatureCancer that the PSME4 cap impairs proteasome activity and antigen diversity, thus weakening anti-tumor immunity and the response to immunotherapy🧵
-
Nature Cancer
@NatureCancer
✨NEW CONTENT @NatureCancer “The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC” by @AaronJavitt @shmueli_merav @YMerbl & Co. #lungcancer
Read it here👇
www.nature.com/articles/s43018-023-00557-4
rdcu.be/dcJoc -
Nature Cancer
@NatureCancer
🔥ONLINE NOW @NatureCancer “Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation” by @WischnewskiVlad @Johanna_A_Joyce & Co! #braintumors #tcells
Read it here 👇
www.nature.com/articles/s43018-023-00566-3
rdcu.be/dcJn1 -
Nature Cancer
@NatureCancer
📢Come join our editorial team!
We're hiring Associate/Senior Editors in our NY, Berlin & Shanghai offices. Other Springer Nature offices in the US, China or Europe will also be considered. Application deadline June 5th.
Details⬇️
go.nature.com/3OxKQ5a
go.nature.com/3IvJAeM -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “Translational advances in pancreatic ductal adenocarcinoma therapy”by #abdelnasserhosein #stephaniekdougan #andrewaguirre @Aiims1742
Find it here👇
www.nature.com/articles/s43018-022-00349-2
rdcu.be/c77QL -
Nature Cancer
@NatureCancer
What is the value of data sharing? Read all about it in our @NatureCancer editorial.
Find it here👇
www.nature.com/articles/s43018-021-00217-5
rdcu.be/c8cr0 -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE –“ Overcoming therapy resistance in EGFR-mutant lung cancer” by @APassaroMD #pasiajänne #tony Mok @peters_solange.
Find it here👇
www.nature.com/articles/s43018-021-00195-8
rdcu.be/c77JD -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer PERSPECTIVE – “Bystander T cells in cancer immunology and therapy” by #stefanielmeier @Satpathology & #danielkwells.
Find it here👇
www.nature.com/articles/s43018-022-00335-8
rdcu.be/c77Z5 -
Nature Cancer
@NatureCancer
Who signs the paper? Find out in our @NatureCancer Editorial.
Find it here👇
www.nature.com/articles/s43018-023-00517-y
rdcu.be/c8cqC -
Nature Cancer
@NatureCancer
💫NEW CONTENT @NatureCancer “The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer” by @michal_bassani & Co.
Don't miss it👇
www.nature.com/articles/s43018-023-00548-5
rdcu.be/dbJDw -
Nature Cancer
@NatureCancer
🔥ONLINE NOW @NatureCancer – “EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance” by @LoweLabMSKCC @Marcus_Ruscetti & Co.
👇Read it here
www.nature.com/articles/s43018-023-00553-8
rdcu.be/dbJDc -
Nature Cancer reposted
Marcus Ruscetti Lab
@Marcus_Ruscetti
Thrilled to share our recent paper published online today at @NatureCancer led by our talented postdoc Lo Chibaya and in collaboration with @LoweLabMSKCC and others at @UMassChan @UMassCancerCtr @UMassChanMCCB and
@MSKCancerCenter!
rdcu.be/dbmYH
www.nature.com/articles/s43018-023-00553-8 -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches” by #stefanopiccolo #titopanciera #paolocontessotto & #michelangelocordenonsi.
Find it here👇
www.nature.com/articles/s43018-022-00473-z
rdcu.be/c77VZ -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “The present and future of PI3K inhibitors for cancer therapy” by @castel_pau @EnedaToska #jeffreyaengelman @ScaltritiLab.
Find it here👇
www.nature.com/articles/s43018-021-00218-4
rdcu.be/c77KW -
Nature Cancer
@NatureCancer
What is the true impact of a paper? Our @NatureCancer editorial discusses approaches to capture impact.
Find it here👇
www.nature.com/articles/s43018-022-00435-5
rdcu.be/c8cq8 -
Nature Cancer
@NatureCancer
💫DON’T MISS our @NatureCancer April issue.
Exciting content on #immunotherapy, #metastasis, #clinicaltrials, #ferroptosis and more – check it out here 👇👇👇
www.nature.com/natcancer/volumes/4/issues/4 -
Nature Cancer
@NatureCancer
Are you attending #cimt2023 @C_IMT in Mainz 🇩🇪Germany? Don’t miss the chance to talk to our Editor @LisaHaas0107 about your work and ask all your ❓related to publishing in @NatureCancer.
#immunotherapy -
Nature Cancer reposted
Nature Conferences
@NatureConf
A new event on exciting breakthrough #tumour #research is now open for registration! Students are welcome to submit abstracts. conferences.nature.com/TumourLandscape
In partnership with @GBeene_MSK @nature @NatureCancer @NatureRevCancer -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “Engineering-enhanced CAR T cells for improved cancer therapy” by #michaelcmilone #jiexu #saijuanchen, #mckensieacollins #jianfengzhou @DJPowellLab & @j_melenhorst.
Find it here👇
www.nature.com/articles/s43018-021-00241-5
rdcu.be/c77Lz -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE - “The metabolic landscape of RAS-driven cancers from biology to therapy” by #frankmccormick #sumanmukhopadhyay & @mvh_lab.
Find it here👇
www.nature.com/articles/s43018-021-00184-x
rdcu.be/c77IK -
Nature Cancer
@NatureCancer
When and where to interact with editors? Our @NatureCancer editorial discusses our commitment to communication.
Find it here👇
www.nature.com/articles/s43018-021-00296-4
rdcu.be/c8crw -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “The current landscape of immunotherapy for pediatric brain tumors” by #eugeneihwang #duaneamitchell & #ianfpollack & Co.
Find it here👇
www.nature.com/articles/s43018-021-00319-0
rdcu.be/c77Qs -
Nature Cancer
@NatureCancer
💫DON’T MISS @NatureCancer “Inferring early genetic progression in cancers with unobtainable premalignant disease” by @getz_lab #jamesrocco @OhioState & Co.
Check it our here👇
www.nature.com/articles/s43018-023-00533-y
rdcu.be/daGD9 -
Nature Cancer reposted
Gad Getz Laboratory
@getz_lab
(1/3) Out now @NatureCancer! Our collab with Dr. James Rocco @OhioState shows that our PhylogicNDT suite of tools can infer early genetic progression and timing of mutations to identify early drivers in HPV- & HPV+ head and neck cancers (#hnscc) rdcu.be/damHp
-
Nature Cancer
@NatureCancer
🔥NEW CONTENT @NatureCancer “Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma” by @snijderlab & Co.
Find it here👇
www.nature.com/articles/s43018-023-00544-9
rdcu.be/daGCy -
Nature Cancer reposted
Snijder Lab @snijderlab
#tweetorial 🧵 for our #multiplemyeloma paper in @NatureCancer:
Despite approved treatment options, MM is incurable, with several patient relapses/disease, leading to ⬆️ #drugresistance &⬇️ fitness. So @KlaraKropivsek & Paul Kachel set out to improve #personalizedmedicine for MM.Snijder Lab @snijderlab
Just out in @NatureCancer: #singlecell #microscopy integrated with #omics uncovers the molecular network underlying #multiplemyeloma drug resistance.
Congratulations to Klara, Paul & @BerendSnijder! go.nature.com/3ozgeFa
#personalizedmedicine #functionalprecisionmedicine -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma” by @LeilaAkkari1 @LuukvanHooren @ShannaHandgraaf & Co.
Read it here👇
www.nature.com/articles/s43018-023-00547-6
rdcu.be/daGA8 -
Nature Cancer reposted
Leila Akkari
@LeilaAkkari1
Excited to see our work out @NatureCancer ! Lead by great post doc @LuukvanHooren and fab PhD student @ShannaHandgraaf, helped by @djkloosterman & others-We asked- what happens to the glioblastoma TME that makes IT fails? A 🧵rdcu.be/damHE
-
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “Cancer vaccines: the next immunotherapy frontier” by @JoshuaBrodyMD & Co.
#immunotherapy
Find it here👇
www.nature.com/articles/s43018-022-00418-6
rdcu.be/c77Vr -
Nature Cancer
@NatureCancer
What to consider before clicking the submit button? Find out in our @NatureCancer editorial.
Find it here👇
www.nature.com/articles/s43018-021-00265-x
rdcu.be/c8crP -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE - “Dysregulation and therapeutic targeting of RNA splicing in cancer” #robertfstanley & @AbdelWahablab.
Find it here👇
www.nature.com/articles/s43018-022-00384-z
rdcu.be/c77Tx -
Nature Cancer
@NatureCancer
💫NEW REVIEW ARTICLE @NatureCancer - “Impact of context-dependent autophagy states on tumor progression” by #aleckimmelman and #mohamadassi.
#autophagy
Read it here👇
www.nature.com/articles/s43018-023-00546-7
rdcu.be/c9988 -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “Moving pan-cancer studies from basic research toward the clinic” by #fengchen #michaelcwendl #matthewawyczalkowski #matthewhbailey #yizeli & #liding.
Find it here👇
www.nature.com/articles/s43018-021-00250-4
rdcu.be/c77O3 -
Nature Cancer reposted
Toni Choueiri, MD
@DrChoueiri
Outstanding work from @mishabeltran Lab and colleagues in @NatureCancer==> "Landscape of Prostate-Specific Membrane Antigen Heterogeneity and Regulation in AR-positive and AR-negative Metastatic Prostate Cancer"
www.nature.com/articles/s43018-023-00539-6
@DanaFarber_GU @DanaFarber @OncoAlert
Dana-Farber News
@DanaFarberNews
New research in @NatureCancer reveals HOXB13 protein as key regulator of PSMA in #prostatecancer and demonstrates PSMA control is complex.
Read more ➡️ www.dana-farber.org/newsroom/news-releases/2023/research-…
CC: @mishabeltran @DanaFarber_GU -
Nature Cancer
@NatureCancer
We are really excited about the AACR annual meeting in Orlando April 14th-19th! ☀️#aacr23
Meet our chief editor @alexia_zz, who will be attending in person and is excited to hear about your work and answer all questions related to @NatureCancer!
www.aacr.org/meeting/aacr-annual-meeting-2023/ -
Nature Cancer reposted
MarleenKokLab
@lab_kok
💪🏼Proud of my team @NKI_nl! we were able to run the FIRST ever trial specifically for lobular breast cancer! Thanks @NatureCancer for seeing the Unseen cancer subtypes! Moreover we hereby validate preclinical findings on immunogenicity of lobular BC by @deVisserKarin @CirielloLab
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial” by @lab_kok @LVoorwerk & Co. #immunotherapy
@NatResCancer
Read it here👇
www.nature.com/articles/s43018-023-00542-x
rdcu.be/c9IWs -
Nature Cancer
@NatureCancer
How does @NatureCancer value preprints? Find out about it in our editorial.
Find it here👇
www.nature.com/articles/s43018-020-00151-y
rdcu.be/c8csb -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer” by @mishabeltran @mkbakht & Co.
@NatResCancer
Read it here👇
www.nature.com/articles/s43018-023-00539-6
rdcu.be/c9IYU -
Nature Cancer
@NatureCancer
✨DON’T MISS @NatureCancer "Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab” by @PughLab #katiehutchinson & Co.
@NatResCancer
Read it here👇
www.nature.com/articles/s43018-023-00534-x
rdcu.be/c9IU4 -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial” by @lab_kok @LVoorwerk & Co. #immunotherapy
@NatResCancer
Read it here👇
www.nature.com/articles/s43018-023-00542-x
rdcu.be/c9IWs -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer PERSPECTIVE – “Targeting public neoantigens for cancer immunotherapy” #shibinzhou & Co.
Find it here👇
www.nature.com/articles/s43018-021-00210-y
rdcu.be/c772D -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “Advances in antibody-based therapy in oncology” by #danielchrist & Co. #therapy
Find it here👇
www.nature.com/articles/s43018-023-00516-z
rdcu.be/c77WH -
Nature Cancer reposted
Scientific American
@sciam
Recognize a changemaker in the cancer community for their innovation from lab to living room! Nominations for the fifth annual #c2awards are open. [with @AstraZenecaUS]
-
Nature Cancer
@NatureCancer
What happens to a manuscript after submission? Read all the details in our @NatureCancer editorial.
Find it here👇
www.nature.com/articles/s43018-021-00253-1
rdcu.be/c8crW -
Nature Cancer
@NatureCancer
Don’t forget to check out the accompanying News & Views “Masking T cell engagers mitigates on-target off-tumor activity” by @SpanglerLab.
Find it here👇
www.nature.com/articles/s43018-023-00529-8
rdcu.be/c88n9
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors” by #volkerschellenberger & Co. #immunotherapy
Read it here👇
www.nature.com/articles/s43018-023-00536-9
www.nature.com/articles/s43018-023-00536-9 -
Nature Cancer
@NatureCancer
💫DON’T MISS @NatureCancer “Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer” by #yingjiang and #zhiyongmao. #breastcancer #therapy
Find it here 👇
www.nature.com/articles/s43018-023-00535-w
rdcu.be/c88nm -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors” by #volkerschellenberger & Co. #immunotherapy
Read it here👇
www.nature.com/articles/s43018-023-00536-9
www.nature.com/articles/s43018-023-00536-9 -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “The cGAS–STING pathway and cancer” by #natashasamson & #andreaablasser.
Find it here👇
www.nature.com/articles/s43018-022-00468-w
rdcu.be/c77VQ -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “Charting roadmaps towards novel and safe synergistic immunotherapy combinations” by #miguelfsanmamed #pedroberraondo #mariaerodriguezruiz @DrIgMelero.
#immunotherapy
Find it here👇
www.nature.com/articles/s43018-022-00401-1
rdcu.be/c77Ut -
Nature Cancer
@NatureCancer
What to consider when peer-reviewing? Our @NatureCancer editorial discusses the labors of referees.
Find it here👇
www.nature.com/articles/s43018-021-00281-x
rdcu.be/c8crI -
Nature Cancer
@NatureCancer
💫"The cornucopia of cancer biology" - don't miss our editorial that highlights some of the beautiful cancer biology published in our recent MARCH ISSUE.
Read it here 👇
www.nature.com/articles/s43018-023-00541-y
Nature Cancer
@NatureCancer
Our @NatureCancer 💐MARCH ISSUE 🌺 is ONLINE! Find out about many new exciting studies related to #metastasis – with links to #metabolism #celldeath and #tme.
Don’t miss it here 👇
www.nature.com/natcancer/volumes/4/issues/3 -
Nature Cancer
@NatureCancer
Don’t miss our @NatureCancer Research Briefing to get additional background info on this beautiful study by @alteam_patricia @FendtLab & Co.
Read it here👇
www.nature.com/articles/s43018-023-00514-1
Nature Cancer
@NatureCancer
🔥Fascinating study on #metastasis @NatureCancer - “A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling” by @alteam_patricia @FendtLab & Co.
Read it here👇
www.nature.com/articles/s43018-023-00513-2
rdcu.be/c4ZPB -
Nature Cancer
@NatureCancer
As part of our @NatureCancer MARCH ISSUE don’t miss – “Disrupting the phase separation of KAT8–IRF1 diminishes PD-L1 expression and promotes antitumor immunity” by #tiebangkang & Co.
@NatResCancer
Read it here👇
nature.com/articles/s43018-023-00522-1
rdcu.be/c8EVU -
Nature Cancer
@NatureCancer
💫Don’t miss this News & Views “Exploiting liver metabolism for tissue-specific cancer targeting” by #zixiwang and #haozhu, highlighting work by #nabeelbardeesy @MassGeneralNews & Co.
👇
www.nature.com/articles/s43018-023-00530-1
Nature Cancer
@NatureCancer
✨NEW ARTICLE @NatureCancer - „SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers” by #nabeelbardeesy @MassGeneralNews & Co.
@NatResCancer
Read it here 👇
www.nature.com/articles/s43018-023-00523-0
rdcu.be/c7EW3 -
Nature Cancer
@NatureCancer
⭐️Don’t miss “Apoptosis-induced nuclear expulsion in tumor cells drives S100a4-mediated metastatic outgrowth through the RAGE pathway” by #liyang & CO. #metastasis
Read it here 👇
www.nature.com/articles/s43018-023-00524-z
rdcu.be/c8ER4 -
Nature Cancer
@NatureCancer
Our @NatureCancer 💐MARCH ISSUE 🌺 is ONLINE! Find out about many new exciting studies related to #metastasis – with links to #metabolism #celldeath and #tme.
Don’t miss it here 👇
www.nature.com/natcancer/volumes/4/issues/3 -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “Molecular pathogenesis and systemic therapies for hepatocellular carcinoma” by #josepmllovet & Co. #hcc
Find it here👇
www.nature.com/articles/s43018-022-00357-2
rdcu.be/c77Ts -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment” by #nidapasha #nicholascturner. #metastasis
Find it here👇
www.nature.com/articles/s43018-021-00229-1
rdcu.be/c77Lh -
Nature Cancer reposted
Saur Lab @SaurLab
Lost overview of all recent single-cell studies in #pancreaticcancer?👀
Check out our new @NatureCancer review with @StefanieBa, @ChiaraFalcomata, @fabian_theis & Roland Rad: www.nature.com/articles/s43018-023-00526-x
#scrna-seq #spatial #tme -
Nature Cancer
@NatureCancer
⭐️NEW REVIEW @NatureCancer “Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy” by @SaurLab @StefanieBa @ChiaraFalcomata @fabian_theis #rolandrad.
Don’t miss it 👇
www.nature.com/articles/s43018-023-00526-x
rdcu.be/c8kbc -
Nature Cancer
@NatureCancer
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE - " Emerging strategies for treating metastasis” by #markesposito #shridarganesan @yibinkang. #metastasis
Find it here👇
www.nature.com/articles/s43018-021-00181-0
rdcu.be/c77JB -
Nature Cancer reposted
Visualizing and Targeting Cancer Stress
@CoE_iFIT
Still three to go! Extremly happy to welcome Ioanna Pavlaki, editor at @NatureCancer! she will provide us with helpful insides on how to publish your next study findings! #cancerresearch #publish #naturecancer
3/5🧵 -
Nature Cancer
@NatureCancer
💫DON’T MISS @NatureCancer - “Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment” by @Vignali_Lab @oesterreichs & Co. @NatResCancer
Read it here👇
www.nature.com/articles/s43018-023-00527-w
rdcu.be/c76Wg -
Nature Cancer reposted
Vignali Lab @Vignali_Lab
Excited to share our latest paper in @NatureCancer entitled "Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment". rdcu.be/c7MWs
-
Nature Cancer
@NatureCancer
☀️NEW REVIEW ONLINE NOW @NatureCancer „CD4+ T cells in cancer” – a beautiful summary by #danielspeiser #christinamünz & Co. Don’t miss it!
Find it here👇
www.nature.com/articles/s43018-023-00521-2?platform=oscar…
rdcu.be/c7EY5 -
Nature Cancer
@NatureCancer
✨NEW ARTICLE @NatureCancer - „SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers” by #nabeelbardeesy @MassGeneralNews & Co.
@NatResCancer
Read it here 👇
www.nature.com/articles/s43018-023-00523-0
rdcu.be/c7EW3 -
Nature Cancer reposted
Mammary Cell News
@MammaryCell
🖨️ Published today in @NatureCancer!
@ICR_London researcher, Dr. @ClareIsacke led this study that highlights the opportunity to target PDGF-C signaling 🚦 to limit metastatic relapse in ER+ #breastcancer.
👉 Full story: go.nature.com/3ywS7Jc -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Age-associated microenvironmental changes highlight the role of PDGF-C in ER+ breast cancer metastatic relapse” by
@ClareIsacke @ICR_London & Co. #metastasis #aging
@NatResCancer
Read it here 👇
nature.com/articles/s43018-023-00525-y
rdcu.be/c7EV7 -
Nature Cancer
@NatureCancer
Attending “Immune Responses & DNA Repair” in beautiful Florence 🇮🇹 this week? Don’t miss the chance to meet our Senior Editor @LisaHaas0107 to discuss your work and all things related to publishing at @NatureCancer.
#easimmuneresponses
@EACRnews @AACR -
Nature Cancer
@NatureCancer
🔥Don’t miss the exciting content of the @NatureCancer FEBRUARY ISSUE – resistance to targeted #therapy, mutational signatures & #genomics in #childhoodcancer, #proteogenomics in pancreatic cancer, master kinases in #glioblastoma and more!
Find it here 👇
www.nature.com/natcancer/volumes/4/issues/2 -
Nature Cancer
@NatureCancer
"Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes" by @ranigeorgelab & Co @NatureCancer.
#iwd2023
Read it here 👇
www.nature.com/articles/s43018-022-00427-5
rdcu.be/c6251 -
Nature Cancer
@NatureCancer
"A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology" by @AlanaWelm & Co @NatureCancer.
#iwd2023
Read it here👇
www.nature.com/articles/s43018-022-00337-6
rdcu.be/c6XnQ -
Nature Cancer
@NatureCancer
"Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer" by #helenhezhu & Co @NatureCancer.
#iwd2023
Read it here👇
www.nature.com/articles/s43018-022-00380-3
rdcu.be/c6XnE -
Nature Cancer
@NatureCancer
"Reciprocal interactions between innate immune cells and astrocytes facilitate neuroinflammation and brain metastasis via lipocalin-2" by @ErezNeta & Co @NatureCancer.
#iwd2023
Read it here👇
www.nature.com/articles/s43018-023-00519-w
rdcu.be/c6Xnr -
Nature Cancer
@NatureCancer
"Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice" by @LoiSher @HuttLab & Co @NatureCancer.
#iwd2023
Read it here 👇
www.nature.com/articles/s43018-022-00413-x
rdcu.be/c6XlP -
Nature Cancer
@NatureCancer
"Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice" by @LoiSher @HuttLab & Co @NatureCancer.
#iwd2023
Read it here 👇
www.nature.com/articles/s43018-022-00413-x
rdcu.be/c6XlP -
Nature Cancer
@NatureCancer
"A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling" by @FendtLab & Co @NatureCancer.
#iwd2023
Read it here 👇
www.nature.com/articles/s43018-023-00513-2
rdcu.be/c6XkB -
Nature Cancer
@NatureCancer
"Structural variants shape driver combinations and outcomes in pediatric high-grade glioma" by @Bando_Lab & Co @NatureCancer.
#iwd2023
Read it here 👇
www.nature.com/articles/s43018-022-00403-z
rdcu.be/c6Xjo -
Nature Cancer
@NatureCancer
"A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC" by @KaramLab & Co @NatureCancer.
#iwd2023
Read it here 👇
www.nature.com/articles/s43018-022-00450-6
rdcu.be/c6Xie -
Nature Cancer
@NatureCancer
"Radiation exposure elicits a neutrophil-driven response in healthy lung tissue that enhances metastatic colonization" by @IMalanchi & Co @NatureCancer.
#iwd2023
Read it here 👇
www.nature.com/articles/s43018-022-00336-7
rdcu.be/c6XgK -
Nature Cancer
@NatureCancer
Happy International Women's Day #iwd2023 !
@NatureCancer supports #womeninscience - please join us to celebrate some of the wonderful female scientists & clinicians who recently published their work with us – we hope you are inspired by them! 👩🔬 -
Nature Cancer
@NatureCancer
Don't miss the chance to talk to our @NatureCancer Senior editor Julia Simundza at the #kscancerimmuno23 Meeting in beautiful Banff 🇨🇦 about your work and all things related to publishing in Nature Cancer. @KeystoneSymp
-
Nature Cancer reposted
International Lung Cancer Summit
@LungSummit
What do we know about #alk as a target in #lungcancer? 🤔🧬
Read this new review by @DrJaimeLaurel, @JessicaJLinMD & Alice Shaw, who discuss resistance mechanisms to ALK-directed therapy & new treatment approaches for ALK+ lung cancers.
@NatureCancer ➡️ go.nature.com/3SdrB0c -
Nature Cancer
@NatureCancer
💫DON’T MISS this Review on “Advances in antibody-based therapy in oncology” @NatureCancer by #saschazinn #rodrigovazquezlombardi #carstenzimmermann #pujasapra #lutzjermutus and #danielchrist.
Read it here 👇
www.nature.com/articles/s43018-023-00516-z
rdcu.be/c51Hc -
Nature Cancer reposted
JessicaJLinMD
@JessicaJLinMD
📢Happy to share our ⭐️NEW REVIEW on ALK⭐️, out today @NatureCancer !
www.nature.com/articles/s43018-023-00515-0
Written with @DrJaimeLaurel & Alice Shaw, meant to be forward-looking.
Integrates impt work by many groups whom we'd like to acknowledge ⬇️⬇️, although impossible to tag all! [1/n] -
Nature Cancer
@NatureCancer
🔥NEW REVIEW ARTICLE @NatureCancer “ALK-positive lung cancer: a moving target” – by @JessicaJLinMD @DrJaimeLaurel #aliceshaw.
www.nature.com/articles/s43018-023-00515-0
rdcu.be/c5M01 -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Reciprocal interactions between innate immune cells and astrocytes facilitate neuroinflammation and brain metastasis via lipocalin-2” by @ErezNeta & Co.
#metastasis @NatResCancer
Don’t miss it 👇
www.nature.com/articles/s43018-023-00519-w
rdcu.be/c5M0P -
Nature Cancer reposted
Neta Erez- ErezLab
@ErezNeta
Our paper is out in @NatureCancer and we are super excited!! Check it out here:
rdcu.be/c5Mva
It was a long journey led bravely by the wonderful @AdlerOmer and @YaelZait together with multiple team members and collaborators.
So what did we find? -
Nature Cancer
@NatureCancer
NEW CONTENT @NatureCancer⭐️- “A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors” by #jeanphilippecoppe & Co.
Read it here 👇
www.nature.com/articles/s43018-022-00508-5
rdcu.be/c5Fou -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer „Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy” by #annalasorella #antonioiavarone.
Don't miss it 👇
www.nature.com/articles/s43018-022-00510-x
rdcu.be/c4ZQF -
Nature Cancer
@NatureCancer
🔥Fascinating study on #metastasis @NatureCancer - “A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling” by @alteam_patricia @FendtLab & Co.
Read it here👇
www.nature.com/articles/s43018-023-00513-2
rdcu.be/c4ZPB -
Nature Cancer reposted
Patricia Altea-Manzano @alteaManzanoLab
Novel link Palmitate and Metastasis! Our study about the importance of this fatty acid in the metastatic niche is out in @NatureCancer !! We find that the secretome of breast primary tumors and high fat diet prime the lung for metastasis formation... (1/4)
www.nature.com/articles/s43018-023-00513-2 -
Nature Cancer
@NatureCancer
February 4th is #worldcancerday‼️
At @NatureCancer we are grateful to work with the fantastic cancer research community and share important preclinical and clinical studies to help understand and treat this devastating disease.
#cancerresearch #closethecaregap -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer – “Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers” #stefanmpfister #nataliejäger @DKFZ @KiTZ_HD
Read it here👇
www.nature.com/articles/s43018-022-00509-4
rdcu.be/c4noN -
Nature Cancer reposted
RJ Autry @rj_autry
Very proud to announce our paper on mutational signatures in pediatric cancer was published today @NatureCancer! Very happy to be included in this great study. @DKFZ @KiTZ_HD
www.nature.com/articles/s43018-022-00509-4 -
Nature Cancer
@NatureCancer
Our editor @LisaHaas0107 is attending the @KeystoneSymp Emerging #cellulartherapies, please get in touch if you would like to meet her in Banff 🇨🇦❄️🌨️ to discuss your work and all things @NatureCancer!
#immunotherapy #cartcells
keysym.us/KSCellTherapy23 #kscelltherapy23 -
Nature Cancer
@NatureCancer
✨NEW CONTENT @NatureCancer – “Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy” by @EricLauLab & Co.
Read it here👇
www.nature.com/articles/s43018-022-00506-7
rdcu.be/c33ns -
Nature Cancer reposted
Andy Minn @andyjminn
A lot of perplexing data showing chronic interferon (IFN) promotes immunotherapy resistance. But why is chronic IFN different from acute, which clearly is important for response? New paper by @jingya & Bihui Xu shows one reason: inflammatory memory! (1/n) www.nature.com/articles/s43018-022-00490-y
-
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer - “Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction” by @andyjminn @jingya_qiu & Co.
👇
www.nature.com/articles/s43018-022-00490-y?platform=oscar…
rdcu.be/c33nl -
Nature Cancer reposted
Mike Thompson, MD, PhD, FASCO
@mtmdphd
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a RCT [Dec 29, 2022] @cdenki et al. @NatureCancer www.nature.com/articles/s43018-022-00503-w #covid19cp #covid19ncancer #idonc #covid19 HT @DrMJoyner
-
Nature Cancer reposted
Jim Jackson @jimjaxn100
Out today in the Dec 2022 @NatureCancer! Our study on how senescent breast tumor cells activate immune-modulatory programs that include diverse checkpoints that create resistance to ICI drugs.
⬇️⬇️⬇️ALL ACCESS SHAREABLE LINK
rdcu.be/c1f58Jim Jackson @jimjaxn100
Happy to announce our latest publication is online!
rdcu.be/c1f58
Huge effort from @ashkanshahbandi and co authors @Raegan2222 @SelinaSMJ_here @AshlynA_99 @LabMachado @Lorax_Bodyspray @Thesrao
#cancer #breastcancer #immunotherapy #sabcs2022
a quick 🧵 tweetorial... -
Nature Cancer reposted
Nature Methods
@naturemethods
It's finally here!! Our Method of the Year 2022 is....long-read sequencing! 🎉
Read our (free!) Editorial to learn why we felt the time was right to select this class of powerful technologies as the Method of the Year.
www.nature.com/articles/s41592-022-01759-x -
Nature Cancer
@NatureCancer
✨ONLINE NOW @NatureCancer – „Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis” by #charlesperou & Co.
www.nature.com/articles/s43018-022-00491-x
rdcu.be/c2HiR -
Nature Cancer
@NatureCancer
ICYMI 🔥 “An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia” by @iannisaifantis1 @AkEisfeld #tanjagruber
& Co.
👇
www.nature.com/articles/s43018-022-00480-0
rdcu.be/c2HiC -
Nature Cancer reposted
Dr. Ron DePinho
@RonDePinho
Presence of alternative immune checkpoints 41BB and LAG3, combined with CXCR1/2 inhibitor, can reprogram the highly suppressive immune microenvironment of pancreas cancer. www.nature.com/articles/s43018-022-00500-z @NatureCancer #pancreaticcancer #immunotherapy
-
Nature Cancer
@NatureCancer
⭐️DON’T MISS @NatureCancer “Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial” by @LabTidow & Co. #covid19
www.nature.com/articles/s43018-022-00503-w
rdcu.be/c2C1I -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer – „The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations” by #davidmalkin #adamshlien & Co.
👇
www.nature.com/articles/s43018-022-00474-y
www.nature.com/articles/s43018-022-00474-y -
Nature Cancer
@NatureCancer
✨@NatureCancer starts 2023 with exciting new studies – “Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer” by @RonDePinho & Co.
👇
www.nature.com/articles/s43018-022-00500-z
rdcu.be/c2CZR -
Nature Cancer reposted
Dr. Ron DePinho
@RonDePinho
Targeting alternative T cell checkpoints and myeloid suppressors reveals that #pancreascancer can be cured by #immunotherapy in faithful mouse models. www.nature.com/articles/s43018-022-00500-z
-
Nature Cancer reposted
Iannis Aifantis
@iannisaifantis1
2022 ends with a bang...after years of work our immune single cell (CITE/TCR-Seq) mapping of adult and pediatric AML is our today @NatureCancer ! The work was headed by two stars in the #aifantislab, @audrey_lasry & @BettinaNadorp #leukemia (1/5)
www.nature.com/articles/s43018-022-00480-0 -
Nature Cancer reposted
Müller-Tidow Lab @LabTidow
Great collaborative effort lead to this publication: Anti-SARS-CoV-2 antibody-containing #plasma improves outcome in patients with hematologic or solid #cancer and severe #covid-19: a randomized clinical trial. www.nature.com/articles/s43018-022-00503-w
Big Thanks go to all authors & Happy New Year -
Nature Cancer reposted
Anirban Maitra
@Aiims1742
Preclinical study by @RonDePinho & colleagues @MDAndersonNews in @NatureCancer:
Targeting T cell checkpoints 4-1BB & LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity & durable response in #pancreaticcancer
www.nature.com/articles/s43018-022-00500-z
Don’t forget the myeloid cells! -
Nature Cancer reposted
Stephen Oh
@mpndoc
🚨Just under the wire before the end of 2022, we are thrilled to announce our manuscript out today @NatureCancer “DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression"! @TimKong_ @challenlab @HmzaCelik @HuangLabMcGill @WashUHeme 1/ www.nature.com/articles/s43018-022-00486-8
-
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma” by #olivertkeppler & Co.
Read it here 👇
www.nature.com/articles/s43018-022-00502-x
rdcu.be/c12TR -
Nature Cancer
@NatureCancer
And don’t miss the accompanying News & Views by @LucyFStead - “Treating glioblastoma often makes a MES” #glioblastoma
Find it here👇
www.nature.com/articles/s43018-022-00471-1
rdcu.be/c11td
Nature Cancer
@NatureCancer
💫NEW CONTENT @NatureCancer - “A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets” by @diazlaboratory & Co.
Read it here 👇
www.nature.com/articles/s43018-022-00475-x
rdcu.be/c10tN -
Nature Cancer
@NatureCancer
💫NEW CONTENT @NatureCancer - “A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets” by @diazlaboratory & Co.
Read it here 👇
www.nature.com/articles/s43018-022-00475-x
rdcu.be/c10tN -
Nature Cancer reposted
LisaCoussens@CoussensLab
@coussens_lisa
Recommended reading for all career stages. Thank you @NatureCancer for featuring perspectives of this generation. The 2022 generation | Nature Cancer. @OHSUKnight www.nature.com/articles/s43018-022-00481-z
-
Nature Cancer
@NatureCancer
🥼💻🗞️"2022 through the eyes of the editors" by @alexia_zz @LisaHaas0107 #ioannapavlaki #juliasimundza.
@NatureCancer editor's reflecting on a busy, exciting and impactful year at the journal.
#2022inreview
Read it here👇
www.nature.com/articles/s43018-022-00496-6
rdcu.be/c1YxZ -
Nature Cancer
@NatureCancer
✨“Immunotherapy advances in cancers with mismatch repair or proofreading deficiencies” by @emilyalouani @BenjcRousseau #thierryandre and #aurelienmarabelle– as part of the @NatureCancer Focus Issue #2022inreview.
Read it here👇
www.nature.com/articles/s43018-022-00497-5
rdcu.be/c1YwP -
Nature Cancer
@NatureCancer
“CAR T cell therapy: looking back and looking forward” by #renierbrentjens #marcodavila as part of the @NatureCancer Focus Issue #2022inreview.
Read it here👇
www.nature.com/articles/s43018-022-00484-w
rdcu.be/c1Yv0 -
Nature Cancer
@NatureCancer
🔥“The emerging promise of liquid biopsies in solid tumors” by #viktoraadalsteinsson #leontiospappas @aparna1024 – as part of the @NatureCancer Focus Issue #2022inreview.
Read it here
www.nature.com/articles/s43018-022-00498-4
rdcu.be/c1YvC -
Nature Cancer
@NatureCancer
💫Highly recommend read – @coussens_lisa on career-defining moments, future goals and hopes for 2023. @NatureCancer Focus Issue #2022inreview
www.nature.com/articles/s43018-022-00493-9
rdcu.be/c1YuY -
Nature Cancer
@NatureCancer
⭐️DON’T MISS “Recent progress in antibody–drug conjugate therapy for cancer” as part of our @NatureCancer FOCUS ISSUE #2022inreview by #sarahurvitz.
Read it here 👇
www.nature.com/articles/s43018-022-00495-7
rdcu.be/c1YuH -
Nature Cancer
@NatureCancer
💫Recruiting, securing funding, building a network – early career investigators face many challenges! In “The 2022 generation” hear the inspiring stories of 12 PIs who started their teams in the past year. #newpi #2022inreview
www.nature.com/articles/s43018-022-00481-z
rdcu.be/c1Ymf
Nature Cancer
@NatureCancer
Thank you for the contributions - @Mhundeyin @CarrotJian @TalyaDayton @shazanfar @lguentherlab @diunguyen_vn_uk @PitarresiLab #sheerienrajput @SantanaCodina @tanaya_shree @ZexianZeng #yingzhang
-
Nature Cancer
@NatureCancer
💫#2022 had many challenges – in “Cancer research in the midst of COVID-19” read about unraveling effects of COVID-19 on cancer research, lessons learned and ideas for a way ahead. #2022inreview
www.nature.com/articles/s43018-022-00483-x
rdcu.be/c1Ykr -
Nature Cancer
@NatureCancer
Wondering what #2022 had in store for oncology drug approvals and setbacks❓ Then this comment @NatureCancer is a must-read for you👇
#2022inreview
www.nature.com/articles/s43018-022-00482-y
rdcu.be/c1YiF -
Nature Cancer
@NatureCancer
💫 OUR FAVOURITE TIME OF THE YEAR HAS ARRIVED 💫
As 2022 comes to an end @NatureCancer is proud to present our Focus Issue #2022inreview!
DON'T MISS all of its exciting content right here 👇
www.nature.com/collections/caaeiaaicb -
Nature Cancer
@NatureCancer
DON’T MISS the News & Views “Bicarbonate transport as a vulnerability in pancreatic cancer” by #stephaniekdougan highlighting work recently published by @LabMazzone in @NatureCancer.
#pancreaticcancer #tme
www.nature.com/articles/s43018-022-00492-w -
Nature Cancer
@NatureCancer
DON'T MISS @NatureCancer “Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer” by @LabMazzone & Co. #pancreaticcancer #immunevasion
Read it here 👇👇
www.nature.com/articles/s43018-022-00470-2
rdcu.be/c1R1H -
Nature Cancer reposted
Mazzone Lab
@LabMazzone
Proud to share our work showing how tumor acidity controls pancreatic cancer cell metabolism and tumor immune landscape. Tampering with tumor acidity elicits anti-tumor immune responses and overcomes resistance to immunotherapy in pancreatic cancer models.
www.nature.com/articles/s43018-022-00470-2 -
Nature Cancer reposted
Anirban Maitra
@Aiims1742
In any profiling study, do not ignore the funny sounding SLC genes. Those transporters show up for a reason!
Out in @NatureCancer:
Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression & immunotherapy resistance in #pancreaticcancer
www.nature.com/articles/s43018-022-00470-2 -
Nature Cancer
@NatureCancer
💫DON’T MISS – a beautiful review on “The cGAS–STING pathway and cancer” by #andreaablasser @epflSV – read it here 👇
www.nature.com/articles/s43018-022-00468-w
rdcu.be/c1FYp -
Nature Cancer
@NatureCancer
⭐️ONLINE NOW @NatureCancer “Two isoleucyl tRNAs that decode synonymous codons divergently regulate breast cancer metastatic growth by controlling translation of proliferation-regulating genes” by @genophoria @SohailTavazoie & Co.
👇
www.nature.com/articles/s43018-022-00469-9
rdcu.be/c1xq7 -
Nature Cancer reposted
Sohail Tavazoie
@SohailTavazoie
The amazing @TriIMDPhD student Lisa Earnest-Noble's paper is out showing that two so called 'synonymous' isoleucyl tRNAs opposingly regulate breast cancer & metastasis by driving distinct gene regulatory programs. @RockefellerUniv also thx to @genophoria
www.nature.com/articles/s43018-022-00469-9 -
Nature Cancer
@NatureCancer
⭐️ONLINE NOW @NatureCancer “Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80” by @jimjaxn100 & Co. #breastcancer #immunotherapy
Read it here👇
www.nature.com/articles/s43018-022-00466-y
rdcu.be/c1sSj -
Nature Cancer reposted
Jim Jackson @jimjaxn100
Happy to announce our latest publication is online!
rdcu.be/c1f58
Huge effort from @ashkanshahbandi and co authors @Raegan2222 @SelinaSMJ_here @AshlynA_99 @LabMachado @Lorax_Bodyspray @Thesrao
#cancer #breastcancer #immunotherapy #sabcs2022
a quick 🧵 tweetorial... -
Nature Cancer
@NatureCancer
We are looking forward to attending #kscancerimmuno23 in March next year, please get in touch if you'd like to meet us in Banff! 🏂 More info (including program & early registration deadlines) here: www.keystonesymposia.org/conferences/conference-listing/m…
-
Nature Cancer
@NatureCancer
„ Translational advances in pancreatic ductal adenocarcinoma therapy” by @Aiims1742 @andrewaguirremd #stephaniekdougan #abdelnaserhosein.
#pancreaticcancerawarenessmonth🗣️💜
👇
www.nature.com/articles/s43018-022-00349-2
rdcu.be/c0HXK -
Nature Cancer
@NatureCancer
“TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer” by @ShivKSingh6 & Co.
#pancreaticcancerawarenessmonth🗣️💜
👇
www.nature.com/articles/s43018-021-00258-w
rdcu.be/c0HWv -
Nature Cancer
@NatureCancer
💫„Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells” by @HalbrookLab @LyssiotisLab & Co.
#pancreaticcancerawarenessmonth🗣️💜
👇
www.nature.com/articles/s43018-022-00463-1
rdcu.be/c0HVT -
Nature Cancer
@NatureCancer
💫“Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial” by #davidtting #theodoreshong & Co. #therapy
#pancreaticcancerawarenessmonth🗣️💜
👇
www.nature.com/articles/s43018-021-00269-7
rdcu.be/c0HU8 -
Nature Cancer
@NatureCancer
“Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer” by #charlesjdavid & Co. #therapy
#pancreaticcancerawarenessmonth🗣️💜
👇
www.nature.com/articles/s43018-020-00134-z
rdcu.be/c0C3h -
Nature Cancer
@NatureCancer
“Cancer-associated fibroblasts employ NUFIP1-dependent autophagy to secrete nucleosides and support pancreatic tumor growth” by #yingzhao & Co.
#autophagy #fibroblasts
#pancreaticcancerawarenessmonth🗣️💜
👇
www.nature.com/articles/s43018-022-00426-6
rdcu.be/c0CO6 -
Nature Cancer
@NatureCancer
💜“Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors” by @winterlab8 & Co. #metabolism
💜🗣️#pancreaticcancerawarenessmonth
👇
www.nature.com/articles/s43018-022-00393-y
rdcu.be/c0COA -
Nature Cancer
@NatureCancer
💜“Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment” by @SaurLab & Co. #immunotherapy
#pancreaticcancerawarenessmonth🗣️💜
👇
www.nature.com/articles/s43018-021-00326-1
rdcu.be/c0CN9 -
Nature Cancer
@NatureCancer
💜Before #pancreaticcancerawarenessmonth November comes to an end, we would like to share with you some @NatureCancer publications on pancreatic cancer. Stay tuned for exciting work on #metabolism, #immunotherapy, #clinicaltrials and much more!
💜🗣️#pancreaticcancerawareness -
Nature Cancer
@NatureCancer
⭐️ONLINE NOW @NatureCancer “Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade” by @lfspurr @SeanPitroda & Co. #lungcancer #immunotherapy
www.nature.com/articles/s43018-022-00467-x
rdcu.be/c0CsK -
Nature Cancer
@NatureCancer
🔥DON’T MISS @NatureCancer “A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC” by #sanadkaram & Co.
Read it here👇
www.nature.com/articles/s43018-022-00450-6
rdcu.be/c0xeV -
Nature Cancer
@NatureCancer
🔥ONLINE NOW @NatureCancer “cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis” by #wenxinqin & #renebernards @NKI_nl & Co.
Read it here👇
www.nature.com/articles/s43018-022-00462-2
rdcu.be/c0xdA -
Nature Cancer
@NatureCancer
The @NatureCancer NOVEMBER ISSUE is LIVE! 💫
Don’t miss the new content on targeting #glioblastoma, combination therapy for #lungcancer, a #clinicaltrial for HNSCC, #pancreaticcancer metabolism, and a 🔪 tool to study #metastasis.
Find it here👇
www.nature.com/natcancer/volumes/3/issues/11 -
Nature Cancer
@NatureCancer
HOT OFF THE PRESS 🔥- “Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect” by @SageJulien #edwardegraves #yokonishiga & Co. #immunotherapy
Read it here 👇👇
www.nature.com/articles/s43018-022-00456-0
rdcu.be/c0a8o -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer - “Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells” by @HalbrookLab @LyssiotisLab & Co.
Read it here 👇
www.nature.com/articles/s43018-022-00463-1
rdcu.be/c0anS -
Nature Cancer reposted
Julien Sage
@SageJulien
Very excited to share this @NatureCancer study from Yoko Nishiga, a joint post-doc with Ted Graves. Yoko found that combining radiation therapy (RT) with blockade of CD47 can promote T-cell-independent and macrophage-dependent abscopal effects: rdcu.be/cZ7Tj
-
Nature Cancer reposted
Chris Halbrook @CJHPhD
🍾It's FINALLY here!🍾Check the latest from the @HalbrookLab and @LyssiotisLab fresh off the press @NatureCancer: Pancreatic cancer cell heterogeneity enables metabolic crosstalk and resistance to mitochondrial inhibition. Read on for the #tweetorial
www.nature.com/articles/s43018-022-00463-1 -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity” by #michaelacaligiuri #jianhuayu & Co. @cityofhope
Read it here:
www.nature.com/articles/s43018-022-00448-0?error=cookies_…
rdcu.be/cZIOl -
Nature Cancer
@NatureCancer
💫Attending #sitc22 #sitc2022 in Boston 🇺🇸 this week?
Please reach out to Lisa Hoffmann-Haas @LisaHaas0107 during or after the meeting to discuss your work and ask questions❓ about publishing in @NatureCancer! -
Nature Cancer reposted
Seeding Labs
@SeedingLabs
And to watch the full conversation on #healthequity with @SpringerNature @TakedaPharma @natAfrica1 @NatMentHealth @NatureCancer @sciam @laurahelmuth @akinlabiJ @alexia_zz @bekrx @PaulinoRobert and @MelissaPWu tune into www.youtube.com/watch?v=d8bv0NuQRuA
-
Nature Cancer
@NatureCancer
🔥ONLINE NOW @NatureCancer “MACHETE 🔪 identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis” @LoweLabMSKCC @dana_peer @barrigafm @ktsanov & co. #metastasis
Read it here:
go.nature.com/3EeJEOw
rdcu.be/cZdip -
Nature Cancer reposted
Lowe Lab
@LoweLabMSKCC
Now out in @NatureCancer, an updated version of our study developing the #machete strategy for modeling large genomic deletions and using it to uncover a key role for type I #ifn deletions in tumor #immuneevasion & #metastasis: www.nature.com/articles/s43018-022-00443-5 (1/3)
Lowe Lab
@LoweLabMSKCC
New Preprint! Led by #dynamicduo @BarrigaFM & @KTsanov, this study set out to understand how somatic copy number alterations (CNAs) promote cancer. CNAs are prevalent across cancer types & correlate w/ clinical outcomes but remain difficult to study. 1/n
www.biorxiv.org/content/10.1101/2022.08.22.504793v1 -
Nature Cancer
@NatureCancer
Our @NatureCancer Editor @LisaHaas0107 is attending the #crcl Symposium in Lyon 🇫🇷.
Approach her to discuss your work 🧪💊and everything you want to know about publishing in @NatureCancer!
#cancerresearch #crclsymposium #cancerconference -
Nature Cancer
@NatureCancer
“The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription” by #shouyuwang #zhibinhu #beichengsun & Co.
go.nature.com/3szxxox
rdcu.be/cYiXK
OCTOBER is #livercancerawarenessmonth 🗣️💚 -
Nature Cancer
@NatureCancer
“Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways” by #shuquncheng #yongzhentao #huiyongyin & Co. #metabolism
go.nature.com/3U24mpX
rdcu.be/cYiXk
OCTOBER is #livercancerawarenessmonth 🗣️💚 -
Nature Cancer
@NatureCancer
⭐️ONLINE NOW @NatureCancer - “Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling” by @QuezadaLab @IdoAmitLab & Co.
Read it here👇
go.nature.com/3SDd5O8
rdcu.be/cYrxH -
Nature Cancer reposted
IdoAmitLab
@IdoAmitLab
Out now- check out our new @NatureCancer paper! Together with @QuezadaLab we started to march down the rabbit hole toward the molecular and cellular dissection of immune checkpoints MOA. Led by @IdoYofe, @tomerlands and @AdamYalin. www.nature.com/articles/s43018-022-00447-1
-
Nature Cancer
@NatureCancer
„Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity” by @MarkYarchoan & Co. @hopkinskimmel
go.nature.com/3gK1dwz
rdcu.be/cYiWo
OCTOBER is #livercancerawarenessmonth 🗣️💚 -
Nature Cancer
@NatureCancer
“Molecular pathogenesis and systemic therapies for hepatocellular carcinoma” – a Review by #josepmllovet & Co. @IcahnMountSinai @MountSinaiLiver #universidadbarcelona
go.nature.com/3D7APUY
rdcu.be/cYiUE
OCTOBER is #livercancerawarenessmonth 🗣️💚 -
Nature Cancer
@NatureCancer
“ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1” by #pinggao #huafengzhang & Co. #celldeath
go.nature.com/3zhVbJW
rdcu.be/cYiVT
OCTOBER is #livercancerawarenessmonth 🗣️💚 -
Nature Cancer reposted
UTSW Simmons Cancer Center
@utswcancer
A phase 2 study of #talazoparib found that it shrank tumors in #breastcancer patients not previously indicated for the treatment. @joshuagruber @NatureCancer www.utsouthwestern.edu/newsroom/articles/year-2022/octobe…
-
Nature Cancer
@NatureCancer
“LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer” by #larszender, #danieldauch & Co. #metabolism
go.nature.com/3N5D1AS
rdcu.be/cYiT7
OCTOBER is #livercancerawarenessmonth 🗣️💚 -
Nature Cancer
@NatureCancer
„Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis” by #eishiromizukoshi #shuichikaneko & Co. #microbiome
go.nature.com/3Fzyjtx
rdcu.be/cYiTl
OCTOBER is #livercancerawarenessmonth 🗣️💚 -
Nature Cancer
@NatureCancer
October is #livercancerawarenessmonth!
In the next few days we will highlight @NatureCancer content on #livercancer – so stay tuned for some exciting research covering #therapy, #metabolism, #clinicaltrials , #microbiome and much more! -
Nature Cancer reposted
Nature Reviews Molecular Cell Biology
@NatRevMCB
New cross-journal collection on #cellcycle: mechanisms, tools, roles in #cancer and therapy. Great collaboration between
@Nature @NatureCellBio @NatureComms @NatRevMCB @CommsBio @naturemethods @NatureGenet @NatMetabolism @NatureCancer @SciReports
www.nature.com/collections/efhfdhegbf -
Nature Cancer
@NatureCancer
⭐️ONLINE NOW @NatureCancer “Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade” by #jiehe #zhiminlu & Co.
Read it here👇
go.nature.com/3FeDy1u
rdcu.be/cYe66 -
Nature Cancer reposted
Nature Portfolio
@NaturePortfolio
A Review in @NatureCancer describes how AI can be used to predict cancer outcome, treatment response, genetic alterations and gene expression from digitized histopathology slides. go.nature.com/3EW7pM4
-
Nature Cancer reposted
Lubka Roumenina @roumenina
Here is the paper we commented:
Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade
Fei Shao et al, @NatureCancer just published
👇
doi.org/10.1038/s43018-022-00444-4
#complementbiology -
Nature Cancer reposted
Lubka Roumenina @roumenina
Read our latest News & Views
COMPLEMENTing immunotherapy
with @CremerIsabelle @CRCordeliers
on lung cancer and the activation of the complement system in @NatureCancer
Free access here 👇
rdcu.be/cX2ag
#complementbiology #immunotherapy @SpringerNature -
Nature Cancer
@NatureCancer
Don’t miss the @NatureCancer 🍃OCTOBER 🍂ISSUE and read exciting new work on #metastasis in #breastcancer, the complement system in #immunotherapy, #machinelearning, #clinicaltrials and much more.
Find it here👇
go.nature.com/3sgJMWP -
Nature Cancer
@NatureCancer
📢📢Do you love cancer research and are looking for an #editorialcareer in #sciencepublishing?
One week left to apply and join our growing Editorial Team @NatureCancer ‼️ Details below.
Please spread the word and RT!
Nature Cancer
@NatureCancer
📢OUR @NatureCancer EDITORIAL TEAM IS GROWING – apply to our 🔥-new position and join our team in NY, Philadelphia & Washington DC in the US; Berlin, London, Madrid in Europe; Shanghai in Asia 🌍. Application deadline October 28th.
Please RT!
Details 👉springernature.wd3.myworkdayjobs.com/SpringerNatureCareers -
Nature Cancer reposted
Vivek Subbiah, MD
@VivekSubbiah
⭐️Expanding biomarkers for PARP inhibitors @NatureCancer rdcu.be/cXYA0
-
Nature Cancer reposted
Matteo Lambertini, MD PhD
@matteolambe
Finally online in @NatureCancer phase II data showing the clinical activity of single agent #talazoparib in patients without germline #brca PVs but with other defects in homologous recombination genes like germline #palb2 PVs
@OncoAlert #parpi #bcsm
Link: www.nature.com/articles/s43018-022-00439-1 -
Nature Cancer reposted
Paolo Tarantino
@PTarantinoMD
After olaparib, talazoparib also shows antitumor activity in MBC patients with #gpalb2 mutations. Small numbers, but the consistency with TBCRC 048 make them very intriguing. Congrats to @joshuagruber & coauthors for this @NatureCancer publication! #bcsm www.nature.com/articles/s43018-022-00439-1.pdf
-
Nature Cancer
@NatureCancer
🔥HOT OFF THE PRESS🔥 – “A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes” by @joshuagruber @melindatelli & Co.
Read it here👇
go.nature.com/3Tuz6iZ
rdcu.be/cXNOl -
Nature Cancer
@NatureCancer
⭐️ONLINE NOW @NatureCancer “Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex” by #dihuayu #mienchiehung & Co.
Read it here👇
go.nature.com/3ME6q4K
rdcu.be/cXNNO -
Nature Cancer
@NatureCancer
“Small-molecule inhibitors that disrupt the MTDH–SND1 complex suppress breast cancer progression and metastasis.” by @yibinkang & Co. #therapy
October is #breastcancerawarenessmonth 💜🗣️
go.nature.com/3Cu0AOW
rdcu.be/cXtHT -
Nature Cancer
@NatureCancer
“Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis” by @LabSevenich @Johanna_A_Joyce @Joycelab &Co.
October is #breastcancerawarenessmonth 💜🗣️
go.nature.com/3TmWgb3
rdcu.be/cXtG3 -
Nature Cancer
@NatureCancer
“Neutrophil oxidative stress mediates obesity-associated vascular dysfunction and metastatic transmigration” by @DanielaQuail @loganawalsh & Co. #metastasis #obesity
October is #breastcancerawarenessmonth 💜🗣️
go.nature.com/3uI3wFm
rdcu.be/cXpZW -
Nature Cancer
@NatureCancer
📢HAPPENING TODAY - 5 more hours left to sign up and hear about cancer #organoids and #tumors on a chip from @KarunaMDPhD and @GVNlab. Join us for the talks and a live Q&A.
Registration is FREE 👇
www.workcast.com/register?cpak=7631934595888225
Nature Cancer
@NatureCancer
SAVE THE DATE 🗓️- In a webcast sponsored by @thermofisher we will discuss developments in 3D models for Cancer Research with @KarunaMDPhD and @GVNlab. #3dmodelscancer
Don’t miss the opportunity to listen and engage in a live Q&A! Sign up for FREE 👇
www.workcast.com/register?cpak=7631934595888225 -
Nature Cancer
@NatureCancer
“ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung” by @JAguirreGhiso & Co. #metastasis
October is #breastcancerawarenessmonth 💜🗣️
go.nature.com/3rJVZ66
rdcu.be/cXk9w -
Nature Cancer
@NatureCancer
“Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer” by #stevenjisakoff & Co. #therapy
October is #breastcancerawarenessmonth 💜🗣️
go.nature.com/3IcaKWR
rdcu.be/cXjgN -
Nature Cancer reposted
MedAppsAB
@MedAppsAB
#artificialintelligence in #histopathology: enhancing #cancerresearch and #clinical #oncology | #healthtech #healthcare #healthdata #ai #ml #pathology - via @NatureCancer www.nature.com/articles/s43018-022-00436-4
-
Nature Cancer
@NatureCancer
“Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer” by @JennGuerriero & Co. #immunology
October is #breastcancerawarenessmonth 💜🗣️
go.nature.com/3Cgyc2A
rdcu.be/cXjfF -
Nature Cancer
@NatureCancer
„Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain” by #jinxiangdai @GhajarLab & Co. #metastasis
October is #breastcancerawarenessmonth 💜🗣️
go.nature.com/3yxTIPb
rdcu.be/cXjdF -
Nature Cancer
@NatureCancer
„Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy” by @AndreaBildLab & Co. #genomics
#breastcancerawarenessmonth
go.nature.com/3T7L6Xj
rdcu.be/cXeGa -
Nature Cancer
@NatureCancer
„Fatty acid synthesis is required for breast cancer brain metastasis” by @mvh_lab #rakeshjain & Co. #metastasis
#breastcancerawarenessmonth
go.nature.com/3RQRdhE
rdcu.be/cXeC3 -
Nature Cancer
@NatureCancer
„A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology” by @BryanWelm, @AlanaWelm & Co. #organoids
#breastcancerawarenessmonth
go.nature.com/3ehdDv4
rdcu.be/cXezA -
Nature Cancer
@NatureCancer
October is #breastcancerawarenessmonth!
In the next few days we will highlight @NatureCancer content on #breastcancer – so stay tuned for some exciting research covering #therapy, #metastasis, #organoids, #immunology and much more! -
Nature Cancer reposted
Nature Portfolio
@NaturePortfolio
A Review in @NatureCancer describes how AI can be used to predict cancer outcome, treatment response, genetic alterations and gene expression from digitized histopathology slides. go.nature.com/3EkwM9I
-
Nature Cancer
@NatureCancer
📢Our next WEBCAST on 3D models for cancer research #3dmodelscancer is coming up next week. Don't forget to sign up for FREE and hear from @KarunaMDPhD and @GVNlab. Sponsored by @thermofisher and hosted by @NatureCancer
🗓️October 12th 1PM EDT
For details see 👇
Nature Cancer
@NatureCancer
SAVE THE DATE 🗓️- In a webcast sponsored by @thermofisher we will discuss developments in 3D models for Cancer Research with @KarunaMDPhD and @GVNlab. #3dmodelscancer
Don’t miss the opportunity to listen and engage in a live Q&A! Sign up for FREE 👇
www.workcast.com/register?cpak=7631934595888225 -
Nature Cancer
@NatureCancer
📢OUR @NatureCancer EDITORIAL TEAM IS GROWING – apply to our 🔥-new position and join our team in NY, Philadelphia & Washington DC in the US; Berlin, London, Madrid in Europe; Shanghai in Asia 🌍. Application deadline October 28th.
Please RT!
Details 👉springernature.wd3.myworkdayjobs.com/SpringerNatureCareers -
Nature Cancer
@NatureCancer
Our @NatureCancer Senior Editor #juliasimundza is attending the 6th CRI-ENCI-AACR International Cancer Immunotherapy Conference #cicon22 in NYC 🇺🇸 Approach her to discuss your work 🧪💊and all things @NatureCancer ! #immunotherapy
-
Nature Cancer reposted
Dr. Ron DePinho
@RonDePinho
@naturecancer reports that JAK/STAT signaling plays a major role in therapeutic resistance in prostate cancer which is driven by lineage plasticity. A targetable pathway with significant therapeutic potential if validated in clinical trials. doi.org/10.1038/s43018-022-00437-3
-
Nature Cancer reposted
ZeminZhangLab
@ZeminZhangLab
So excited that our paper "Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade" is now out in @NatureCancer
. Check out the commentary www.nature.com/articles/s43018-022-00432-8 and our paper here, nature.com/articles/s43018-022-00433-7… -
Nature Cancer reposted
Moritz Gerstung
@MoritzGerstung
Check out the review on digital pathology in oncology by my student @artem_shmatko, Narmin Ghaffari Laleh and @jnkath in @NatureCancer
www.nature.com/articles/s43018-022-00436-4 -
Nature Cancer reposted
Dr. Ron DePinho
@RonDePinho
Identification of tumor-reactive T cells using phenotypic markers is established in treatment-naive tumors. @NatureCancer paper shows CXCL13 is a robust marker that identifies tumor-reactive T cells before and after ICB, tracking with treatment response. doi.org/10.1038/s43018-022-00433-7
-
Nature Cancer reposted
Rani George Lab @ranigeorgelab
Our work led by @senspeaks and @sanjuktadas25,
connecting tumor cell lineage to immunogenic phenotypes in neuroblastoma, is now online in
@NatureCancer rdcu.be/cV7ug. These studies highlight the immunogenic potential of the mesenchymal lineage tumors. -
Nature Cancer
@NatureCancer
💫A new REVIEW just online @NatureCancer "#artificial_intelligence in histopathology: enhancing cancer research and #clinicaloncology" by @jnkath @MoritzGerstung & co.
Read it here👇
go.nature.com/3C4uSJa
rdcu.be/cV7JA -
Nature Cancer
@NatureCancer
⭐️DON'T MISS - "Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade" @NatureCancer by #zeminzhang & Co.
Read it here
go.nature.com/3QZfnX2
rdcu.be/cV78Y -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer "METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma" by #jianyuan #kaixiongtao #zhenkunlou!
Read it here
go.nature.com/3UuCWK9
rdcu.be/cV78Q -
Nature Cancer
@NatureCancer
The @NatureCancer 🍂SEPTEMBER ISSUE🍃 is out - it is beautiful on the outside🧬and filled with exciting science on #immunotherapy #covid19 #therapyresistance #artificial_intelligence #digitalpathology #cancerplasticity!
DON'T MISS IT 👇
go.nature.com/3r24JUI -
Nature Cancer reposted
Jakob Nikolas Kather
@jnkath
Just out in @NatureCancer: #ai in histopathology is not only relevant for pathologists, but also for cancer researchers and clinicians. Excellent collaboration with @MoritzGerstung at @emblebi & @DKFZ 🇪🇺🔬👩⚕️💻 @GhaffariNarmin
www.nature.com/articles/s43018-022-00436-4 @EKFZdigital @NCT_HD -
Nature Cancer
@NatureCancer
SAVE THE DATE 🗓️- In a webcast sponsored by @thermofisher we will discuss developments in 3D models for Cancer Research with @KarunaMDPhD and @GVNlab. #3dmodelscancer
Don’t miss the opportunity to listen and engage in a live Q&A! Sign up for FREE 👇
www.workcast.com/register?cpak=7631934595888225 -
Nature Cancer reposted
Lurie Cancer Center
@LurieCancer
ERK1/2 phosphorylation predicts survival following anti-PD-1 #immunotherapy in recurrent #glioblastoma via @NatureCancer @VictorA_Arrieta @adam_sonabend www.nature.com/articles/s43018-021-00260-2
-
Nature Cancer reposted
Nature Medicine
@NatureMedicine
⭐ Research Highlight: A mouse study published in @NatureCancer
suggests that checkpoint inhibitors could negatively impact female fertility, highlighting a major clinical research gap in the cancer immunotherapy field.
www.nature.com/articles/d41591-022-00095-z -
Nature Cancer reposted
Dr Imran Sheikh 🩺 @DrImranSheikh
.@NatureCancer “Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance” by @PingMu_PhD & Co @PCF_Science @utswcancer. Find it here:
rdcu.be/cU29q -
Nature Cancer reposted
Seeding Labs
@SeedingLabs
There's still time to register for Tuesday's virtual panel on #healthequity, hosted by @SpringerNature & @TakedaPharma. 10am EST on 13 Sept! (1/2) conferences.nature.com/event/92c3f065-4905-480c-9fcb-3c98…
Springer Nature
@SpringerNature
We have partnered with @TakedaPharma to launch a free panel event bringing together leading thinkers in health equity, and establish a programme of activity to enhance understanding of, and empower change around health inequities. group.springernature.com/gp/group/media/press-releases/ne…
-
Nature Cancer
@NatureCancer
Our Senior Editor #juliasimundza is attending #esmo22 @myESMO in beautiful Paris 🇫🇷! Approach her to discuss your work 🧪💊and hear about publishing in @NatureCancer!
-
Nature Cancer
@NatureCancer
⭐️ONLINE NOW @NatureCancer “Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance” by @PingMu_PhD & Co @PCF_Science @utswcancer.
Find it here:
rdcu.be/cU29q
go.nature.com/3RrYtBy -
Nature Cancer
@NatureCancer
💫DON’T MISS “ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung” by @NobreAnaRita @JAguirreGhiso & Co. #metastasis
Read it here:
rdcu.be/cU28R
go.nature.com/3x0kkaW -
Nature Cancer reposted
Ping Mu 🇺🇦
@PingMu_PhD
Our work on Nature Cancer today: Ectopic activation of JAK-STAT is the crucial executor of lineage plasticity. It is specifically required for stem-like and multi-lineage cancer cells, but NOT neuroendocrine-like cells. @PCF_Science @utswcancer www.nature.com/articles/s43018-022-00431-9
-
Nature Cancer
@NatureCancer
💫DON’T MISS this Review on #cancervaccines as part of our #seriescancerimmunotherapy – a beautiful overview by @joshuabrodyMD @matthew_j_lin @DrIgMelero & Co.
Read it👇
nature.com/articles/s43018-022-00418-6
rdcu.be/cUg9N
Series 👇
go.nature.com/3QTc70m -
Nature Cancer reposted
Nature Portfolio
@NaturePortfolio
Data in a study published in @NatureCancer demonstrate that immune checkpoint inhibitors have the potential to impair both immediate and future fertility, and studies in women should be prioritized. go.nature.com/3pXscGd
-
Nature Cancer reposted
Sohrab Shah
@SohrabShah
Thank you @NatureCancer for reviewing our study www.nature.com/articles/s43018-022-00416-8 demonstrating multimodal data integration increases capacity to predict ICB response in non-small cell lung cancer. Terrific work led by @RamiVanguri @JL_Sauter @Jia_Luo and many others. 1/8
-
Nature Cancer
@NatureCancer
Don't miss the @NatureCancer 🌞AUGUST🌞 ISSUE– this month read all about #cancervaccines, #cafs & #autophagy, #immunotherapy & implications on #fertility, #stemcells, #tumorevolution #neuroblastoma and so much more!
Find it all here:
go.nature.com/3AyEN7F -
Nature Cancer reposted
Pavlos Msaouel
@PavlosMsaouel
Emerging data on the immediate and long-term impact of immune checkpoint therapy on fertility may be particularly important to consider in settings such as the adjuvant therapy of #kidneycancer. @KidneyCancer @kidneycan @kcCURE
Arndt Vogel
@ArndtVogel
🤔Important preclinical observation:
Checkpoint inhibitor immunotherapy diminishes
oocyte number and quality in mice in @NatureCancer
doi.org/10.1038/s43018-022-00413-x
👉Clinical studies are needed
👉Fertility preservation should be strongly considered
@myESMO @OncoAlert -
Nature Cancer reposted
Monash Biomedicine Discovery Institute
@MonashBDI
1/Published in @NatureCancer, a team led by Monash BDI’s @Lauren_Alesi @HuttLab @amy_winship & @PetermacCC's @LoiSher have discovered that some immunotherapy treatments used to treat #cancer can cause fertility damage in female cancer survivors. Read more: www.monash.edu/discovery-institute/news-and-events/news/2…
-
Nature Cancer reposted
Arndt Vogel
@ArndtVogel
🤔Important preclinical observation:
Checkpoint inhibitor immunotherapy diminishes
oocyte number and quality in mice in @NatureCancer
doi.org/10.1038/s43018-022-00413-x
👉Clinical studies are needed
👉Fertility preservation should be strongly considered
@myESMO @OncoAlert -
Nature Cancer reposted
Matteo Lambertini, MD PhD
@matteolambe
Out in @NatureCancer important study in mice on potential gonadotoxicity of #immunotherapy: super congrats @LoiSher @drkellyphillips et al for this effort...why #io (neo)adjuvant trials did not collect reproductive outcomes?@NarjustFlorezMD
Link rdcu.be/cUlAA
@OncoAlert -
Nature Cancer reposted
Anirban Maitra
@Aiims1742
Nicely done! #openaccess in @NatureCancer:
Cancer vaccines: the next immunotherapy frontier
www.nature.com/articles/s43018-022-00418-6 -
Nature Cancer reposted
Peter Mac Cancer Centre
@PeterMacCC
A study published in @NatureCancer - by Peter Mac’s @LoiSher plus @Lauren_Alesi, @HuttLab & @amy_winship at @MonashBDI - shows how immunotherapy can impair ovarian function & highlights importance of pre-treatment steps to preserve fertility. More: www.petermac.org/news/study-shows-importance-fertility-di…
-
Nature Cancer reposted
Sherene Loi, MD
@LoiSher
➡️today @NatureCancer
1. we show in a preclinical model how checkpoint inhibitors can cause ovarian inflammation potentially affecting #fertility #bcsm @OncoAlert Gr8 work w @Huttlab 🙏 @sneha_sant @Lauren_Alesi @amy_winship @PeterMacRes @MonashBDI
👉rdcu.be/cUlAA -
Nature Cancer reposted
Hutt Lab
@HuttLab
So exciting to see this new work published on immunotherapy impacts to fertility @NatureCancer. This research strongly advocates we must include reproductive endpoints in clinical trials moving forward! www.nature.com/articles/s43018-022-00413-x
-
Nature Cancer reposted
Enrique Grande
@drenriquegrande
⚡️ On @NatureCancer - Cancer vaccines: the next #immunotherapy frontier
www.nature.com/articles/s43018-022-00418-6 -
Nature Cancer reposted
Aegean Conferences
@AegeanConf
Still have time to submit an abstract until Aug 31: 8th Int'l Conference on #tumormicroenvironment and Cellular Stress: Signaling, #metabolism, Imaging and #therapeutic Targets www.aegeanconferences.org/src/App/conferences/view/161
-
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “cfDNA methylome profiling for detection and subtyping of small cell lung cancers” by @crukmi_cbc, #dominicgrothwell, #carlonedive, @charlesrudin & Co.
#lungcancer
Read it here 👇
rdcu.be/cTpiS
go.nature.com/3dlot1X -
Nature Cancer reposted
Cancer Research UK National Biomarker Centre
@cruk_nbc
NEW PUBLICATION in @NatureCancer!
In collaboration with @charlesrudin lab @MSKCancerCenter, we demonstrate potential clinical utility of a new ctDNA methylation based blood test which enables detection, monitoring and sub-typing of Small Cell Lung Cancer
www.nature.com/articles/s43018-022-00415-9 -
Nature Cancer
@NatureCancer
⭐️DON’T MISS the N&Vs covering this work by
#stefaniegöller and @LabTidow - “AKTing on XPO1 inhibition in AML”.
Read it here:
rdcu.be/cSXQ0
go.nature.com/3bp0gaL
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia” by @kcw00d @LabPuissant
👇
Read it here:
rdcu.be/cO8Wa
go.nature.com/3NSwt7C -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer - “Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5” by #liweizhang @Xi_Lab_Tsinghua & Co.
Read it here👇
rdcu.be/cSXPr
go.nature.com/3zQGz4X -
Nature Cancer reposted
Parker Institute
@parkerici
Why does #dinutuximab, an anti-GD2 therapy that helps the immune system find and kill #neuroblastoma cells, not help every patient? A study led by #picinetwork member Robbie Majzner, MD, @Majzner_Lab @StanfordMed may explain stan.md/3yzbOiV @NatureCancer #pediatriccancer
-
Nature Cancer reposted
Qiaoran Xi @Xi_Lab_Tsinghua
rdcu.be/cSPbQ
link of the paper @NatureCancer enjoy! -
Nature Cancer reposted
Arndt Vogel
@ArndtVogel
👉Exploiting metabolic vulnerability in #pancreaticcancer in @NatureCancer
doi.org/10.1038/s43018-022-00393-y
🔥🎯wildtype IDH1
✅metabolic stress & low Mg2+ -> Ivosidenib💊 -> αKG ⬇️& NADPH⬇️->ROS⬆️->💀
🤔👉Trial in IDH1wt PDAC: Ivosidenib + CTx?
@myESMO #precisionmedicine -
Nature Cancer reposted
Nature Cancer
@NatureCancer
⭐️DO NOT MISS - ONLINE NOW @NatureCancer: "#epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated #leukemia" - a *fantastic* study by Ali Shilatifard and Co @NorthwesternU
Find it here:
go.nature.com/3yQbDzk
rdcu.be/cllzH -
Nature Cancer reposted
Eytan Ruppin, MD, PhD
@EytanRuppin
Cancer-associated fibroblasts in the single-cell era @NatureCancer www.nature.com/articles/s43018-022-00411-z
-
Nature Cancer reposted
Enrique Grande
@drenriquegrande
⚡️ On @NatureCancer - Cancer-associated fibroblasts heterogeneity across #cancer types using single-cell technology
www.nature.com/articles/s43018-022-00411-z -
Nature Cancer reposted
Müller-Tidow Lab @LabTidow
Nature Cancer, news & views: AKTing on XPO1 inhibition in AML. Stefanie Göllner and Carsten Müller-Tidow about a promising therapeutic strategy in acute myeloid leukemia #cancer_therapy #aml www.nature.com/articles/s43018-022-00395-w
-
Nature Cancer reposted
Phillip M. Galbo Jr., PhD @pmgalbo
A much-needed review summarizing the current understanding of CAF heterogeneity across cancer types using single-cell technology. @NatureCancer
www.nature.com/articles/s43018-022-00411-z -
Nature Cancer reposted
Daniel Gerlach
@gerlach_d
Our new paper on novel EGFR WT-sparing HER2 TKIs with efficacy in exon 20 insertion-driven tumors now published in @NatureCancer. Great #teamscience @Boehringer with @birgitwilding, @Ralph_A_N, Flavio Solca and others! #her2
Open read access for everyone: rdcu.be/cSrk6 -
Nature Cancer reposted
allen institute
@AllenInstitute
😍 Check out this beautiful cover on the latest issue of @NatureCancer: www.nature.com/natcancer/volumes/3/issues/7 This image by @aaandmoore, showing the endoplasmic reticulum, was made using AGAVE, an #openscience tool built by our researchers to visualize cell structures in greater detail.
-
Nature Cancer reposted
Dirk Kessler
@Real_Dr_Kessler
Great work by our BI colleagues: Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling | Nature Cancer @NatureCancer www.nature.com/articles/s43018-022-00412-y
-
Nature Cancer
@NatureCancer
💫Don’t miss this exciting review on “Cancer-associated fibroblasts in the single-cell era” by
@ErezNeta @shouval & Co. There is a lot to learn in this one 📰(and beautiful figures 🎨)!
go.nature.com/3PXuPmh
rdcu.be/cStsx -
Nature Cancer
@NatureCancer
💫NEW @NatureCancer “Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling” by @norbertkraut1 & Co @Boehringer #vienna🇦🇹. #lungcancer
go.nature.com/3PYaFIZ
rdcu.be/cSut5 -
Nature Cancer reposted
Norbert Kraut
@norbertkraut1
Now online @NatureCancer "Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors which preserve wild-type EGFR signaling" by our #her2 #lungcancer team @boehringer in #vienna
Nature Cancer
@NatureCancer
THE @NatureCancer JULY ISSUE – 🌡️🔥off the press and just in time for summer reading🏖️! This month- read about #cartcell therapy, #therapy for AML and lung cancer, #tumormetabolism in PDAC, ER stress in #breastcancer and much more!
Find it here👇
go.nature.com/3zd6O49 -
Nature Cancer reposted
Neta Erez- ErezLab
@ErezNeta
Very happy to share our review on CAFs in the single cell era, a co-production with Ruthie @shouval and @AviadBenShmuel just published in @NatureCancer. @alexia_zz. It was a pleasure to discuss our favorite #caf. Read all about it!
rdcu.be/cSrk7 -
Nature Cancer
@NatureCancer
THE @NatureCancer JULY ISSUE – 🌡️🔥off the press and just in time for summer reading🏖️! This month- read about #cartcell therapy, #therapy for AML and lung cancer, #tumormetabolism in PDAC, ER stress in #breastcancer and much more!
Find it here👇
go.nature.com/3zd6O49 -
Nature Cancer
@NatureCancer
📢DON'T MISS THE CHANCE TO APPLY - 4 days left until 17th of July! Become part of the editorial team at @NatureCancer and work from many cities across the globe 🌎! #sciencecareers
Details 👇
Nature Cancer
@NatureCancer
📢We’re hiring and expanding the @NatureCancer team in new locations🌍!
Apply to join our team in NY, Philadelphia & Washington DC in the US; Berlin, London, Madrid, Milan in Europe; Shanghai in Asia. Application deadline July 10th.
Please RT!
Details👉springernature.wd3.myworkdayjobs.com/SpringerNatureCareers -
Nature Cancer
@NatureCancer
🔥ICYMI - in our @NatureCancer webcast #marcelamaus and @ImmunoTx #josmelenhorst discussed "The Advance of CAR T cell therapy". #immunotherapy
This content is now available ON DEMAND and FOR FREE❗️Sponsored by @BDBiosciences
Find it here: www.workcast.com/register?cpak=3103777316483010&referrer=… -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer - "Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1" by @Nathaniel_Mabe, @majzner_lab, @KStegmaier_DFCI & CO. #neuroblastoma
👇
rdcu.be/cRrFB
go.nature.com/3aAo236 -
Nature Cancer reposted
Nathaniel Mabe,PharmD,PhD @Nathaniel_Mabe
Very excited to share our new research linking anti-GD2 response to cell state in neuroblastoma. Published in @NatureCancer. A collaboration between the @KStegmaier_DFCI and @Majzner_Lab labs. A huge thank you to all of the collaborators and contributors. www.nature.com/articles/s43018-022-00405-x
-
Nature Cancer
@NatureCancer
📢Application deadline 17th of July 📢
10 days left to apply and join our team @NatureCancer from NY, Philadelphia & Washington DC in the US; Berlin, London, Madrid, Milan in Europe; Shanghai in Asia.🌎 #sciencecareers #editorial
Please RT and spread the word!
Nature Cancer
@NatureCancer
📢We’re hiring and expanding the @NatureCancer team in new locations🌍!
Apply to join our team in NY, Philadelphia & Washington DC in the US; Berlin, London, Madrid, Milan in Europe; Shanghai in Asia. Application deadline July 10th.
Please RT!
Details👉springernature.wd3.myworkdayjobs.com/SpringerNatureCareers -
Nature Cancer
@NatureCancer
⭐️ICYMI - read the Review “Engineering-enhanced CAR T cells for improved cancer therapy” by Jan Joseph Melenhorst @ImmunoTx & Co as part of our #seriescancerimmunotherapy #cartell (go.nature.com/3QTc70m).
Find it here 👇
rdcu.be/cQ6vN
go.nature.com/3yoDHKq -
Nature Cancer
@NatureCancer
📢Don’t miss the chance to meet our editor #juliasimundza at #eacrcancergenomics to discuss science🧪and publishing📰 in @NatureCancer.
#eacr #eacrcg2022 #oxford #uk -
Nature Cancer
@NatureCancer
🔥HOT OFF THE PRESS 🔥 – “Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer” by #stevenjisakoff & Co. #breastcancer #therapy
Read it here 👇
rdcu.be/cQ0y8
go.nature.com/3IcaKWR -
Nature Cancer
@NatureCancer
🔥DON’T MISS @NatureCancer - “Structural variants shape driver combinations and outcomes in pediatric high-grade glioma” by #frankdubois @KeithLigon5 #rameenberoukhim #pratitibandopadhaya & Co.
#glioma
Find it here👇
rdcu.be/cQ0xt
go.nature.com/3ImhOjF -
Nature Cancer reposted
Anton Henssen
@anton_gh
Great work by Frank Dubois and colleagues out today : Structural variants shape driver combinations and outcomes in pediatric high-grade glioma @NatureCancer www.nature.com/articles/s43018-022-00403-z
-
Nature Cancer reposted
Paolo Tarantino
@PTarantinoMD
Interesting phase 2 trial of neoadjuvant niraparib for BRCA-mutated breast cancer out on @NatureCancer. 90% achieved a radiologic response & 6/21 achieved a pCR with only niraparib. Intratumoral niraparib concentrations were >30-fold higher than in plasma.
www.nature.com/articles/s43018-022-00400-2 -
Nature Cancer
@NatureCancer
💫As part of our #seriescancerimmunotherapy (go.nature.com/3QTc70m) we would like to highlight a beautiful review - “The current landscape of immunotherapy for pediatric brain tumors” by #eugenehwang & co.
Find it here 👇
rdcu.be/cQWxY
go.nature.com/3nIsn6Z -
Nature Cancer reposted
The BATLLE Lab
@BatlleLab
Celebrations are well in order 🎉🎊🎈🥂. First author Adrián Álvarez-Varela 🍾 and the rest of the team at 17:00 hrs this afternoon, as the paper on Mex3a chemoresistant cells is published @NatureCancer !!!
-
Nature Cancer
@NatureCancer
💫As part of our #seriescancerimmunotherapy (go.nature.com/3QTc70m) we would like to highlight “Bystander T cells in cancer immunology and therapy” by @StefanieLMeier @Satpathology #danielkwells
#immunotherapy
Read here👇
rdcu.be/cQJEP
go.nature.com/3uffO74 -
Nature Cancer reposted
The BATLLE Lab
@BatlleLab
🧵1/13 Thrilled to announce this terrific work 🔝 by Adrián Álvarez, @lnovellasdemunt, & the rest of the team @NatureCancer. Many congrats to all 👏. Mex3a identifies latent stem cells
in #colorectalcancer that resist #chemotherapy & fuel disease relapse
www.nature.com/articles/s43018-022-00402-0 -
Nature Cancer
@NatureCancer
📢 TODAY IS THE DAY - happening in only 5 hours from now - don't miss #marcelamaus and @ImmunoTx discussing #cartcell therapy and join us for a live Q&A to get your ❓answered. @NatureCancer @BDBiosciences
Register here for FREE 👇
www.workcast.com/register?cpak=3103777316483010&referrer=… -
Nature Cancer reposted
Sohrab Shah
@SohrabShah
Really happy to see this work published. This was a very enjoyable study that brought together @MSKCancerCenter investigators from multiple disciplines - pathology, radiology, genomics, machine learning. Major props to new MD/PhD and now @MSK_RadOnc fellow @kevinmboehm ...
Nature Cancer
@NatureCancer
💫DON’T MISS - “Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer” by @kevinmboehm @SohrabShah @CompOncMSK. #cancerdiagnosis #machinelearning
Read it here
go.nature.com/3QWiQXy
rdcu.be/cQDQg -
Nature Cancer
@NatureCancer
“A decade of CAR T cell evolution” gets you in the mood for today's WEBCAST - in this N&Vs #marcelamaus discusses the work of @ImmunoTx & Co. Today at 5 PM CEST (11AM EDT) they will join us both and talk about #cartcell therapy.
📢Registration: www.workcast.com/register?cpak=3103777316483010&referrer=…
Nature Cancer
@NatureCancer
✨“A decade of CAR T cell evolution” – don’t miss this beautiful News & Views by @MarcelaMaus covering groundbreaking work by @MelenhorstLab @carlhjune @cdktmw & Co published in @Nature!
rdcu.be/cI1nx
go.nature.com/3CKMCb5 -
Nature Cancer
@NatureCancer
⭐️And don’t forget to check out the accompanying News & Views “Ovarian cancer through a multi-modal lens” by @lab_pearson. #cancerdiagnosis #machinelearning
Read it here 👇
rdcu.be/cQDQ7
go.nature.com/3OUaPAF -
Nature Cancer
@NatureCancer
💫DON’T MISS - “Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer” by @kevinmboehm @SohrabShah @CompOncMSK. #cancerdiagnosis #machinelearning
Read it here
go.nature.com/3QWiQXy
rdcu.be/cQDQg -
Nature Cancer reposted
Elsa Anagnostou
@ValsamoA
Where do we stand with tumor mutation burden as a #biomarker of response for #cancer #immunotherapy? Read our viewpoint and #virtual discussion with @GeneCollector @SamraTurajlic and @Albert0Bardelli , just out in #seriescancerimmunotherapy @NatureCancer
rdcu.be/cQzw5 -
Nature Cancer reposted
Kevin Boehm @kevinmboehm
Multimodal machine learning improves patient risk assessment in ovarian cancer.
Excited to share our new study of imaging biomarkers in @NatureCancer. @SohrabShah @CompOncMSK
www.nature.com/articles/s43018-022-00388-9 -
Nature Cancer
@NatureCancer
Another ⭐️highlight⭐️ from our #seriescancerimmunotherapy – “The status of tumor mutational burden and immunotherapy” – a viewpoint by #valsamoanagnostou, @Albert0Bardelli, @GeneCollector and @SamraTurajlic!
Read it here:
go.nature.com/3QTd6O6
rdcu.be/cQzGQ -
Nature Cancer
@NatureCancer
💫As part of our newly launched #seriescancerimmunotherapy don’t miss this exciting Review on "Novel and safe #immunotherapy combinations" by @DrIgMelero & Co.
Read it here 👇
go.nature.com/3QS8DeK
rdcu.be/cQzFO -
Nature Cancer
@NatureCancer
⛱️🌅🌞The @NatureCancer June issue is out!
This month read about #epigenetics, #therapy for ALK mutated lung cancer, #machinelearning, #tumorimmunology and #cancerdiagnosis!
And don’t miss our artistic cover🎨
Find it here:
go.nature.com/3bA2seY -
Nature Cancer
@NatureCancer
📢One week left to sign up for the @NatureCancer webcast with #marcelamaus and Jos Melenhorst @ImmunoTx discussing #cartcell therapy. Join us and ask you questions❓in a live Q&A. #immunotherapy
Sign up for FREE, sponsored by @BDBiosciences!
June 30th❗️
Nature Cancer
@NatureCancer
In a webcast sponsored by BD Marcela Maus and Jos Melenhorst @ImmunoTx will discuss recent developments in the CAR T cell space.
Don’t miss the opportunity to listen and engage with 2 pioneers of CAR T cells in a live Q&A! Sign up here for free 👇
www.workcast.com/register?cpak=3103777316483010&referrer=… -
Nature Cancer reposted
Javier Carmona 🇪🇺
@FJCarmonas
🚨This is a first!! Editor positions open in other cities in Europe (including Madrid)! 🌍
🤩Kudos to @NatureCancer for breaking borders and expanding the talent pool! Great step towards enhancing interactions with the global #scientificcommunity
#sciencecareers #editorlife 👇
Nature Cancer
@NatureCancer
📢We’re hiring and expanding the @NatureCancer team in new locations🌍!
Apply to join our team in NY, Philadelphia & Washington DC in the US; Berlin, London, Madrid, Milan in Europe; Shanghai in Asia. Application deadline July 10th.
Please RT!
Details👉springernature.wd3.myworkdayjobs.com/SpringerNatureCareers -
Nature Cancer
@NatureCancer
📢We’re hiring and expanding the @NatureCancer team in new locations🌍!
Apply to join our team in NY, Philadelphia & Washington DC in the US; Berlin, London, Madrid, Milan in Europe; Shanghai in Asia. Application deadline July 10th.
Please RT!
Details👉springernature.wd3.myworkdayjobs.com/SpringerNatureCareers -
Nature Cancer reposted
Thomas Walle @science_wallet
Finally published underlining the safety of COVID-19 vaccination under immune checkpoint therapy, focusing on a specific adverse event: cytokine release syndrome.
doi.org/10.1038/s43018-022-00398-7
Great experience working cofirst @SunanjayB and Guy Ungerechts. (1/6) -
Nature Cancer
@NatureCancer
🔥ICYMI🔥 – “Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy” by @science_wallet & CO ONLINE NOW @NatureCancer. #covid19 #immunotherapy
👇
rdcu.be/cP4At
go.nature.com/3N7S0IT -
Nature Cancer
@NatureCancer
And 🌟DON’T MISS🌟 this beautiful News & Views by @DarArvin & Co. highlighting “Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer”. #lungcancer #therapy
rdcu.be/cP4zD
go.nature.com/3OveWD2 -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer” by #jessicajlin #sathoshiyoda #aaronnhata & Co. #lungcancer #therapy
👇
rdcu.be/cP4xJ
go.nature.com/39BCKGE -
Nature Cancer reposted
EACR
@EACRnews
Thanks for joining us for an honest discussion on publishing! Roshan Ahmed @GenomeMedicine @mvicaracal @Nature Priscilla Kelly @ScienceMagazine Steve Mao @Cancer_Cell Maria Papatriantafyllou @MolOncology @imsmd @CD_AACR @Cindy_JExpMed @JExpMed @alexia_zz @NatureCancer #eacr2022
-
Nature Cancer
@NatureCancer
In a webcast sponsored by BD Marcela Maus and Jos Melenhorst @ImmunoTx will discuss recent developments in the CAR T cell space.
Don’t miss the opportunity to listen and engage with 2 pioneers of CAR T cells in a live Q&A! Sign up here for free 👇
www.workcast.com/register?cpak=3103777316483010&referrer=… -
Nature Cancer
@NatureCancer
🔥DON’T MISS “Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors” by @JordanMWinterMD @winterlab8 @NatureCancer.
Read it here 👇
rdcu.be/cPIqn
go.nature.com/3QqNDLG -
Nature Cancer reposted
Jordan M. Winter MD @JordanMWinterMD
Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors | Nature Cancer. @winterlab8 latest publication showing #idh1 as a target in #pancreatic cancer @PanCAN www.nature.com/articles/s43018-022-00393-y
-
Nature Cancer reposted
Duke Pharmacology & Cancer Biology Department
@Duke_PCB
A new study by Kevin Lin in the @kcw00d lab discovers a potential new drug therapy for acute myeloid leukemia (AML). The authors use a combination of high throughput proteomics and CRISPR screens to reveal a pro-survival pathway that is activated by nuclear exportin inhibitors.
-
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia” by @kcw00d @LabPuissant
👇
Read it here:
rdcu.be/cO8Wa
go.nature.com/3NSwt7C -
Nature Cancer reposted
Nikos Kourtis @nkourtis
I am excited to share our study from @Regeneron , published today in @NatureCancer! We generated the first single-cell epigenetic map (along with gene expression and TCR information) of immune cells from patients with Renal Cell Carcinoma (RCC).
www.nature.com/articles/s43018-022-00391-0
1/5 -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress”
Read it here 👇
rdcu.be/cOTbz
go.nature.com/3xeIKhn
Nature Cancer
@NatureCancer
@Gr8straj, @utswcancer, @utswnews, @utswcancerbio, @utswurology, @jungmo_ahn, @UTDallasChemBio, @UT_Dallas, @ratnavadlamudi, @XLiu_01#ER stress #cancer therapy #lipa.
-
Nature Cancer reposted
Ganesh Raj @gr8straj
Thankful for an awesome group of scientists and collaborators who enabled the discovery of a new therapeutic approach to solid tumors- enhancing endoplasmic reticulum stress. www.nature.com/articles/s43018-022-00389-8.pdf @naturecancer @utswcancer
-
Nature Cancer reposted
Malachi Griffith @malachigriffith
We are very excited to share our latest CIViC related publication (civicdb.org) in @NatureCancer describing among other things our increasing partnership with the @ClinGenResource. Congrats to @KilanninK, @AMDanos, and the whole team. rdcu.be/cOsSz.
-
Nature Cancer
@NatureCancer
Our @NatureCancer editor @LisaHaas0107 is attending keysym.us/22B1Nature in 🇨🇦 starting a week from today. #ksimmunecheckpoints22 #immunology #autoimmunity #oncology #neoantigens #vaccines #cancer
Reach out if you want to discuss 🥼🧪 -
Nature Cancer reposted
Charles Swanton
@CharlesSwanton
gd T cells in cancer: at the front lines. New from @SwantonLab and @HaydayLab out in @NatureCancer today: “A local human Vd1 T-cell population is associated with survival in nonsmall-cell lung cancer” led by @dr_yinwu, @CharlesSwanton & @HaydayLab: www.nature.com/articles/s43018-022-00376-z 1/12
-
Nature Cancer
@NatureCancer
💫Approach our editor #ioannapavlaki at the #embocancerevolution 🇮🇹 if you want to discuss science – we would love to hear from you @NatureCancer!
-
Nature Cancer reposted
First World Africa ✊🏾 @AfricaRch
#africancancerscientists , shine the light on your #cancerresearchafrica scholarship by submitting a Blog to the @NaturePortfolio @NatureCancer @AORTIC_AFRICA
“Africa and Cancer” Channel! | Nature Portfolio Cancer Community cancercommunity.nature.com/posts/welcome-to-the-africa-an… -
Nature Cancer
@NatureCancer
💫ONLINE NOW @NatureCancer “IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia” @Armstrong_dfci by & Co. #therapy
Read it here👇
rdcu.be/cNbJL
go.nature.com/3yjERJ0 -
Nature Cancer reposted
Vivek Subbiah, MD
@VivekSubbiah
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors @NatureCancer www.nature.com/articles/s43018-022-00359-0
-
Nature Cancer reposted
Vivek Subbiah, MD
@VivekSubbiah
The dynamics of an immunotherapy duo @NatureCancer www.nature.com/articles/s43018-022-00362-5
-
Nature Cancer reposted
Parker Institute
@parkerici
New findings support the rationale for combination #immunotherapies incorporating #neoantigen vaccines with immune checkpoint therapy, PICI Bridge Scholar @GubinMatthew and Alexander Shavkunov write in @NatureCancer. go.nature.com/37R2q17
Nature Cancer
@NatureCancer
✨The @NatureCancer April issue IS LIVE! Read about #therapy in lung cancer, concurrent delivery of #immunotherapy, mitochondrial fission in macrophages 🧫, #tumormetabolism, #metastasis and so much more!
And don’t miss the beautiful cover! 👇👇
go.nature.com/36UOaUm -
Nature Cancer reposted
The BATLLE Lab
@BatlleLab
Nice News & Views of our MCLA-158 paper by Norihiro Goto & Ömer H. Yilmaz. @ohyilmaz
➡️ doi.org/10.1038/s43018-022-00368-z
And also an Editorial Comment @NatureCancer
➡️doi.org/10.1038/s43018-022-00377-y
Many Thanks! 👌🏻 -
Nature Cancer reposted
Tsunaki Hongu @Tsunaki3
So excited to share our latest work on #metastaticniche in lung that is now online @NatureCancer! Thank you so much our co-authors, colleagues in @hi_stem_lab @DKFZ and amazing friends in Oskarsson lab!!
www.nature.com/articles/s43018-022-00353-6 -
Nature Cancer reposted
MountSinaiLiver @MountSinaiLiver
New review published on molecular pathogenesis and systemic therapies in #hcc @naturecancer by Josep Llovet @augustoNYC @IcahnMountSinai @TischCancer @DOMSinaiNYC #livertwitter
-
Nature Cancer reposted
James Olzmann
@OlzmannLab
Exciting new work in @NatureCancer examining mechanisms of #ferroptosis sensitivity and therapeutic targeting of ferroptosis in MYCN-amplified neuroblastoma. www.nature.com/articles/s43018-022-00355-4
-
Nature Cancer reposted
Hamed Alborzinia @HamedAlborzy
Excited to share our paper published in @NatureCancer, describing MYCN-amplified neuroblastoma sensitivity to ferroptosis. 🥳🥳A big thanks to @AndresBatflorez and @hi_stem_lab. www.nature.com/articles/s43018-022-00355-4
-
Nature Cancer
@NatureCancer
🔥“MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis” NOW @NatureCancer by @HamedAlborzy & CO @DKFZ.
rdcu.be/cMjNk
go.nature.com/3LuxJgs -
Nature Cancer
@NatureCancer
⭐️DON’T MISS THIS ONE – a beautiful review on “Molecular pathogenesis and systemic therapies for hepatocellular carcinoma” @NatureCancer by #jospemllovet & Co.
rdcu.be/cMjNi
go.nature.com/3rUehC8 -
Nature Cancer
@NatureCancer
🔥NOW @NatureCancer “Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition” by #shichengsu & Co.
Additional info go.nature.com/3KoUnps
👇
go.nature.com/3rYrzO2
rdcu.be/cMjMj -
Nature Cancer reposted
Medical Xpress
@medical_xpress
Tumors on withdrawal: Amino acid deficiency shrinks childhood tumors @DKFZ @naturecancer medicalxpress.com/news/2022-04-tumors-amino-acid-deficien…
-
Nature Cancer
@NatureCancer
✨The @NatureCancer April issue IS LIVE! Read about #therapy in lung cancer, concurrent delivery of #immunotherapy, mitochondrial fission in macrophages 🧫, #tumormetabolism, #metastasis and so much more!
And don’t miss the beautiful cover! 👇👇
go.nature.com/36UOaUm -
Nature Cancer reposted
Hans Clevers
@HansClevers
A bispecific #antibody which distinguishes #cancer cells from healthy cells, doesn't care about #kras mutations & was developed entirely on human cancer #organoids. In 3 years from drawing board to clinic. Congrats to all collaborators. Read: rdcu.be/cL4xS
-
Nature Cancer reposted
Charles Danko
@charlesdanko
Our BayesPrism paper, led by the incredibly talented @tinyichu, is finally published!
BayesPrism accurately infers both cell types *and* gene expression in each cell type from bulk RNA-seq data using scRNA-seq.
www.nature.com/articles/s43018-022-00356-3 -
Nature Cancer reposted
dana_peer
@dana_peer
(1) I am pleased to share our BayesPrism algorithm in collaboration with the @charlesdanko lab, lead by the amazing @tinyichu who demonstrated incredible independence, innovation and technical chops in this work www.nature.com/articles/s43018-022-00356-3
-
Nature Cancer reposted
Jacob Insua-Rodríguez
@JInsuaRodriguez
Check out this sophisticated work driven by my friend @Tsunaki3, published now in @NatureCancer.
#cancer cells instruct #macrophages to turn #endothelial cells into a pro-#metastatic molecular factory. Happy to have contributed!
@DKFZ @hi_stem_lab
www.nature.com/articles/s43018-022-00353-6 -
Nature Cancer reposted
The BATLLE Lab
@BatlleLab
🧵1/ We’re delighted to share “The Making of” MCLA-158, a therapeutic bispecific antibody targeting EGFR in LGR5 positive cancer stem cells, just published in @NatureCancer. #mcla-158 #petosemtamab #cancer
➡️rdcu.be/cL4xS -
Nature Cancer reposted
IRB Barcelona
@IRBBarcelona
🔬An international consortium, led by #irbbarcelona & the biotech company @MerusNV, reports the discovery of MCLA-158, the first clinical candidate screened in #organoids targeting 🎯 #cancer #stemcells of solid tumors.
📰@NatureCancer
➡️www.irbbarcelona.org/en/news/scientific/mcla-158-first-cl…
#irbscience -
Nature Cancer
@NatureCancer
✨Have you read “Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs” by @Tsunaki3, @ThordurOskarss2, @hi_stem_lab❓ #metastasis
👇
rdcu.be/cL7To
go.nature.com/3kb8ML1 -
Nature Cancer
@NatureCancer
💫DON’T MISS “Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology” by @charlesdanko & Co.
Find it here 👇
rdcu.be/cL7Sy
go.nature.com/39hCvjn -
Nature Cancer
@NatureCancer
🔥ONLINE NOW @NatureCancer “Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors” by @BatlleLab @IRBBarcelona @MerusNV & Co.
👇
rdcu.be/cL5Tu
go.nature.com/3EURnQw -
Nature Cancer reposted
Daniel Bondeson @DanB0nD1
Did you know too much phosphate can be toxic to cancer? Super excited to see our paper describing phosphate dysregulation as an anti-cancer strategy, out now in @naturecancer!
www.nature.com/articles/s43018-022-00360-7 -
Nature Cancer
@NatureCancer
🔥DON’T MISS @NatureCancer “KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming” by #chongchen & Co.
Read it 👇
rdcu.be/cLP9z
go.nature.com/3L8UAOK -
Nature Cancer
@NatureCancer
✨ONLINE NOW @NatureCancer “Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer” by #lianghu, #hongbinji & CO.
Read it 👇
rdcu.be/cLP9f
go.nature.com/3MpzbB5 -
Nature Cancer
@NatureCancer
✨NOW OUT ✨@NatureCancer “Phosphate dysregulation via the XPR1–KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer” by #toddrgolub & Co.
Read it here: rdcu.be/cLE4k
go.nature.com/3JWA7v9 -
Nature Cancer
@NatureCancer
🌷DON’T MISS @NatureCancer “An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer” by #pasiajänne & Co.
rdcu.be/cLE3P
go.nature.com/3EtANa1 -
Nature Cancer
@NatureCancer
🔥 NOW @NatureCancer
“Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome” by #stephencmack #sameeragnihotri & Co.
Read it here 👇
rdcu.be/cLE2i
go.nature.com/3jPQf6K -
Nature Cancer reposted
Jennifer Perez, MD, PhD @DrJennyPerez
Proud to be a part of this exciting new work in @NatureCancer with my medical school mentor Dr. Sameer Agnihotri
Pitt Neurosurgery
@PittNeurosurg
Research published in @NatureCancer suggests potentially better, non-invasive way to treat diffuse midline gliomas, targeting the amino acids that these aggressive tumors need to grow. go.nature.com/37dsTFO @ChildrensPgh @HealthPitt
-
Nature Cancer reposted
Fred Hutch Cancer Center
@fredhutch
New work from Fred Hutch's @GhajarLab published in @NatureCellBio and @NatureCancer reveals why muscle tissue doesn’t get #mets and how dormant tumor cells in the brain wake up and proliferate. www.fredhutch.org/en/news/center-news/2022/04/understandi… #mbc #bcsm
-
Nature Cancer
@NatureCancer
🔥ONLINE NOW @NatureCancer – “Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity” by #yangxinfu, #boli & Co. Read it here👇
rdcu.be/cKSAS
go.nature.com/3JoqnJv -
Nature Cancer reposted
Communications Medicine
@CommsMedicine
From @NatureCancer: Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17 #cartcells without toxicity to normal tissues | @CommsMedicine #editorspicks
idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nat… -
Nature Cancer
@NatureCancer
We are recruiting an editor to join the @NatureCancer team - 6 days left to apply 📅 Please RT and spread the word - we look forward to hearing from you 🙂
❗️Application deadline: April 11th
More details 👇
career5.successfactors.eu/sfcareer/jobreqcareer?jobId=414…
Nature Cancer
@NatureCancer
📢NEW JOB ALERT!
We are recruiting an editor to join our *fabulous* editorial team @NatureCancer
🤩
Please spread the word and get in touch if you are interested - we want to hear from you! 👩💼🧑🔬
❗️Application deadline: April 11th
More details 👇
career5.successfactors.eu/sfcareer/jobreqcareer?jobId=414… -
Nature Cancer reposted
Nature Portfolio
@NaturePortfolio
A paper in @NatureCancer reports on a study on the risk factors and outcomes in a large cohort of patients with cancer infected with SARS-CoV-2 from a tertiary care cancer center in India. go.nature.com/3NIoUkO
-
Nature Cancer reposted
Leila Akkari
@LeilaAkkari1
Super happy to host @LisaHaas0107 from @NatureCancer at the @NKI_nl today and tomorrow- great overview of the editors commitments to research and the process behind the ‘submit’ button- thanks Lisa for visiting us on-site!
-
Nature Cancer reposted
Núria Vázquez-Bellón 👩🔬
@nuriavazquezbe
A comprehensive review of translational advances in #pancreaticcancer therapy💊in @NatureCancer. #pancreaticcancer is an aggressive cancer normally detected at advanced stages reducing treatment options with limited responses💉. A must read #openaccess!👀
www.nature.com/articles/s43018-022-00349-2 -
Nature Cancer reposted
Anirban Maitra
@Aiims1742
We hope you enjoy this #openaccess @NatureCancer review on translational advances in #pancreaticcancer with a special emphasis on targeted & #immunotherapy.
Many thanks to Drs. Abdel Hosein, Stephanie Dougan & @andrewaguirremd.
www.nature.com/articles/s43018-022-00349-2 -
Nature Cancer reposted
Top Science
@isciverse
Online NOW | Nature Cancer
Translational advances in #pancreatic ductal #adenocarcinoma #therapy.
@isciverse @NatureCancer #publicationalert #science #research #academictwitter #scitwitter #medtwitter #scicomm #news #newsbreak #trending #cancers #review
www.nature.com/articles/s43018-022-00349-2 -
Nature Cancer
@NatureCancer
⭐️"Zooming in on dendritic cells for CD40 agonists" -don't miss this News & Views by #juliahübner & @FNimmerjahn covering recent work @NatureCancer by @DahanLab & Co.
go.nature.com/3qK6iqW
rdcu.be/cJ6lw
Nature Cancer
@NatureCancer
⭐️ONLINE NOW @NatureCancer “Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting” by @DahanLab & Co 👏. #therapy
Check it out here 👇
go.nature.com/35dW61Z
rdcu.be/cHsr9 -
Nature Cancer
@NatureCancer
🔥Don't miss this beautiful review @NatureCancer on translational advances in pancreatic ductal adenocarcinoma by #abdelnasserhosein, #stephaniekdougan, #andrewjaguirre & @Aiims1742
Read it here🔥👇
go.nature.com/36xMWOT
rdcu.be/cJ6j9 -
Nature Cancer
@NatureCancer
🔥 ICYMI - the new study by @IdoAmitLab @MiriamMerad #amostanay & Co is now highlighted in a News & Views @NatureCancer by #tingzhang & #chendong !
Read it here 👇
rdcu.be/cJ6kN
go.nature.com/3INeuMX
Nature Cancer
@NatureCancer
🔥🔥 ONLINE NOW @NatureCancer: "The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response", by @IdoAmitLab @MiriamMerad #amostanay & Co
Find it here!
go.nature.com/35nKOsq
rdcu.be/cIaAQ -
Nature Cancer
@NatureCancer
🌷A spring treat🌹 from @NatureCancer - our March Issue IS LIVE! Read about many different aspects of #immunotherapy - covering resistance in #breastcancer, #tme remodeling in PDAC, bi-specifics, new #technology and much more.
Find it here 👇
go.nature.com/3uA19mh -
Nature Cancer reposted
Vivek Subbiah, MD
@VivekSubbiah
A decade of CAR T cell evolution | Nature Cancer @NatureCancer www.nature.com/articles/s43018-022-00347-4
-
Nature Cancer reposted
Nature Reviews Cancer
@NatureRevCancer
NEW #researchhighlight!
Writing in @NatureCancer,
Nolan et al. show that radiotherapy can create a pro-metastatic lung microenvironment in mice, an effect mediated by neutrophils.
go.nature.com/3qz2eJQ
@NatResCancer -
Nature Cancer reposted
Nature Portfolio
@NaturePortfolio
A News & Views article published in @NatureCancer reports the milestones and the evolution of T cell response in two patients with chronic lymphocytic leukemia who achieved remission after CAR therapy in 2010. go.nature.com/3NcUhDO
-
Nature Cancer reposted
Nature Portfolio
@NaturePortfolio
A paper in @NatureCancer presents the UK PROSECO study, which assesses humoral and cellular immune responses to one, two and three doses of vaccination against SARS-CoV-2 in patients with B-cell malignancies. go.nature.com/3D6Ju9D
-
Nature Cancer reposted
Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉
@BLLPHD
🚨NEW: Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues (in🐁) @PennMedicine @NatureCancer #cartcell #immunotherapy #tcellrx www.nature.com/articles/s43018-022-00344-7
-
Nature Cancer reposted
Nature Portfolio
@NaturePortfolio
A study in @NatureCancer identifies ligand-dependent corepressor-low cancer stem cells driving tumor immunity and proposes LCOR induction with mRNA therapy as an enhancer of immunotherapy response. go.nature.com/3wjW8AL
-
Nature Cancer
@NatureCancer
✨ONLINE NOW @NatureCancer “LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer” by @TCeliaTerrassa and Co. #breastcancer #immunotherapy
Here👇
rdcu.be/cJcDy
go.nature.com/3icyE8x -
Nature Cancer reposted
Toni Celia-Terrassa
@TCeliaTerrassa
So delighted to share our findings in breast cancer #immunotherapy and first study of the celiaterrassalab.com in @Naturecancer impressively performed by the PhD student @IPerezNunez and co-directed with Dr. Joan Albanell @psmar @IMIM_research
www.nature.com/articles/s43018-022-00339-4 -
Nature Cancer reposted
Iván Pérez @IPerezNunez
Very proud to share with you the research of my PhD at @TCeliaTerrassa lab published in @NatureCancer.
Thank you so much @NatureCancer, @alexia_zz and all the staff! Also thanks to all the people that has participated in the study!!!
www.nature.com/articles/s43018-022-00339-4 -
Nature Cancer
@NatureCancer
📢NEW JOB ALERT!
We are recruiting an editor to join our *fabulous* editorial team @NatureCancer
🤩
Please spread the word and get in touch if you are interested - we want to hear from you! 👩💼🧑🔬
❗️Application deadline: April 11th
More details 👇
career5.successfactors.eu/sfcareer/jobreqcareer?jobId=414… -
Nature Cancer
@NatureCancer
✨“A decade of CAR T cell evolution” – don’t miss this beautiful News & Views by @MarcelaMaus covering groundbreaking work by @MelenhorstLab @carlhjune @cdktmw & Co published in @Nature!
rdcu.be/cI1nx
go.nature.com/3CKMCb5 -
Nature Cancer
@NatureCancer
🔥🔥 ONLINE NOW @NatureCancer: "The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response", by @IdoAmitLab @MiriamMerad #amostanay & Co
Find it here!
go.nature.com/35nKOsq
rdcu.be/cIaAQ -
Nature Cancer
@NatureCancer
⭐️ONLINE NOW⭐️ @NatureCancer “A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology” by @AlanaWelm @BryanWelm &Co.
Read it here:
go.nature.com/3BMgFyB -
Nature Cancer
@NatureCancer
⭐️ONLINE NOW @NatureCancer “Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting” by @DahanLab & Co 👏. #therapy
Check it out here 👇
go.nature.com/35dW61Z
rdcu.be/cHsr9 -
Nature Cancer
@NatureCancer
🔥🔥 ONLINE @NatureCancer: 2 studies from @yibinkang &Co discover MTDH-SND1 inhibitors for metast #breastcancer therapy via cell- and non-cell-autonomous effects
DON'T MISS THEM! 👇
go.nature.com/3D7lJg1
rdcu.be/cChCa
go.nature.com/3cYSAJ9
rdcu.be/cChCc -
Nature Cancer
@NatureCancer
⭐️ONLINE NOW @NatureCancer: "APOBEC3A drives deaminase domain-independent Chromosomal Instability to promote pancreatic cancer #metastasis" , a fantastic study by Sonia Woermann @adrpdaclab &Co
Find it 👇
go.nature.com/3Cq2lut
rdcu.be/cBzDh
#worldpancreaticcancerday -
Nature Cancer
@NatureCancer
⚡ Work by @SerenaNikZainal systematically defined mechs & mutational signatures induced by DNA damage sources
Paper @NatureCancer 👇
go.nature.com/3zG5ncq
#worldcancerresearchday
#sept24th #researchworks
#letsteamupforcancerresearch
@WCRD24Sept @NatResCancer @Cambridge_Uni -
Nature Cancer
@NatureCancer
⭐️DO NOT MISS - ONLINE NOW @NatureCancer: "#epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated #leukemia" - a *fantastic* study by Ali Shilatifard and Co @NorthwesternU
Find it here:
go.nature.com/3yQbDzk
rdcu.be/cllzH -
Nature Cancer
@NatureCancer
We @NatureCancer strive to support #womenandgirlsinscience every day! Today we celebrate some of the fantastic women researchers who recently published their work with us. We hope their achievements will inspire you! #february11 #womeninscience @WomenScienceDay @UN_Women
-
Nature Cancer
@NatureCancer
⭐️ONLINE NOW @NatureCancer: "Pan-cancer image-based detection of clinically actionable genetic alterations" by @jnkath, @tom_luedde, @lab_pearson & co.
Read it: go.nature.com/3hGq6EC
Free access: rdcu.be/b5Sbh
NVs: rdcu.be/b5SaU
#thread by auths👇
Jakob Nikolas Kather
@jnkath
Our new paper is out in @NatureCancer 📜👉 "Pan-cancer image-based detection of clinically actionable genetic alterations"(www.nature.com/articles/s43018-020-0087-6). 🔬🖥️ It is published back-to-back with @MoritzGerstung & @yufu0413 's excellent study (www.nature.com/articles/s43018-020-0085-8) 👌 (1/5)
-
Nature Cancer
@NatureCancer
🔴We are looking for an Associate or Senior Editor to join the #editorial team @NatureCancer
If you are passionate about #science and have a PhD in #cancer research or a related field, have a look at the link below and feel free to reach out to us.
career5.successfactors.eu/sfcareer/jobreqcareer?jobId=321…





































































































































































































































































